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General introduction
9A bone conduction hearing implant is a partially implantable hearing aid system, which 
makes use of the ability to transfer sound through bone conduction. The field of bone 
conduction hearing implants is rapidly evolving over the past years and the most recent 
developments within this field are discussed in this thesis. A variety of topics within the field 
are studied, from advances in implant technology and surgical procedures, to evaluation 
of clinical and audiological outcomes. In order to understand the functioning of a bone 
conduction hearing implant, it is important to first shortly discuss the physiology and patho-
physiology of (bone conduction) hearing and the concept of the bone conduction hearing 
implant systems. This introduction aims to give a concise description of these topics.
Air and bone conduction physiology
Auditory stimulation can occur by either means of air or bone conduction. Both pathways 
result in a stimulation of the inner ear or cochlea and consequential excitation of the 
cochlear nerve. In air conduction (AC) a sound pressure wave (defined by its frequency 
in Hertz and amplitude in decibels) is transmitted through the outer ear canal, via the 
middle ear to the inner ear. More specific, the sound vibrations are captured by the auricle 
and directed onwards by the external acoustic meatus to the tympanic membrane (Figure 
1). The mechanical vibrations from the tympanic membrane are transmitted via the three 
middle ear ossicles (malleus, incus and stapes) to the oval window at the cochlea. Here 
the mechanical vibrations are converted in a longitudinal fluid wave of perilymph within the 
two scalae or chambers of the cochlea, the scala vestibuli and scala tympani, and reaches 
onto a second membrane-covered opening of the cochlea, the round window. Transmis-
sion of the mechanical fluid waves into nerve signals takes place in the cochlea at the 
basilar membrane in the third scala, the scala media. The fluid wave causes the membrane 
to vibrate and the amplitude of the fluid wave will have a peak at a distinct distance from 
the oval and round window, related to the frequency of sound. At the location of maximal 
amplitude, the sensory hair cells of the organ of Corti at the basilar membrane are excited, 
causing action potentials that are transmitted to the brain via the auditory nerve (Figure 1).
Bone conduction can cause a pressure wave of the perilymph in the cochlea similar 
to that or air-conducted sound, also resulting in a vibration of the basilar membrane and 
consequently causing an action potential transmitted via the auditory nerve 1. Mechanical 
vibrations of the skull result in a perilymph wave as a result of inertia of the cochlear 
fluid. This mechanism is considered the most dominant contributor to bone conduction 
perception. The perilymph wave in the scalae is a result of compliance of the oval and 
round window. Furthermore, alteration of the cochlear space by means of compression and 
expansion of the cochlear walls is believed to play an important role. This alteration is the 
result of propagation of the longitudinal sound wave in the skull and consequent compres-
sion and expansion of the bone with this wave. Asymmetry in scala vestibuli and tympani, 
as well as in impedance of the oval and round window, results in fluid flow and excitation 
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of the basilar membrane (primarily in higher frequencies). Other factors are generally minor 
contributors to bone conduction hearing (with exceptions in anatomical variations), these 
are elaborately discussed by Stenfelt et al 2.
The mechanisms of vibration transmission from the skull bone to the cochlea are not only 
applicable to the ipsilateral cochlea, but additionally transcranial vibration transmission will 
result in stimulation of the contralateral cochlea. Especially in frequencies up to 1 kHz the 
transcranial attenuation is close to 0 dB, i.e. sound transmission to the contralateral cochlea 
is assumed to be (near) equal to that of the ipsilateral cochlea. For higher frequencies the 
transcranial transmission starts to decrease and the attenuation becomes +15 to +20dB 
at 10kHz 3. This aspect of bone conduction hearing is important with application of bone 
conduction hearing implants, which will be discussed later on.
Hearing loss
The previous paragraph described the physiology in air and bone conduction hearing. In 
normal hearing patients sound transmission is generally achieved by means of the more 
efficient air conduction hearing resulting from a sound wave captured by the auricle. 
Figure 1. The ear and air conduction hearing
The cochlear duct is drawn as though unrolled from its original spiral shape. Segments ‘c’, ‘b’, and ‘a’ 
indicate high, to middle, to low frequency regions. Vestibular system not shown. Based on a figure from 
M. Brodel, 1930
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When, however, one of the contributing parts of the ear is abnormally developed or 
dysfunctioning, this will result in a hearing loss. Sensorineural hearing loss (SNHL) is the 
most common type of hearing loss, this is caused by any dysfunction or abnormality in the 
cochlea or auditory pathway to the brain and can often be rehabilitated by means of air 
conduction hearing aid. Conductive hearing loss (CHL) is caused by any developmental 
disorder or dysfunction of the external and/or middle ear. In these cases hearing is limited 
by an ineffi cient sound transmission and consequently diminished auditory input to the 
cochlea. Mixed hearing loss (MHL) is a combination of both conductive and sensorineural 
components. Furthermore, each type can either be congenital (present at birth) or acquired 
in onset and have various underlying causes. For some hearing problems medical or surgi-
cal interventions are available, while in other diagnosis rehabilitation options like hearing 
aids are preferable or sometimes the only option available. Bone conduction hearing 
implants are mainly applied for conductive or mixed hearing loss, either unilateral or bilat-
eral. Especially for patients with external auditory canal and/or middle ear disorders, in 
which the use of a conventional air conduction hearing aid is contraindicated, not possible 
(atresia/microtia) or when reconstructive surgery is not a feasible option 4. Furthermore, 
in unilateral sensorineural hearing loss the previously described transcranial transmission 
of vibrations to the contralateral functioning ear can be utilized for hearing aid fi tting 5,6.
a.  Image A shows the separate parts (image provided 
by Oticon Medical™. Reprinted with permission)
b.  Image B shows the system as implanted (image pro-
vided by Cochlear™ BAS. Reprinted with permission)
Figure 2. The percutaneous bone conduction hearing implant.
The system consists of three parts; a titanium implant, an abutment and a sound processor or bone conduc-
tion device (BCD).
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Bone conduction hearing implants
The classic percutaneous system, which is the standard device system in our clinic and main 
subject of this thesis, consists of three parts; a titanium implant, an abutment and a sound 
processor or bone conduction device (BCD) (Figure 2). Before the development of this 
system, bone conduction hearing solutions comprised a vibrator that was pressed against 
the skin at the mastoid, by a steel spring or headband. That bone conduction vibrator was 
connected to a body-level power processor. Later on, the bone conduction vibrator was 
supported by eyeglasses, where the microphone and amplifier where mounted in the arms 
of the spectacles 7-9. These conventional bone conduction hearing aids were fitted success-
fully, and from the 1960s to the 1990s these were the most widely used bone conduction 
hearing devices. However, various problems remained, like dampening of sound by skin 
and subcutaneous tissue, pressure related skin problems and a variable position of the trans-
ducer. To overcome these problems, the idea to create a direct connection of the vibrator 
with the mastoid bone through a percutaneous implant was developed. The percutaneous 
bone conduction hearing implant was developed in 1977 at Gothenburg Sweden by a 
team led by Tjellström, Håkansson and Brånemark 10; and is commercially available since 
1987. The concept of using titanium implants for a rigid fixation between a titanium fixture 
and bone was derived from dental implantology, were these implants were used as a 
means of providing an anchor for dental prostheses 11. The titanium implant is inserted in 
the temporal bone and a skin-penetrating abutment is attached to the implant to facilitate 
coupling of the BCD. The sound processor microphone captures the sounds and the sound 
processor with vibrator converts the sound pressure waves into mechanical vibrations that 
vibrate the mastoid bone through the titanium abutment and implant, stimulating the cochlea. 
As a result any problems in the outer of middle ear are bypassed in patients with conductive 
or mixed hearing loss 10. In patients with single sided deafness, the vibrations are sent to 
the contralateral ‘good’ inner ear 12. The percutaneous system is currently a well-established 
method and is considered the gold standard in bone conduction hearing in our clinic 4,13.
Advances in surgery, implants and sound processors
Since the introduction of the bone conduction hearing implant in 1977, many improvements 
have been made in the sound processors, implants and in the surgical procedure 14,15. 
Amongst others, the introduction of digital and more powerful sound processors and 
wireless options has resulted in advances 16,17. More recently, the introduction of wider 
and differently shaped implants for percutaneous systems, new surgical techniques and 
(re-introduction) transcutaneous systems have expanded the field 18. Some of these new 
implants and surgical techniques are discussed in more detail in this thesis (Chapters 5-8).
The re-introduction of transcutaneous implants needs some extra explanation. As discussed 
previously, bone conduction hearing devices were originally introduced as transcutaneous 
solutions, positioned by a steel spring or mounted in eyeglasses. Due to more effective sound 
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transmission, the percutaneous coupling was adopted as a new standard. At approximately 
the same time as the percutaneous coupling, a magnetic transcutaneous BCD was introduced, 
the Xomed Audiant 19. This system resulted in insufficient sound transmission and pressure 
related skin issues, which resulted in a withdrawal from the market soon after its introduc-
tion. In recent years however, a revival of transcutaneous applications has been observed. 
These systems are re-introduced with the intention to overcome some of the disadvantages 
or complications of percutaneous coupling (loss of the titanium implant, recurrent soft tissue 
problems around the abutment, and potential aesthetic issues related to the percutaneous 
abutment). The availability of new and more powerfull bone conduction processors have 
played an important factor in this revival. These transcutaneous applications yield a magnetic 
coupling over/through the skin; however, they can either be passive or active transcutane-
ous. In the passive transcutaneous systems the mechanical vibrations from the vibrator are 
transmitted through an intact skin to a passive subcutaneously placed magnet attached to 
the temporal bone (Sophono® 20 or Baha® Attract 21, the latter is discussed in Chapter 8, 
also see Figure 3). In active transcutaneous devices the vibrator is implanted under the skin 
and electromagnectic signals from the sound processor are transmitted through the intact skin 
(Bonebridge® 22, Sentio which was previously named Bone Conduction Implant 23 or OSIA, 
last two are not commercially available at the time of writing this thesis; Figure 3).
Another transcutaneous, non-surgical option, is the use of a bone conduction device on 
a softband. This softband option is frequently used in younger children bridging the period 
untill old enough for implantation as a more comfortable alternative to the metal headband 
and sometimes in a selection trial before implantation in adults 24. This option obviously has 
a less efficient sound transmission compared to the percutaneous system, hence generally 
is not a definite rehabilitation option.
A more complete overview of different systems has been provided previously by Dun et 
al. 15 and more recently by Reinfeldt et al 18. Furthermore, elaborate reviews can be found 
in prior Nijmegen theses about bone conduction devices 25-32.
Outline of this thesis
The aim of the first part of this thesis is the evaluation of various clinical outcomes of bone 
conduction hearing implants.
In chapter 2 the association between the occurrence of soft tissue reactions, revision 
surgeries and implant loss and several comorbidity factors is evaluated. This study was 
initiated based on previously identified other comorbidity risk factors and suggested patho-
physiological mechanisms, as well as results in clinical practice. A large patient cohort 
of 581 patients with long-term follow-up was used to assess the association of several 
comorbidity factors.
A remarkable increase in soft tissue complications in the paediatric patients compared 
to the previous generation implants was the motive for initiation of the study described in 
14
a c
b
d
Figure 3. Transcutaneous bone conduction hearing implants
a. Sophono® Alpha 2 (Image provided by Medtronic™. Reprinted with permission)
b. Baha® Attract (Image provided by Cochlear™ BAS. Reprinted with permission)
c. Bonebridge ® (Image provided by MED-EL™. Reprinted with permission)
d. Sentio (Image provided by Oticon Medical™. Reprinted with permission)
The Sentio system is not yet commercially available
e. OSIA
The OSIA system is not yet commercially available, no images are available yet
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chapter 3. This increase in complications was noticed from the time of introduction of a 
new type of implant, the Cochlear™ BI300 implant. This implant previously showed good 
results in adult patients, however, the results in the paediatric patient population were not 
yet reported in full. The rate of complications with this new implant was assessed in two 
tertiary referral centres.
Chapter 4 focuses on directional hearing. The results of a spatial discrimination and a 
sound localization test in children with a bilateral conductive hearing loss, who where re-
habilitated with bilateral bone conduction devices, are discussed in this chapter. An added 
value of bilateral versus unilateral application was expected in this patient population 
based on previous studies. The current study served to provide more evidence on improved 
directional hearing and to provide a closer insight in these directional hearing abilities.
The second part of this thesis discusses the clinical effectiveness and safety of new 
implants and a new surgical technique. In chapter 5 the five-year follow-up of a post-market 
trial on a new type of implant type is described. This study compares the BI300 implant 
from Cochlear™ to the preceding (previous generation) flange fixture. The studied implant 
included a wider diameter implant and a differently shaped abutment, aimed to reduce soft 
tissue reactions and increase implant stability. The current study focuses on these outcomes 
at long-term (five year) follow-up.
Chapter 6 describes the results from a randomized controlled trial comparing two per-
cutaneous implants from Oticon Medical™. The wide Ponto® implant (4.5mm diameter 
implant) was compared with the previous generation Ponto® implant (3.75mm diameter 
implant). This study focused on stability outcomes and implant survival, which were ex-
pected to improve with the new implant. Furthermore, soft-tissue outcomes and subjective 
benefit were evaluated.
In chapter 7 a new surgical technique for implantation of percutaneous bone conduction 
hearing implants is discussed. At the time of the study a simplified linear incision surgery, 
without a soft tissue reduction step, was recently introduced by another bone implant 
research centre (Hultcrantz et al, Karolinska University Hospital, Stockholm, Sweden). In 
order to further evaluate the results of this surgical technique, a study was conducted within 
our centre comparing the results of this new technique with the standard linear incision 
technique using the same type of bone conduction hearing implants (Ponto® wide from 
Oticon Medical™) in both groups.
Chapter 8 discusses the results of a post-market trial on a new transcutaneous implant 
system, the Baha® Attract from Cochlear™. This passive transcutaneous implant system 
was recently introduced and this was the first, and largest multicentre trial after it became 
commercially available. Patients with conductive/mixed hearing loss, as well as single-
sided deafness patients, were included and evaluated on various clinical and audiological 
parameters.
All studies are discussed and summarized in chapter 9.
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Objective  To identify risk factors for complications after bone anchored hearing 
implant (BAHI) surgery
Study design  Retrospective cohort study
Setting  Tertiary referral centre
Patients  All adult patients who received titanium bone-anchored hearing im-
plants at our clinic between September 1, 1988, and December 31, 
2007, were approached to fill out a questionnaire on comorbidity 
factors. A total of 581 patients with 669 implants were included in 
the analysis.
Main outcome 
measures
 Implant loss, soft tissue reactions and revision surgery after BAHI 
implantation
Results  Skin disease and profound learning difficulties were risk factors for 
time to first soft tissue reaction, hazard rate ratio of 3.41 (95% CI 
1.45-8.01) and 3.42 (1.03-11.39) respectively. Female gender 
showed a trend toward a negative risk for time to first soft tissue reac-
tion, hazard rate ratio 0.60 (0.35-1.03). In multivariable analysis 
skin disease and female gender were observed as independent as-
sociative factors, adjusted hazard ratio 3.08 (1.32-7.16) and 0.56 
(0.33-0.94). For revision surgery, female gender and cardiovascular 
disease were identified as negative risk factors in univariable analysis 
and smoking showed a trend toward a negative risk, with hazard ra-
tios of 0.15 (0.07-0.32), 0.07 (0.03-0.20) and 0.51 (0.24-1.07) 
respectively. In multivariable analysis smoking and female gender 
were observed as independent associative factors, adjusted hazard 
ratio 0.45 (0.22-0.95) and 0.14 (0.06-0.30). Smoking could be 
identified as a risk factor for implant loss with a hazard ratio of 3.32 
(1.36-8.09).
Conclusions  Retrospective analysis of comorbidity factors and clinical outcomes re-
vealed risk factors for postoperative complications after BAHI surgery.
25
Introduction
The percutaneous bone anchored hearing implant (BAHI) was introduced in 1977 by 
Tjellström1. For more than 35 years, it has been used successfully as a treatment for patients 
with conductive or mixed hearing loss. The BAHI shows a high degree of safety and 
the success rate concerning audiometric outcomes and patient satisfaction is stable over 
time 2. Nevertheless, complications are encountered during follow-up. The most frequent 
complications of the BAHI involve soft tissue reactions around the titanium skin-penetrating 
implant and implant loss3-7.
The most commonly used classification for soft tissue reactions around percutaneous 
implants was proposed by Holgers et al. in 19883. This classification describes five differ-
ent degrees of soft tissue reactions. A reaction of Holgers grade 2 or higher is generally 
considered as an adverse reaction in need of treatment. Subsequently, these soft tissue 
reactions may result in more serious adverse outcomes, such as implant extrusion and 
chronic wound infection 5,6. In a large series described by Dun et al. 4, a soft tissue reaction 
Holgers grade 2 or higher was recorded in 4.5% of all observations. Higher soft tissue 
reaction scores were seen in children and patients with profound learning difficulties. As 
for comorbidity factors, some studies 8-10 identified a relationship between obesity and soft 
tissue complications at the implant site. The influence of other comorbidity factors on soft 
tissue reaction in BAHI implantation has been analysed in a study by Zeitler et al 11. This 
study describes an increased risk of skin-site complications for African American patients, 
but for the other predisposing factors (tobacco use, diabetes mellitus, immunosuppression) 
no relation could be found in this relatively small series. In other medical fields where 
comparable titanium implants are used for even a longer period of time, especially the 
field of dental implantology, larger retrospective studies show that diabetes mellitus and a 
history of cardiovascular disease are significant risk factors for peri-implant disease 12,13. 
Furthermore, dermatologic diseases such as eczema and psoriasis might influence soft 
tissue reactions post BAHI surgery. Two BAHI studies report a high number of patients 
with skin disease in those presenting with an adverse skin reaction 14,15. Most studies on 
complications after BAHI surgery merely mention possible influence of comorbidity factors 
on soft tissue reaction in a descriptive manner, with no further analysis.
A more serious complication, also likely to be affected by comorbidity, is implant loss. 
Reported frequency of implant loss varies from 3% to 27% in adult patients 4,5,7,16. Few 
articles have been published on risk factors for implant loss. Previous irradiation of the 
implant site is shown to be a risk factor for implant failure 17. Furthermore, Horstink et al. 
18 showed a significantly higher rate of implant loss in Type 2 diabetes mellitus (DM2) 
patients compared to non DM patients. Impact of other comorbidity factors on implant loss 
is not yet identified. However, conditions that influence bone remodelling might affect the 
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process of osseointegration around a BAHI. Numerous potential local and systemic factors 
are mentioned in various studies; however, definite evidence is often lacking.
The aim of the current retrospective cohort study was to identify the influence of comorbid-
ity on soft tissue reaction, revision surgery and implant loss in a large population of patients 
with the same type of BAHI. Studies on wound healing in general have led to the hypothesis 
that among patients with relevant comorbidities, peri-implant complications might be higher 
compared with healthy adult patients. Knowledge of these potential risk factors could be 
useful in patient counselling, selection of surgical procedure, and postoperative surgical 
site care. We retrospectively analysed a consecutive series of more than 1000 implants 
on clinical outcomes, with emphasis on adverse events and potential risk factors. The same 
series was previously analysed by Dun et al. 4, focusing on age differences and loading 
time, and by Horstink et al. 18, focusing on the effect of diabetes mellitus on implant loss. 
For the current study, the available data were re-analysed and combined with additional 
topics focusing on these extended clinical research questions.
Material and methods
Participants
All patients who received titanium bone-anchored hearing implants at our clinic between 
September 1, 1988, and December 31, 2007, were identified. This resulted in a cohort 
of 974 patients with 1150 implants. During follow-up, 140 patients passed away. All 
other patients were asked to fill out a questionnaire. Patients were contacted by mail and 
after not responding the first time, two more attempts were made to contact these patients 
by mail or telephone. One hundred and eighty-seven patients were unable to be contacted 
during follow-up or did not want to participate in this study. This resulted in a total of 647 
patients who were eligible for inclusion in the analysis of this retrospective cohort study, of 
which only the adult patients (aged 18 or older) were included in the definitive analysis 
(n=581).
Surgical techniques and post-surgery protocol
The original Tjellström skin graft technique 19 was used from 1988 until 1995, after which 
the Nijmegen linear incision technique with tissue reduction was implemented 14,20. After 
implementation this was the only technique used. Only one type of implant was used 
(as-machined Baha flange fixture, Cochlear Bone Anchored Solutions AB, Mölnlycke, 
Sweden). The frequency of postoperative visits to the outpatient clinic varied from once 
every four months in the first years after BAHI surgery, to once a year, which is the current 
standard. During all follow-up visits, a standardised checklist was used, which included 
registration of soft tissue reaction according to the Holgers grading system.
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Questionnaire and case analysis
The questionnaire was composed of 11 questions. Patients were asked if they were still 
using the bone conduction device and if they had ever been diagnosed with skin disease, 
hypertension, cardiovascular disease, or other comorbidity factors (not further specified; 
thyroid disease was mentioned as an example), including the year of diagnosis. For the 
patients with missing information on the year of diagnosis, medical files were searched and 
the database was completed with this missing information. Only diagnoses made before 
or in the year of operation were taken for further analysis. An exception was made for 
DM2, where a separate analysis was conducted for patients diagnosed during follow-up, 
as was also carried out in our previous analysis on largely the same series18. Reanalysis of 
the effects of DM2 was included in the current study, as the current study emphasises on the 
relation between DM2 and soft tissue reactions and revision surgery. In addition, a longer 
period of follow-up was available for implant loss, until January 2013.
Furthermore, patients were asked for their height and weight, smoking and alcohol intake 
status, and any changes in these factors since BAHI surgery. Smoking was handled as 
either active or non-smoker, and when patients stated they had quit smoking the year before 
BAHI surgery, they were counted as non-smokers. For alcohol, drinking two or more units 
daily reported in the questionnaire was included as a risk factor. Body Mass Index (BMI) 
was calculated for all patients, and changes reported since surgery were included in this 
calculation. In addition, data concerning age at implantation, gender, profound learning 
difficulties, soft tissue reactions, revision surgery and implant failure were collected from 
patients’ medical charts and our BAHI database. A soft tissue reaction grade 2 or higher 
was interpreted as an adverse soft tissue reaction.
For baseline characteristics time and age of first implantation, as well as comorbidity 
status at first implantation are presented.
Statistical analysis
The influence of risk factors on time to implant loss, first soft tissue reaction and time to 
revision was analysed with a proportional hazards regression model to obtain hazard rate 
ratios.
Because of multiple implants per patient (up to 5 implants) each patient can potentially 
experience several events. When no event was observed during observation time of an 
implant the time-to-event was censored at the time of implant loss or, for the last implant, 
the end-of-study date. This censoring mechanism was applied to all three time-to-event 
analyses.
To take into account the dependency of the observations a random effects proportional 
hazards model with Weibull baseline hazard was performed for the time-to-event data. A 
normal distributed frailty was incorporated for each individual. We assumed independent 
data within an individual.
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The influence of risk factors on the number of tissue reactions during observation time 
of an implant was analysed with a normal random effects Poisson regression model. 
Again incorporation of a random effect for each individual accounted for the dependency 
structure of the data. The logarithm of the observation time was used as offset.
Because previous analyses identified a significantly higher implant loss and soft tissue 
reactions in children, influence of comorbidity factors was only studied in adult patients 
(over the age of 18 years).
For each time-to-event analysis potential risk factors (P<0.10) in univariable analysis were 
incorporated in a multivariable regression model. All analyses were performed using SAS 
software version 9.2.
Results
Participants
The adult study population consisted of 581 patients with a total of 669 implants. A total 
of 65 patients were implanted bilaterally. The median age at first implantation was 52 
years (interquartile range 42-60 years), 54% of patients were female. The prevalence of 
skin disease was 8.3%. Approximately 30% of patients were active smokers at time of 
surgery and 19.7% had a type of cardiovascular disease. Frequency of DM2 at time of 
surgery was 5.4%; during entire follow-up it was 11.2%. Total follow-up time for all patients 
was 7120 person-years, median implant time per patient was 10.9 years. All baseline 
characteristics are shown in Table 1.
Soft Tissue Reaction
A Holgers grade 2 soft tissue reaction or higher was noticed at least once in 123 implants 
(18.4%). Over 40% of these adverse soft tissue reactions per implant were noticed in the 
first year after surgery.
Skin disease could be identified as a new risk factor for the time to first adverse soft tissue 
reaction, with a hazard rate ratio of 3.41 (95% CI 1.45-8.01, p=0.005). The presence 
of profound learning difficulties resulted in a hazard ratio of 3.42 (95% CI 1.03-11.39, 
p=0.045) for time to first adverse soft tissue reactions, female gender resulted in a hazard 
rate ratio of 0.60 (95% CI 0.35-1.03, p=0.062). The unadjusted hazard ratios for all 
risk factors with 95% confidence intervals are shown in table 2 and graphically displayed 
in figure 1.
When including comorbidity factors with a p-value of < 0.10 in a multivariable model, 
the hazard ratios only changed marginally. For gender, the hazard ratio was 0.56 (95% 
CI 0.33-0.94; p=0.029), for skin disease 3.08 (95% CI 1.32-7.16; p=0.009) and for 
profound learning difficulties 2.89 (95% CI 0.88-9.55; p=0.081).
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The influence of risk factors on the number of adverse soft tissue reactions during observa-
tion time of an implant was also analysed. The estimated mean number of adverse soft 
tissue reactions was 0.027 per year. Skin disease induced an incidence rate ratio of 1.98 
(95% CI 1.05-3.72, p=0.034). The unadjusted hazard ratios for all risk factors with 95% 
confidence intervals are shown in table 2 and graphically displayed in figure 2.
Revision surgery: soft tissue revision & abutment replacements
During the complete follow-up, in 79 of 669 implants, one or multiple revisions were per-
formed (11.8%). Of these, 41 included soft tissue revision, 32 a higher abutment and 6 both 
procedures. Female gender and cardiovascular disease were identified as new negative 
risk factors and for smoking a trend toward a negative risk was seen, respectively hazard 
rate ratios of 0.15, 0.07 and 0.51. The unadjusted hazard ratios for all comorbidity factors 
with 95% confidence intervals are shown in table 2 and graphically displayed in figure 3.
When including comorbidity factors with a p-value of < 0.10 in a multivariable model, 
virtually the same hazard ratios were seen, except for cardiovascular disease. For female 
gender, the hazard ratio was 0.14 (95% CI 0.06-0.30; p<0.001), for cardiovascular 
disease 0.95 (95% CI 0.41-2.18; p=0.897) and for smoking 0.45 (95% CI 0.22-0.95; 
p=0.036).
Table 1. Baseline characteristics
N %
Total patients 581 100%
Total implants 669 100%
Time 1988-1994 60 10,3%
1995-2001 206 35.5%
2002-2007 315 54.2%
Gender Male 268 46.1%
Female 313 53.9%
BMI >30 80 13.8%
DM 2 DM2 31 5.4%
DM2+ prediabetes 65 11.2%
Skin disease Eczema 33 5.7%
Psoriasis 15 2.6%
Total 48 8.3%
Cardiovascular disease Hypertension 86 14.9%
Total 114 19.7%
Thyroid disease Yes 37 6.4%
Profound learning difficulties Yes 23 4.0%
Smoking status Active time surgery 189 32.5%
Alcohol status More than 2 daily time surgery 78 13.4%
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Figure 1. Influence of comor-
bidity factors on time to first 
adverse soft tissue reaction (Hol-
gers score ≥ 2). Hazard rate 
ratio ± 95% CI. Random effects 
proportional hazards model: 
*p<0.05. Ref = Reference cat-
egory.
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Figure 2. Influence of comor-
bidity factors on the number of 
adverse soft tissue reactions dur-
ing observation time of implants 
(Holgers score ≥ 2). Hazard 
rate ratio ± 95% CI. normal ran-
dom effects Poisson regression 
model: *p<0.05. Ref = Refer-
ence category.
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Figure 3. Influence of comor-
bidity factors on revision surgery 
(soft tissue revision and/or abut-
ment replacement). Hazard rate 
ratio ± 95% CI. Random effects 
proportional hazards model: 
*p<0.05. Ref = Reference cat-
egory.
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Figure 4. Influence of comor-
bidity factors on implant loss. 
Hazard rate ratio ± 95% CI. 
Random effects proportional 
hazards model: *p<0.05. Ref 
= Reference category.
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Implant Loss
During complete follow-up, 50 of the 669 implants were lost (7.5%). In the first year after 
surgery, 11 implants were lost (22%). 29 of the 50 implant losses (58%) occurred in first 
five years. Smoking was the only risk factor that could be identified in univariable analysis, 
hazard rate ratio 3.32 (95% CI 1.36-8.09, p=0.009). A trend for higher implant loss 
was seen in patients with cardiovascular disease (HRR 2.10) and when during follow-up 
DM2 was present (HRR 2.21). The unadjusted hazard ratios for all risk factors with 95% 
confidence intervals are shown in table 2 and graphically displayed in figure 4.
Discussion
Principal findings
In the current study, clinical outcomes of 581 patients with 669 implants were studied with 
a total follow-up time of 7120 person-years, implant loss was observed in 7.5% of implants 
and adverse soft tissue reactions in 18.4% of implants. For adverse soft tissue reactions, 
skin disease could be identified as a risk factor. Smoking was a risk factor for implant loss. 
In addition, fewer revisions were seen in the female gender and cardiovascular disease 
group in univariable analysis; in multivariable analysis female gender and smoking were 
identified as negative risk factors for revision surgery.
Comparison with other studies
Evaluation of clinical outcomes of BAHI surgery has been extensively reported on since 
its introduction. Over the past years, several risk factors were evaluated, mostly in small 
populations and with short follow-up, as briefly reviewed in the introduction of this manu-
script. Younger age, profound learning difficulties, obesity, tobacco use, diabetes mellitus, 
cardiovascular disease, ethnic background, and skin disease have all been discussed 
4,14,15,21-23. In the current study, our entire BAHI database was evaluated for all these 
factors combined. Moreover, evaluation was done not only with respect to implant loss 
but also referring to revision surgery and soft tissue reactions, being more difficult outcome 
parameters to interpret. The current study is one of the largest series to date studying risk 
factors for these parameters. Some risk factors reported elsewhere can be confirmed by 
this study, such as skin disease and smoking. The negative effect of smoking on implant 
survival was already reported in numerous dental implant studies 22,24,25. For dermatologic 
diseases such as eczema and psoriasis the skin barrier function and immune response are 
negatively affected, and a higher bacterial colonization of the skin is found in several stud-
ies 26-29, which could possibly explain the higher soft tissue complication rate. However, 
other risk factors previously described could not be confirmed. As stated in the introduction, 
Berenholtz et al. 8, Rebol 9 and Kraai et al. 10 identified high BMI as a risk factor for soft 
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tissue problems, explained by the relation between body mass index and retroauricular 
subcutaneous tissue thickness 30. Such a significant relation between BMI and soft tissue 
reactions could not be identified in this series; only a trend towards higher incidence was 
noticed in our series. Prevalence of BMI ≥ 30 was 30% in the series by Berenholtz et al., 
compared to 14% in the current study. This difference in patient group might explain the 
fact that this risk factor was not confirmed in the current study. Notable are the outcomes of 
the current study on diabetes mellitus and implant loss. DM was not seen as a risk factor in 
the current study, merely a trend was noticed. This can be seen as contradicting a previous 
analysis by Horstink et al 18, especially since it is the same patient dataset. However, the 
reduced study group due to methodological constraints, longer follow-up and different 
statistical analysis can explain this discrepancy.
Strengths and limitations
The current study has several strengths. First of all, the size and duration of follow-up of 
the analysed patient group lend for more robust conclusions. Moreover, homogeneous 
exposure was achieved since only one implant type was used and in the majority of 
patients the same surgical technique was applied. Additionally, over 95% of operations 
were performed by 3 surgeons (CC, EM, DK), so it was expected that the learning curve 
was relatively short and when comparing three time periods (1988-1994, 1995-2001, 
2002-2007) no major differences were noticed in the complication rate, albeit not formally 
analysed. Lastly, there was a high response rate with nearly 70% of all our patients filling 
out the questionnaire and thus could be included in the analysis.
Selection bias in the selected patient group for analysis was considered to be minor. 
Reported incidences of, for instance, smoking and alcohol are comparable to numbers 
in the total Dutch population 31. Moreover, clinical outcomes were comparable to what 
was seen in previous report on the entire patient group 4. The somewhat higher incidence 
of implant loss and revisions in the current study can be considered to be due to longer 
follow-up. With a similar follow-up, the selected patient group (including patients < 18 
years of age) results in an implant loss of 8.1% of all implants compared to the 8.3% found 
in the study by Dun et al 4.
Confounding effects of age on all clinical outcomes were corrected for in univariable 
analysis by excluding patients <18 years of age. Distribution of gender in cardiovascular 
disease groups was equal; however, in multivariable analysis smoking was identified as a 
confounding factor in the relation between cardiovascular disease and revisions. A higher 
number of patients with skin disease, 19.2% versus 8.1%, was seen in the patient group 
with profound learning difficulties versus no profound learning difficulties. However, in 
multivariable analysis on time to first soft tissue reactions, hazard ratios of skin disease and 
profound learning difficulties were approximately the same as in univariable approach.
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To obtain information and identify potential risk factors in such a large group, a retrospec-
tive design was selected for the study. Obviously this design has some inherent limitations. 
A questionnaire was used in which patients were asked to report information on diagnosis 
made in the past, consequently, the data might include some inaccuracies as a result of 
this strategy. Potential information bias due to measurement errors in recall of comorbidity 
factors are expected to result in an underestimation of associations between comorbidity 
factors and complications. All missing information in the questionnaires was completed 
by a search of patient charts. Nevertheless, this design still depends on proper clinical 
documentation and an appropriate follow-up. Follow-up protocol in our centre adheres 
to strict guidelines; visits are planned at 1 week, 3 weeks and after this yearly. During all 
visits, a Holgers score is noted, whereby an appropriate follow-up is guaranteed.
Conclusion
In conclusion, several risk factors for adverse events following BAHI implantation could 
be identified in the current retrospective cohort analysis. For soft tissue reactions the effect 
of skin diseases was newly identified and negative risk factors for revision surgery were 
recognized. Furthermore, smoking was identified as a risk factor for implant loss. These 
factors should be included in patient counselling and selection of surgical and postopera-
tive procedures. Moreover the current results could be seen as a reference for upcoming 
(long-term) clinical results of new implants and advances in surgical technique, like the tis-
sue preservation technique. Developments and expected improvements in bone anchored 
hearing implants, abutments and concomitant surgical technique can be compared to the 
current results. The current study adds important data to what is available to date, as it is 
the first large series analysis on comorbidity risk factors in BAHI surgery.
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Objectives To evaluate clinical outcomes of the Cochlear™ BIA300 in the pedi-
atric population.
Study design Historical cohort study
Setting Two tertiary referral centers
Patients All patients implanted with the BIA300 from November 2011 to Janu-
ary 2014 and 17 years or younger during surgery were included in 
this cohort study.
Main outcome 
measures
Number of soft tissue reaction scores according to Holgers, local 
and systemic treatment of soft tissue reactions, revision surgeries and 
implant loss.
Results Since introduction of the BIA300, 79 children have been implanted 
in both centers. During the mean follow-up of 11.7 months per im-
plant, 15.7% of 115 implants received at least two local treatments 
for peri-abutment soft tissue reactions. Moreover, in 32 implants an 
adverse soft tissue reaction (Holgers 2 or higher) was noted at least 
once. In 28.7% of implants one or multiple revision surgeries were 
required. Implant loss occurred in 4 patients (3.5% of all implants), 
additionally, in five children the abutment had to be removed because 
of persistent soft tissue problems.
Conclusions The current study confirms good implant survival for these implants in 
pediatric patients. The number of adverse soft tissue reactions found in 
the current study resembles numbers reported on previous generation 
implants and abutments in children. However, for revision surgery (soft 
tissue revision and/or abutment change), an increase in frequency is 
noticed compared to reported results on previous generation implants 
and abutments, whether this is the result of the new implant or other 
factors cannot be concluded on the current series. The total aspect 
of the presented data are of importance in the decision making for a 
specific type of percutaneous bone anchored hearing implant.
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Introduction
The first clinical report on titanium implants in the temporal bone for anchorage of hearing 
devices dates back to 1981 1. This article reports on a two-staged surgical technique 
in unilaterally implanted, adult patients. During the follow-up of 26-46 months no major 
soft tissue complications or implant losses were reported in this article. Over the past few 
decades indications for bone anchored hearing implants (BAHIs) have extended, younger 
patients are now being implanted and new surgical techniques and implants have become 
available. More than ever, in recent years new bone conduction devices and several types 
of implants and abutments have been developed rapidly. One of the new implant systems, 
the Cochlear™ BIA300, became commercially available in 2010. By then, the first clini-
cal trial with this implant in adult patients was already conducted and soon after reported 
on 2. The six-month report showed higher mean Implant Stability Quotient (ISQ) values and 
less soft tissue reactions for the new, wider implant compared to the previous generation 
implant. The good outcomes could be confirmed in other studies 3-5 and in long term 
follow up 6, and resulted in a complete substitution of the previous generation implant in all 
new BAHI surgeries, not only in adult patients but also in the pediatric population. During 
the last few years, however, in both centers, we noticed a high incidence of soft tissue 
reactions, revision surgery and non-users in our pediatric BAHI population. It is important 
to emphasize that the first report on this novel BIA300 2, like the first clinical report 1, just 
included adult patients. This is the case in most studies reporting on clinical outcomes, since 
children are usually not included in clinical trials and smaller numbers of patients are avail-
able. However, clinical outcome evaluation in children is highly relevant, as previous series 
showed a significantly higher incidence of complications in children compared to adults 
(implant loss approximately 15%), all implanted with the previous generation implants 7. 
The aim of the current study was to verify the subjective increase of soft tissue problems in 
our pediatric BAHI population. We reviewed the results of soft tissue complications and 
implant survival in our pediatric patients implanted with this specific implant.
Methods
Patients
All patients implanted with the Cochlear™ BIA300 between November 2011 and January 
2014, and 17 years or younger during surgery were selected from our BAHI database 
and included in this historical cohort study. Patients with previous bone conduction hearing 
implant surgery on the same side were excluded. A minimum of 1 postoperative visit after 
abutment insertion (i.e. second stage surgery) had to be available. The records for this 
study spanned a 3-year period, November 2011 till October 2014. Since all medical 
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charts were reviewed at the end of this period, surgeries were at least 10 months before 
the final verification.
Surgical and postoperative procedures
Patients underwent a two-staged procedure under general anesthesia when younger than 
10 years of age; when major craniofacial abnormalities were present; or other reasons 
for osseointegration problems were anticipated. In general, time between these two 
stages was 12 weeks. All other patients underwent a single-staged procedure with direct 
placement of the abutment. In Nijmegen the linear incision technique with tissue reduction 
was used. In Birmingham, additionally both the U-shaped and dermatome incisions were 
performed. All children had their first postoperative visit a week after surgery. During this 
visit the healing cap and the gauze with antibiotic ointment was removed, inspection of 
the incision was performed and it was standard care to start local cream (steroid-antibiotic 
cream). This was followed by an appointment for sound processor fitting after 6-12 weeks 
in case of single stage surgery, and after wound healing in case of two-staged surgery 
(varying from 1 to 4 weeks). Further follow-up protocol was as follows: Birmingham: 3, 6, 
9, 12 months, followed by yearly visits; Nijmegen: 3, 9, 12 months, followed by yearly 
visits. If needed, appointments tailored to the individual clinical needs of the patients were 
available. At each visit, the degree of soft tissue reaction according to Holgers 8, or a 
description of soft tissue reactions and medical treatment were noted.
Case analysis
Data regarding patient demographics, indication for BAHI, comorbidity, surgical proce-
dures and postoperative complications were collected from patients’ medical charts. Age 
of implantation was defined as the patient age at the time of insertion of the abutment, 
i.e. age at second stage in case of two-staged surgery or age at single stage surgery. For 
patients with bilateral and sequential implantations the age at first implantation was taken. 
End of follow-up was defined as last visit to the ENT outpatient clinic within the indicated 
time frame. Main outcome parameters included soft tissue reactions classified with the Hol-
gers grading system 8; treatment given for adverse soft tissue reactions (excluding during the 
first two weeks after surgery, since this was standard care); revision surgery, i.e. soft tissue 
revision or abutment change, for soft tissue overgrowth; and implant loss. The Holgers’ soft 
grading system is scored on a 5-point scale: 0, no signs of soft tissue reaction; 1, mild 
inflammation with slight redness; 2, moderate inflammation with redness and slightly moist 
skin; 3, redness, moist skin and granulation tissue; 4, an infection for which removal of 
implant and/or abutment is needed. Holgers 2, 3 and 4 skin reactions are classified as 
adverse soft tissue reactions.
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Statistical analysis
All data was analyzed using Descriptive Statistics in the Statistical Package for Social 
Sciences (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp), version 20.0. For 
continuous variables means, standard deviations and ranges are reported; for dichotomous 
variables frequencies are reported.
Results
Baseline characteristics
Since introduction of the BIA300, 79 patients younger than 18 years have been implanted; 
27 in Nijmegen and 52 in Birmingham. In Nijmegen 10 patients and in Birmingham 26 
patients were implanted bilaterally. Except for one patient, all bilateral implantations were 
performed simultaneously. Mean follow-up per implant was 11.7 months (SD 7.7; range 
0.2-30.2). A difference in follow-up time between centers was noticed; for Birmingham 
mean follow-up was 8.7 months per implant (SD 5.1; range 0.2 – 19.6) and for Nijme-
gen 17.9 months per implant (SD 8.6; range 3.7 – 30.2). Mean age at surgery was 
9 years and 4 months. In 39 patients a congenital syndrome was present. Nine patients 
presented with childhood obesity. Other comorbidity factors were present in 27 patients; 
6 with skin disease, 2 with diabetes mellitus, and 23 with a cardiopulmonary medical 
history. Cardiopulmonary history ranged from well-controlled asthma to severe cardiac 
abnormalities or obstructive airway problems for which surgery was indicated. In most 
patients, 50 of 79, etiology of hearing loss was defined as congenital.
All patient characteristics and its division per center are shown in Table 1.
Surgery characteristics
A total of 115 implants were placed, from these, 22 implants were placed during a 
single stage procedure. In 62 implantations a linear incision was used, in 44 a u-shaped 
incision and in 9 implants a dermatome approach was selected. Soft tissue reduction was 
performed in all but 35 cases. In most of the 115 implants, a 3mm BI300 implant (n=63) 
and a 6 mm BA300 abutment (n=85) was placed at initial surgery.
All surgery characteristics and its division per center are shown in Table 2.
Soft tissue reactions
In 76 implants, soft tissue scores according to Holgers grading system were recorded at 
least once. Of these implants, 32 presented with an adverse soft tissue reaction (Holgers 2 
or higher) at least once (43.6% of implants with a Holgers notation, 27.8% of all implants). 
Out of a total of 290 Holgers observations, 55 were grade 2 or higher (18.9%). Highest 
Holgers noted in the entire group was Holgers grade 4 (2 implants). Of total of 55 implants 
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(47.8%) received at least one local treatment for a soft tissue reaction, of these, 18 implants 
(15.7%) were treated with local care at least twice. Local treatment regimens included a 
cream applied around the abutment (predominantly an antibiotic and/or steroid cream), 
silver nitrate cautery, or placement of a healing cap and gauze with antibiotic ointment. 
Systemic antibiotics were given to 14 patients in the total group, in one patient a total of 
three successive regimens were needed.
Results on soft tissue reactions for both centers are shown in more detail in Table 3.
Revision surgery
In total, 33 implants (28.7% of all 115 implants) needed revision surgery, i.e. an abutment 
change, soft tissue revision or both combined in one or multiple settings. A total of 4 
implants required only soft tissue revision (3.5%), 9 implants required only an abutment 
Table 1. Patient characteristics
Birmingham Nijmegen
Nr 
patients %
Nr 
patients %
Total patients 52 100% 27 100%
Sex Male 30 57.7% 14 51.9%
Female 22 42.3% 13 48.1%
Age at surgery Mean (SD), years 9.5 (3.9) 8.9 (3.7)
Range 4.3 – 16.5 3.8 – 17.3
Syndrome Total 29 55.8% 10 37.0%
Down 7 13.5% 0
Goldenhar/hemifacial 
microsomia
5 9.6% 3 11.1%
CHARGE 5 9.6% 1 3.7%
DeGrouchy 1 1.9% 2 7.4%
Comorbidity 
factors
Skin disease 4 7.7% 2 7.4%
Diabetes mellitus 0 2 7.4%
Childhood obesity 8 15.4% 1 3.7%
Cardiopulmonary disease 19 36.5% 4 14.8%
Type of hearing 
loss
Congenital 29 55.8% 21 77.8%
Acquired 23 44.2% 6 22.2%
Etiology of hearing 
loss
Congenital aural atresia / 
microtia
20 38.5% 17 64%
Chronic otitis media 23 44.2% 5 18.5%
Unilateral profound hearing 
loss, (all congenital)
7 13.5% 4 14.8%
Congenital middle ear 
malformation
2 3.8% 1 3.7%
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change (7.8%) and 20 implants required both soft tissue revision and an abutment change 
(17.4%). Out of the total of 29 abutment changes (25.2%), a new abutment was placed 
because of soft tissue problems (n=27) or abutment loss (n=2), with a longer abutment in 
26 cases. In 27 implants, one revision was conducted, for four implants a second revision 
was needed and two implants required three revisions. Time to first revision was mean 7.9 
months (SD 6.1; range 1.2-21.9). In 16 patients one revision under general anesthesia 
was required (including 5 bilateral revisions in one setting), three patients required two revi-
sions under general anesthesia and one patient needed revision under general anesthesia 
three times.
Results on revision surgery for both centers are shown in more detail in Table 3.
During the last few years we noticed a preference for longer abutment placement and 
performing the initial surgery without soft tissue reduction (i.e. tissue preservation) in one of 
the two centers. When comparing the results on revision surgeries in Birmingham between 
the different surgical strategies, there seems to be better results for the patients with longer 
abutments and/or tissue preservation during initial surgery. Less soft tissue revisions are 
noticed after soft tissue preservation; furthermore, both soft tissue revision and abutment 
change are less frequent after placement of the 9mm abutment during initial surgery. 
However, some (minor) differences in patient characteristics are also noted between these 
groups, for example more children with a positive cardiopulmonary history in the soft tissue 
reduction group.
Results of revision surgery in different initial surgical strategies are shown in Table 4.
Table 2. Surgery characteristics
Birmingham Nijmegen
Nr
implants %
Nr
implants %
Total implants 78 100% 37 100%
Stages Single stage 14 17.9% 8 21.6%
2-staged 64 82.1% 29 78.4%
Surgical technique Linear incision 25 32.1% 37 100%
U-shaped 44 56.4% 0
Dermatome 9 11.5% 0
Soft tissue reduction Yes 45 57.7% 35 94.6%
No 24 30.8% 2 5.4%
Dermatome 9 11.5% 0
Implant 3mm 33 42.3% 30 81.1%
4mm 45 57.7% 7 18.9%
Abutment length at first 
implantation
6mm 49 62.8% 36 97.3%
9mm 29 37.2% 1 2.7%
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Implant loss
Implant loss occurred in 4 patients (3.5% of all implants), in three patients within 2 months 
of implantation, in one patient after 2 years of follow up. Implant loss could not be linked 
directly to soft tissue problems in these patients; one patient however was treated with local 
treatment and systemic antibiotics multiple times in the months prior to the implant loss. 
Table 3. Soft tissue outcomes
Nr of
events
Birmingham Nijmegen
Nr
implants
Percentage of 
total implants 
Birmingham 
(percentage of 
implants with 
Holgers notations)
Nr
implants
Percentage of 
total implants 
Nijmegen 
(percentage of 
implants with 
Holgers notations)
Number of adverse 
soft tissue reactions
0 17 21.8% (42.5%) 27 72.9% (75%)
1 13 16.7% (32.5%) 7 18.9% (19.4%)
2 6 7.7% (15%) 2 5.4% (5.6%)
3 2 2.6% (5%) 0
4 1 1.3% (2.5%) 0
5 1 1.3% (2.5%) 0
Number of local 
treatments
0 49 62.8% 11 29.7%
1 20 25.6% 17 45.9%
2 5 6.4% 3 8.1%
3 1 1.3% 3 8.1%
4 2 2.6% 3 8.1%
5 0 0
6 1 1.3% 0
Number of 
systemic 
treatments
0 57 73.1% 36 97.3%
1 19 24.4% 1 2.7%
2 1 1.3% 0
3 1 1.3% 0
Revisions 
(abutment change 
and soft tissue 
revision)
0 53 67.9% 28 78.4%
1 19 24.4% 8 21.6%
2 4 5.1% 0
3 2 2.6% 0
Revision under 
general anesthesia
0 56 71.8% 32 86.5%
1 16 20.5% 5 13.5%
2 4 5.1% 0
3 1 1.3% 0
Abutment removed 0 70 89.7% 37 100%
1 8 10.3% 0 0%
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Additionally, one patient presented with in intruded abutment after trauma (no implant loss) 
and needed surgery under general anesthesia for a new, longer abutment. In 5 patients the 
abutment was removed because of soft tissue problems in order to let the skin heal properly 
(3 patients with bilateral implants, both abutments were temporarily removed), from these, 
1 patient was given a new abutment after 2.5 months. In the other 4 patients the abutments 
were not replaced before end of follow-up, a mean duration of approximately a year. 
Hearing rehabilitation was established with a bone conduction device on a softband or 
headband during the months of skin healing in these children.
Discussion
Principal findings
The aim of the current study was to verify a subjective increase of soft tissue problems in 
our pediatric BAHI population since the introduction of the BIA300. During mean follow-up 
of 11.7 months, 18 of 115 implants (15.7%) received local treatment for a soft tissue 
reaction on at least two occasions and in 32 implants (43.6% of implants with a Holgers 
notation, 27.8% of all implants) an adverse soft tissue reaction (Holgers 2 or higher) was 
noted at least once. In 28.7% of implants one or multiple revision surgeries were required, 
additionally, in five children the abutment had to be removed because of persistent soft 
tissue problems.
Table 4. Soft tissue outcomes - soft tissue reduction and abutment length during initial surgery (Birmingham) 
(excluding dermatome technique)
Total nr
implants
Soft tissue
revision
Abutment
change
Nr
implants %
Nr
implants %
Soft tissue reduction, 6mm abutment 
(follow-up mean 8.6 months, SD 4.7)
35 13 37.1% 16 45.7%
Soft tissue reduction, 9mm abutment 
(follow-up mean 6.8 months, SD 5.9)
10 2 20.0% 2 20.0%
Without soft tissue reduction, 6mm 
abutment (follow-up mean 9.2 months, SD 
6.1)
8 1 12.5% 3 37.5%
Without soft tissue reduction 9mm 
abutment (follow-up mean 7.7 months, SD 
4.5)
16 0 0
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Comparison with other studies
Implant loss occurred in 3.5% of all implants in the current study. This is much less compared 
to what is described in literature for previous generation implants in children 7,9-12. The 
reduced frequency of implant loss for the new generation implant was expected based on 
the results of implant stability studies in adult patients, seen in the clinical trial by Dun et al 
2. Implant stability studies on the BIA300 have also been conducted in pediatric population 
by McLarnon et al 13, Marsella et al 14 Felton et al 15 and Mierzwinski et al 16. These studies 
report favorable results on implant stability for the new implant. Soft tissue outcomes were 
overall good, with only few adverse soft tissue reactions. The study by Mierzwinski et al 
focused additionally in more detail on soft tissue reactions using dermatome technique 
and single-staged surgery. In a total of 68 postoperative observations on the BIA300 with 
a follow-up of approximately 5 months post-surgery, this study recorded five adverse soft 
tissue reactions, i.e. Holgers grade ≥ 2 (7.4%). This percentage of soft tissue reactions 
is lower than what we found in our study. However, definitive conclusions for soft tissue 
outcomes are hampered due to the relatively small inclusion numbers and short follow-up.
If we compare the current results to reports from Birmingham and Nijmegen on soft tissue 
outcomes in previous generation implants, some differences are noticed. In a cohort on the 
previous generation implant and abutment by McDermott et al. 9, 24 out of 182 patients 
(13.2%) were considered to have adverse soft tissue reactions. Adverse was defined as 
a soft tissue problem requiring repeated visits to clinic for wound care, repeated silver 
nitrate cautery, or antibiotic therapy. Since we have chosen a different outcome measure 
in the current series, comparison of results is difficult. When we compare the number of 
patients who received multiple treatments in the current series with the outcome chosen 
by McDermott et al, no major differences are observed though. Regarding the outcome 
measure soft tissue revision, 7.7% of children required a skin revision in the series by 
McDermott at all, compared to 20.9% for both centers found in the current series (24.4% 
for Birmingham only in the current series). Longer abutment placement was needed in 
8.2% in the previous series, compared to 25.2% in the current for both centers (28.2% 
for Birmingham only in the current series). This comparison is complicated by different 
follow-up duration, in the series by McDermott et al follow-up time was 4 to 13 years. 
This longer follow-up would, however, be expected to result in higher number of soft tissue 
reactions and revision surgeries.
De Wolf et al. 12 evaluated the results of the linear incision technique with previous gen-
eration abutments in the pediatric population. Adverse soft tissue reaction were recorded 
in 22.3% of all Holgers observations in this series, this is comparable to the number in the 
current series (18.9% adverse soft tissue reactions of all 290 Holgers observations). 14 of 
129 patients (11%) needed revision surgery (soft tissue revision) in the study of de Wolf et 
al. Longer abutments were not discussed in this series as these were not yet available. In 
the current series, 28.7% of implants needed a soft tissue revision and/or longer abutment 
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because of soft tissue problems for both centers (21.6% for Nijmegen only in the current 
series). The same remark has to be made for this study regarding follow-up time; a much 
longer follow-up was available in the study by de Wolf et al. compared to the current study.
Soft tissue reactions are not easily to directly compare with previous studies, but they 
do not appear to have increased. Regarding revision surgery, an evident increase is 
observed. Whether this increase is a result of the new implant design or other causes, for 
example new surgical techniques, is not clear. Availability of longer abutments may be 
an explanatory factor for the increase in revisions (abutment changes). Nowadays many 
abutment changes are frequently carried out in the outpatient clinic, and the reduced need 
for general anesthesia may minimize reservations for revision surgeries. However, in many 
children an abutment change in the outpatient clinic will not be an option and excessive 
skin overgrowth can make this even more difficult in this setting.
The reported patient characteristics in the current study, do not differ much from what 
is described in the aforementioned studies. BMI, however, was not documented in our 
previous studies, so an increase in childhood obesity in general as explanatory factor 
cannot be excluded.
An extra remark has to be made on the sort of soft tissue reactions we noticed during 
the past few years. Previously, the surrounding soft tissue had complications for which local 
treatment was often adequate. Nowadays, more extensive overgrowth of the soft tissue 
over the abutment itself is noticed, while the skin often looks healthy and not particularly 
inflamed. In this case less response to medication was seen and revision surgery was 
needed to allow the sound processor to attach.
Strengths and limitations
The current study is the first report on soft tissue complications in a larger, multicenter series 
of the BIA300 in the pediatric patient population. The study included surgeries during the 
last three years, from which all records could be retrieved and the quality of information 
in the patient files was considered good. Retrospective review of charts is, however, well 
known to have problems with missing information. Another important limitation of the study 
was the mixed patient group. Between the two centers evident differences in patient and 
surgical characteristics were observed. Additionally, differences in postoperative protocol 
and treatment regimens were noticed. The evident difference in follow-up could be partly 
explained by the good attendance to the standard one-year visit in Nijmegen, where in 
Birmingham patients often only attend the standard one-year visit when having problems. 
The differences in patient characteristics might additionally be an important factor in the 
observed difference in soft tissue outcomes between the two centers, with results for the 
center including patients with less comorbidities being relatively more favorable. Moreover, 
the documentation of soft tissue reaction was in many cases unfortunately not according 
to the Holgers grading system. As a result we included other outcome measures as well, 
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such as the number of treatment regimens for local and systemic treatment. The absence of 
a uniform outcome reporting standard for all patients was a limitation in the current study, 
as well as the absence of a uniform standard in surgical strategy, i.e. linear incision versus 
U-shaped and dermatome and tissue reduction versus tissue preservation.
The differences noticed in the different surgical strategy groups, i.e. 6 or 9 mm abutment 
and soft tissue reduction at initial surgery, although large in numbers, should be interpreted 
carefully. Some differences were already noted in the recorded baseline characteristics of 
these patients and a confounding by indication in these results cannot be excluded.
Recommendations
For future research a prospective study would be warranted to give a more accurate 
insight in the discussed clinical outcomes, especially with respect to conclusions on results 
of initial placement of longer abutments and tissue preservation, as shown in Table 4. The 
authors would emphasize the importance of correct documentation of soft tissue reactions 
according to the Holgers grading system and full documentation of local and systemic treat-
ments. This standardized evaluation is essential when new implants come to the market. 
As stated already in the introduction, since children are known to suffer significantly more 
from soft tissue problems, these clinical results should be closely monitored and reported. 
The increased number of soft tissue problems, especially revision surgeries, consequences 
of more visits to the outpatient clinic, and in some cases even lifelong treatments to soft 
tissue around the percutaneous abutment result in a higher burden rate for the patient, 
family and clinician, which should be taken into account. Specifically in the pediatric 
population, this might have a huge impact on time away from school and time way from 
work for many parents and caretakers. Moreover, when soft tissue problems become even 
worse, this can result in non-usage of the bone conduction device as seen in 5 children 
in this study. In these cases it may be necessary to remove the abutment and choose an 
audiological inferior solution such as the sound processor (or bone conduction device) on 
a softband or headband. Although in purpose a temporarily solution it turned out these 
patients were satisfied with this inferior solution in terms of audiological outcomes. It is 
important to realize that the kind of currently reported problems (skin overgrowth, removal 
of abutment, transfer to softband solutions) have not been reported before. Finally the soft 
tissue problems we noticed in the current study emphasize another important limitation of 
the BI300 implants, namely the incompatibility with other abutment systems. The choice 
of an abutment with a different shape or longer length other than the previously existing 
maximum 9 mm length in may offer alternative solutions to skin reduction surgery for these 
children with skin problems. Longer length abutments are currently only available with a 
hydroxyapetite coating which has not been fully evaluated in children
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Conclusion
In summary, soft tissue reactions seem to be comparable to previous generation implants 
in the pediatric population. This in contrast to the adult population where less soft tissue 
reactions are noticed with the Cochlear™ BIA300 6. Revision surgery appears to be 
increased in the past few years. The continued peri-abutment skin problems and increased 
revision surgeries would result in more visits and a higher burden for the patient, family 
and the health-care system. However, as stated before, whether this is the result of the new 
implant or other factors cannot be concluded on the current series. Regarding stability, the 
BIA300 implant was shown to be a very stable implant system in this pediatric patient 
population, with an implant loss rate of 3.5%. Additional large and preferably prospective 
studies are needed in order to draw more firm conclusions in this specific and vulnerable 
population of children.
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Objectives This study aims to demonstrate the differences in spatial hearing 
between bilaterally and unilaterally fitted bone conduction devices 
(BCDs) in children with bilateral conductive hearing loss (BCHL).
Design Both spatial discrimination and sound localization abilities were 
investigated. Spatial discrimination was measured with the minimum 
audible angle (MAA) test. Sound localization abilities were measured 
with a localization test. This test provides more detailed information 
about directional hearing, by presenting the stimuli at randomly se-
lected locations in a dark environment and by roving stimulus levels. 
Ten children with congenital BCHL and one child with acquired BCHL 
participated.
Results Both spatial discrimination and sound localization scores improved 
with bilateral BCDs compared to the unilaterally aided conditions. 
However, discrepancies were found between both tests. While 
spatial discrimination showed good results in (nearly) all children, 
most children demonstrated sound lateralization rather than sound 
localization during the localization test. The child with acquired BCHL 
showed near-normal sound localization. Furthermore, it was noticed 
that children who were listening with one BCD did not use monaural 
(proximal sound level) cues for sound localization.
Conclusions Children with BCHL demonstrate a significant improvement in their 
sound localization abilities when listening with two BCDs compared 
to listening with a single BCD. Because both spatial discrimination and 
sound localization behaviour was tested, it could be demonstrated 
that sounds were lateralized rather than localized. The comparison 
between the two tests provides more insight in directional hearing 
capabilities of children with BCHL who are listening with BCDs.
61
Introduction
Bone conduction devices (BCDs) are one of the treatment options for rehabilitating conduc-
tive hearing loss 1,2. For patients with bilateral conductive hearing loss (BCHL), application 
of bilateral BCDs has shown to be beneficial compared to application of a unilateral BCD 
3-6. Several reviews suggested that more studies are needed to provide evidence on the 
advantage of bilateral BCD application over a unilateral BCD 7,8. Moreover, bilateral ap-
plication is not standard of care in all clinics and in some countries not (fully) reimbursed 9.
The advantage of bilateral over unilateral application of BCDs is related to bilateral 
input and potentially to binaural hearing (i.e. processing of binaural cues) 10,11. The latter 
depends on accurate processing of interaural differences in level (ILDs) and timing (ITDs). 
Testing and demonstrating the accuracy of processing binaural cues can be done using an 
operational tool like a sound localization test 12. Unfortunately, the set-up of sound localiza-
tion tests is not standardized. They range from setups with a few loudspeakers positioned in 
the azimuth plane 600 apart 13, to setups were stimuli can be presented from many different 
positions 14,15. Furthermore, the setups differ in: i) response method, ii) stimulus bandwidth, 
iii) stimulus duration, iv) loudspeaker visibility, v) sound level roving.
Several studies have reported good results on subjective benefit of bilateral BCDs and on 
effective daily use of both devices, both in adult and paediatric patients 16-18. Audiometric 
evaluation of bilaterally fitted BCDs demonstrated improved speech recognition in noise 
with spatially separated speech and noise sources, and improvements in sound localization 
3,5,6,19-22. Only three of these studies were performed in children 4,6,20. The advantage of 
bilateral BCDs was less pronounced in children with congenital BCHL compared to adults 
4. In general, in case of hearing with bilaterally applied BCDs, limited transcranial attenu-
ation of bone conduction vibrations results in concomitant stimulation of the contralateral 
cochlea (cross-stimulation) 23. This could affect accurate perception of ILDs and ITDs, and 
consequently hamper proper binaural hearing. However, literature has implied that patients 
with congenital BCHL can detect ILDs and ITDs 24
The aim of the present study was to strengthen the evidence on the added value of bi-
lateral BCDs over unilateral BCDs in children with BCHL by evaluating spatial hearing. By 
including both a spatial discrimination and a sound localization test we aim to demonstrate 
whether bilaterally fitted children can indeed utilize binaural cues.
Material And Methods
Patients with bilateral conductive hearing loss (BCHL)
We identified 33 children (implanted at 6-16 years) with BCHL and bilateral percutaneous 
bone conduction hearing implants from our clinical database. All children had at least 
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6 months experience with two BCDs. For the directional hearing tests children with a 
performal IQ ≤ 80 and/or poor co-operation during previous testing (n=6) and temporarily 
using just one BCD (n=5) were excluded. We could not find up-to-date contact details 
for three children. Finally, we invited 19 children to participate in the hearing tests, and 
parents or caretakers of 11 children agreed to participate. Four of these 11 children took 
part in a previous study on directional hearing 6.
Table 1. Demographic and audiological characteristics of the participating children. PTA4 = pure tone 
averaged of 0,5-1-2-4kHz, AD = right, AS = left, AC = air-conduction, BC = bone-conduction, C = con-
genital, A = acquired, X = no data, Time is indicated by months (M) and/or years (Y).
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TA
4
 A
S 
B
C
P1 F 7Y 4Y 3M** 1Y C Atresia III Goldenhar Baha 4 59 1 74 5
P2 F 7Y 4Y 4M** 1Y 11M C Ossicular chain 
anomalies
Goldenhar Baha 4 59 -1 58 8
P3 M 7Y 4Y 5M** 1Y 5M C AS Atresia III
AD Atresia I
Goldenhar Divino 32 -3 61 10
P4 F 7Y 5Y 1Y** 4Y C Atresia IIa De Grouchy BP100 60 4 60 3
P5 F 8Y 4Y 7M** 5Y C Atresia III Treacher Collins Divino 75 15 70 13
P6 F 8Y 7Y 1y 3M** 4Y C Atresia iII Treacher Collins BP100 64 0 59 -
P7 M 9Y 4Y 1y 9M** 4Y C Atresia III 
(reconstruction 
microtia ADS 
+ external 
auditory canal 
AD)
BP100 34 -1 70 6
P8 F 14Y 6Y 9M** 2y 12M C Atresia III BP100 61 4 64 8
P9 M 15Y 7Y 2M** 7Y**** C Atresia III BP100 53 3 68 10
P10 M 16Y 6Y 1y 7M 6Y**** C Atresia IIa Divino 54 3 58 0
P11* F 16Y 11Y 8Y 8Y A Chronic otitis 
media
Divino 44 10 66 10
* child P11 had acquired bilateral conductive hearing loss and used air-conduction hearing aids up till 
age 8
** used one BCD on (soft)band before implantation (alternately right/left ear or medially)
*** 2-phased bilateral simultaneous percutaneous bone implant surgery
****rehabilitation elsewhere, referral at this age to our center for percutaneous bone implant surgery
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Of the 11 children, one had an acquired BCHL while ten children had congenital BCHL 
due to microtia/aural atresia. Table 1 presents the characteristics of the 11 participants. 
Congenital BCHL due to bilateral microtia/atresia is a relatively rare condition with an 
incidence of 1:50.000 newborns 25. Hence, it is important to provide these patients and 
their caretakers with evidence on outcomes on hearing rehabilitation, like spatial hearing.
Age and sex distribution of the 11 participants were comparable to those of the whole 
group of 33 BCHL children. The whole group contained relatively more acquired cases (6 
out of 33) than the test group (1 out of 11). All children in the test group used their BCDs 
intensively; six days a week (N=1), and seven days a week (N=10). Children used their 
BCDs either 8 to 12 hours a day (N=2) or more than 12 hours a day (N=9). All children 
were either satisfied (N=4) or very satisfied (N=6) with their devices. The answer of one 
child is missing. A slightly lower usage time was noted in the whole group (N=2 out of 29 
usage 6 days a week and N=3 usage less than 6 days a week; N=3 usage less than 
8 hours a day and N=9 usage 8 to 12 hours a day). Additionally, as expected with an 
exclusion criterion of IQ<80, the education level was higher in the test group compared to 
the whole group of 33 children.
The hearing tests were performed with the child’s own devices (either Baha Divino, 
Baha BP100, or Baha 4; Cochlear BAS, Gothenburg). All BCDs were set in auto- or 
omnidirectional microphone mode and tests were performed with the child’s own habitual 
volume settings. The BCD conditions were randomized: unilateral BCD on the left side, 
unilateral BCD on the right side and bilateral BCDs.
This study was conducted in accordance with the Declaration of Helsinki and approved 
by the local ethics committee.
Minimum Audible Angle (MAA) Test
Ten out of eleven children were tested with the MAA test. This test measures the smallest 
difference in the position of two sound sources in the horizontal plane, in the frontal position 
2,26,27. A broadband noise (BB noise; bandwidth 0.5-20 kHz, 500 ms duration) was pre-
sented at three randomly selected sound levels of 55, 60, 65 dB SPL. The sound level was 
roved to minimize effects of head shadow as a monaural localization cue 28. The MAA test 
was carried out in a sound attenuated booth; the children were positioned in the centre of 
an arc with a 1-m radius. After a practice run, the loudspeakers were positioned at -900 (far 
left) and +900 (far right). Stimuli were presented at random by one of the two loudspeakers 
and the child was asked to identify the loudspeaker. After four correct responses out of 
four stimuli, the loudspeakers were repositioned to -600 and +600. This procedure was 
continued for positions at 300, 150, 100 and 50. In case of an incorrect answer, a series 
of four stimuli was presented in the previous speaker position. The final score was defined 
as the smallest angle at which a series of four stimuli was correctly identified in two out of 
three runs. No feedback was given during the measurements.
64
Sound localization test
Sound localization was tested in all eleven children, but the data of only eight children 
could be used for analysis. The localization experiment was conducted in a dark and 
sound-attenuated room. Children were seated in the centre of the room. Stimuli were 
delivered from loudspeakers at a distance of 1.15 m from the child. Stimuli were presented 
at different azimuth positions, ranging from -750 (left) to +750 (right). The broadband (BB; 
bandwidth 0.5-8kHz) noise bursts with a duration of 150 ms, were at random presented 
from selected speaker locations, at three random sound levels of 50, 60 or 70 dB SPL. 
A complete trial comprised 36 stimuli. The response task was a head movement towards 
the noise source. Head movements were recorded with the magnetic search-coil induction 
technique 29, which has been shown to be adequate for testing normal hearing children 30 
and hearing impaired children 31.
Each child participated in a short practice session at the beginning of the experiment. 
During the measurements, children were only corrected when distracted or when they were 
in an incorrect seating position; no other feedback was given. The unilateral and bilateral 
aided conditions were tested in a random order. The perception of ILD and/or ITD was 
studied separately by testing the four oldest children with an additional set of stimuli in the 
bilateral BCD condition only. This set included 60 stimuli, BB (12 stimuli at 60 dB SPL), 
low-frequency (bandwidth 0.5 to 1.5 kHz; 12 stimuli at 60 dB SPL), and high-frequency 
noise bursts (bandwidth 3 to 20 kHz; 36 stimuli at roved sound levels: 50, 60 and 70 dB 
SPL). The 60 stimuli were presented interleaved.
 n = 33 
Children identified in database 
n = 19 
Children invited to participate in 
directional hearing tests 
n = 11 
Children participated in 
directional hearing tests 
n = 11 
Children participated in 
localization test 
n = 10  
Children participated in MAA test 
n = 8  
Data available for analysis 
n = 6 performal IQ < 80 or poor 
cooperation in previous study 
n = 5 (temporarily) use of no or 
1 BCD  
n = 3 no contact information 
available 
n = 8 did not agree to 
participate 
n = 3 insufficient data available 
(less than half of responses 
reliable, criteria see text) 
Figure 1. Flowchart of the children with BCHL eventually participating in the experiments.
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Localization of visual stimuli
Some of the younger children (7-8 years old) had difficulties with performing and/or com-
pleting the sound localization task. To investigate whether this was related to their impaired 
hearing or related to understanding and execution of the task, a visual localization task 
was additionally performed in three of the younger children (P1, P3 and P5) by replacing 
the auditory stimuli by visual stimuli at the position of the loudspeakers. A series of 36 visual 
stimuli (duration 150 ms) was presented with light-emitting diodes.
Data analysis
Spatial discrimination (MAA) and sound localization data were analysed for each child 
and each condition separately. Data of the localization test for three individual subjects 
(P6, P10 and P11) are shown as stimulus-response plots in Figure 2. Because the data of 
the bilaterally aided condition was not uniformly distributed, linear regression analysis (as 
done usually) was not feasible. Consequently, linear regression was only carried out for 
the unilaterally aided conditions In these conditions, the bias is expected to be towards the 
site of the BCD, consequently negative when the left BCD is active, and positive when the 
right BCD is active. The MAE is the mean of all the (absolute) errors, in degrees, between 
the azimuth response and the position of the target loudspeaker. This measure does not rely 
on regression analysis and can thus be used for both the unilateral and bilateral conditions.
We adopted the following criteria for analysing the localization data i) each trial begins 
with a stable head position between -200 and +200, ii) head movement starts at least 150 
ms after stimulus onset and iii) head movement ends with a stable head position for at least 
250 ms. The dataset of a condition was included for further analyses when at least half of 
the responses were reliable. These criteria resulted in including only 8 out of 11 datasets 
for analysis.
Further analysis of the localization data in the unilateral aided condition (left and right 
side only) was conducted to evaluate the possible contribution of the head shadow effect 
(i.e. usage of sound levels as a localization cue, despite of roving) in comparison to 
the actual target azimuth 28,32. A standardized multiple linear regression analysis was 
performed to separate the contribution of the azimuth stimulus coordinates and of the 
stimulus intensity at the BCD position (i.e. head shadow effect) on the azimuth response. 
Normal hearing listeners rely on the actual azimuth coordinates as a cue and consequently 
present with an azimuth coefficient around one and a proximal sound level coefficient (i.e. 
the coefficient for the stimulus intensity at selected BCD) close to zero. A proximal sound 
level coefficient close to one with an azimuth coefficient around zero illustrates the listener’s 
localization abilities rely on perceived sound level (using head shadow cues). These data 
were compared to those of adult normal hearing listeners and patients with single sided 
deafness from a previous study 32.
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Data analysis was done using Matlab (the MathWorks) and Statistical Package for 
Social Sciences (IBM SPSS Statistics for Windows, Armonk NY; IBM Corp, Version 22).
Results
Bilateral BCDs improve spatial discrimination of sounds and 
directional hearing
In Table 2 the outcomes of the spatial hearing tests are presented. Some of the younger 
children could not be tested in all conditions. Both the MAA outcomes and the sound local-
ization outcomes show a clear improvement when listening with two BCDs as compared 
to listening with one BCD (paired samples t-test MAA p<0.001). In 8 out of the 10 tested 
children, the MAA improved from 600-900 in one of the unilateral conditions to ≤150 in the 
bilateral BCD condition. Only one child (P5) did not demonstrate an improvement when 
listening with two BCDs; the MAA was 900 in all conditions. Surprisingly, in the unilateral 
conditions of the MAA, this subject did not perceive all stimuli at the aided side, in contrast 
to the other children. The localization data of this child were not included in the analysis, 
due to a small number of reliable data points. Also, this child was only tested in the bilateral 
condition.
Table 2. The minimum audible angle (MAA), bias and mean absolute error (MAE) results of all children 
(P1 – P11) for the unilateral aided left, unilateral aided right and bilateral conditions with BB stimuli. All 
measures are expressed in degrees.
Unilateral Left Unilateral Right Bilateral
MAA Bias MAE MAA Bias MAE MAA Bias MAE
P1 90 6 68 90 37 61 15 N.A. 38
P2 15 - - 60 - - 5 N.A. -
P3 90 -59 66 90 63 67 15 N.A. 51
P4 90 - - 90 - - 10 N.A. -
P5 90 - - 90 - - 90 N.A. -
P6 90 -52 54 90 49 55 5 N.A. 19
P7 - -28 58 - - - - N.A. 53
P8 90 -65 72 30 81 83 5 N.A. 28
P9 90 -32 51 90 39 55 30 N.A. 36
P10 15 -31 46 90 61 69 5 N.A. 45
P11* 60 -42 52 90 48 52 10 N.A. 10
* acquired conductive bilateral hearing loss
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Figure 2 shows exemplary stimulus-response plots for three listeners with distinctive re-
sponse patterns (P6, P10 and P11), for BB stimuli. Responses of the three sound levels were 
pooled. The bias and MAE are indicated when appropriate. Stimulus-response plots for 
both the unilateral BCD and the bilateral BCDs conditions are presented. The localization 
abilities in the unilateral BCD conditions are clearly impaired. In the unilateral condition, 
stimuli are mainly perceived at one location. For example in child P6, the bias in the 
unilateral left condition is -520 and in the unilateral right condition 490. An exception is the 
unilateral BCD-left condition of P10, which shows a different response pattern. This was the 
only child that reported a preference for the left BCD when using only one BCD.
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Figure 2. Sound-localization stimulus-response plots for children P6, P10 and P11. Responses of the three 
sound levels (50, 60 and 70 dB SPL) are pooled and plotted for BB noise bursts in the unilateral left (left col-
umn), unilateral right (middle column) and bilateral (right column) BCD condition. P6 and P10 demonstrate 
lateralization of stimuli in the bilateral BCD condition while P11, the only patient with acquired bilateral 
conductive hearing loss, demonstrates good localization abilities. MAE = Mean absolute error, in degrees.
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In the bilateral aided condition, P6 and P10 demonstrated bimodal response patterns 
reflecting sound lateralization and not localization behaviour. These two children were 
able to discriminate left and right stimuli, but they could not identify the correct sound loca-
tion. Patient P11 with an acquired BCHL does seem to be able to localize in the bilateral 
aided conditions, since the majority of data points lie along the diagonal and yielded a 
small thus profitable MAE of 10°. Localization performance of P11 (gain = 0.91, r2 = 
0.93, bias -4.5) is close to that of normal hearing children (gain = 0.91, r2 = 0.97, bias 
7.7°) 30. The results of this child indicate that it is possible to process binaural cues properly 
when listening with two BCDs.
In Figure 3 the MAE of the bilateral aided condition is plotted against the MAE in both 
unilateral conditions. Each data point represents one child. The aided left condition is 
marked by black circles and aided right by white circles. The three children (P6, P10, P11) 
of Figure 2 are indicated. The asterisk represents the child with an acquired BCHL (P11). 
The bold black line represents the mean of normal-hearing controls and the grey area 
illustrates ±2 standard deviations 32. In this figure all data points are above the diagonal, 
meaning that the MAE is smaller (better) in the bilateral condition than in the unilateral 
conditions. However, only child P11 is within the normal range (grey area). In the unilateral 
conditions (vertical axis), generally, spatial discrimination was poor (MAE > 500) with an 
obvious bias towards the side with BCD (see Table 2; bias generally > 0 degrees for the 
unilateral right condition and < 0 degrees for the unilateral left condition). Patient P7 and 
P10 showed minimal improvement in the bilateral aided condition compared to aided left 
condition (Figure 3, data point close to the diagonal). A significant difference between the 
MAE unilateral aided left (58.3°) and right (63.1°) to the bilateral aided (35°) condition 
was found (paired t-test, p = 0.002; p = 0.001).
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Figure 3. Sound localization test: Mean abso-
lute error (MAE) in degrees. The unilateral aided 
left (black circles) and unilateral aided right (white 
circles) condition are plotted against the bilateral 
condition, for broad band (BB) stimuli. Data points 
from the children depicted in Figure 2 (P6, P10 and 
P11), are indicated in the figures. Also, average lo-
calization scores (vertical black lines) ± 2 standard 
deviations (grey area) of normal hearing listeners 
are shown. Asterisk (*) indicates the only patient 
(P11) with acquired BCHL.
**P7 was not tested in the aided right condition, 
hence, one less data point than in the aided left 
condition is plotted.
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The four oldest children (age ≥ 14y, P8-P11) were additionally tested on their sound 
localization abilities using broad-band, low-pass and high-pass noise bursts interleaved, 
to study the effective use of ILDs and ITDs separately. No major effect is observed for 
these participants in their stimulus-response patterns when stimulated with low-frequency, 
high-frequency and broadband noise bursts. Formal statistical testing was not performed 
due to small sample size.
Proximal sound level cues
Further analysis was carried out to quantify the contribution of the head shadow effect when 
localizing with one BCD. The results are shown in Figure 4. Each data point represents 
one listening condition (aided left condition = black circles; aided right condition = white 
circles). The grey square indicates scores for normal-hearing listeners with an azimuth coef-
fi cient around one and proximal sound level coeffi cient close to zero, indicating optimal 
use of azimuth information and not relying on level cues. The black line schematically 
represents previously reported results from patients with long-term unilateral hearing (second 
ear deaf, single-sided deafness or SSD) 32. These patients effectively used sound level 
cues for localization. In Figure 4 the data of the children in the unilaterally aided condition 
scatter mainly around a proximal sound level coeffi cient and an azimuth coeffi cient of 0 
to 0.5. These low coeffi cients indicate that, in contrast to the SSD patients, the studied 
children with BCHL listening with one BCD do not use monaural cues.
Visual condition versus hearing condition
Figure 5 demonstrates accurate localization of visual stimuli in two of the youngest children 
(P1 and P3) and therefore demonstrates that the inaccurate localization of auditory stimuli 
is related to impaired hearing abilities, and not to limitations of understanding and perform-
ing the test.
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Figure 4. Proximal sound level coeffi cient (y-axis) 
plotted against azimuth coeffi cient (x-axis) of unilat-
eral aided left (black circles) and unilateral aided 
right (white circle) conditions for broadband (BB) 
stimuli in all tested patients. Grey coloured square 
is a schematic representation of the results from un-
aided SSD patients; 32. Children from fi gure 2 (P6, 
P10 and P11) are indicated. Asterisk (*) indicates 
the only acquired hearing loss patient (P11).
** A partial correlation analysis was performed to 
dissociate the potential contribution of the proximal 
sound level from the actual stimulus location.
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Discussion
This study demonstrates the importance of bilateral application of BCDs in children with 
BCHL. When fitted with one BCD, all children had great difficulty in discriminating hori-
zontal sound positions. In this condition the majority of children had a minimum audible 
angle > 600. In the sound localization test, children perceived the stimuli mainly at one 
position, on the aided side. When fitted with both BCDs, spatial discrimination, as well 
as directional hearing, improved. However, directional hearing in the bilaterally aided 
condition can be characterized as ‘lateralization’ instead of ‘localization’. Bilaterally fitted 
children can distinguish sounds coming from left or right side, but they cannot indicate 
the exact sound source location. The results from the localization test were validated with 
a visual localization test in the two youngest children (P1 and P3). This visual control test 
demonstrated that visual stimuli were correctly localized, indicating that the children did not 
experience problems with the test procedure, so poor scores on the sound localization test 
indeed relate to poor sound localization abilities.
The variation in proximal sound level coefficients in the unilateral aided condition (Fig. 
4) indicates a different behaviour compared to subjects with single-sided deafness 32. In 
contrast to SSD, children with microtia and/or aural atresia do not have access to spectral 
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(pinna) cues due to their ear anomaly. Also, head shadow induced sound level cues were 
hardly used. Hence, our data strongly support the importance of a second BCD for patients 
with BCHL to enable optimal directional hearing. Although the main benefit is improved 
lateralization rather than exact localization, the second BCD is beneficial, as sound lo-
calization with one device is absent. Especially promising is the good sound localization 
ability with two BCDs of patient P11 (best performer), with almost normal results. This 
child was the only child with acquired BCHL, suggesting that binaural experience might 
be beneficial. The worse localization results in the congenital cases might indicate that 
a sensitive period for the development of binaural hearing exists. Bosman et al. (2001) 
however, found good localization in a group of adults with bilateral conductive or mixed 
hearing loss using two BCDs, with limited differences between acquired and congenital 
onset. These results indicate that the brain is plastic and not in line with our results. Further 
research on these differences seems indicated.
Another interesting finding is the good localization ability of P10 in the unilateral BCD-left 
condition. This was the only child reporting a preference for using the left BCD over the 
right BCD for the unilateral condition. This child was initially, before implantation, fitted with 
a BCD on a softband on the left side, whereas all other children alternated BCD usage 
between left and right side.
Earlier studies have also shown benefits of bilateral BCDs and effective daily use of both 
devices 16,17,18. Since the current evaluation only provides data on usage time and some 
subjective data, searching for a link between subjective and objective results would not be 
accurate. All previous studies have either focused on audiometric and spatial hearing tests, 
or on subjective benefit. It would be interesting to explore this combination in more detail.
The current study was limited to children with BCHL and bilateral BCDs and did not 
include children with one implant. In our study the unilaterally aided condition was rather 
new to all children, i.e. the children were accustomed to listening with bilateral inputs and 
not to an ‘acute’ unilateral input. This acute condition might have influenced our results, i.e. 
long-term unilateral rehabilitation of patients with BCHL might present different unilateral 
results. Especially, long-term experiences with one BCD might result in more effective use of 
monaural cues like the proximal sound level cue.
With respect to a choice between both tests, the MAA test is well suited to show an 
advantage of bilateral versus unilateral application of BCDs. Since the MAA test is easy 
to conduct, it might be the preferred clinical test, especially in young children. However, 
to study directional hearing (e.g. assessing binaural processing and the use of (monaural) 
intensity and frequency cues) a full sound localization test is preferred.
To conclude, our results emphasize the need for bilateral BCD application in children 
with BCHL. Despite obvious inter-subject variability, the advantage of bilateral BCDs over 
unilateral BCDs was outspoken, especially with respect to lateralization. Directional hear-
ing is important in daily life, for example in the classroom but also for understanding 
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speech in noise (especially in children developing speech and language abilities). Optimal 
localization abilities are expected to improve safety outdoors, as this might decrease traffic 
risks 33. In many practical situations sound sources are also visible. In these cases sound 
lateralization as seen in the children with a bilaterally fitted BCD, might be sufficient for 
audio-visual source localization. However, this situation is obviously less optimal compared 
to a situation with adequate localization, hence counselling of parents and children on 
these differences is deemed necessary. Additionally, behavioural training programs (using 
this audio-visual input) might improve directional hearing and should be considered as a 
topic for future research as this might include a potential therapeutic strategy 34,35.
The current study focuses on results of bilateral input of percutaneous BCD’s on directional 
hearing in patients with (mainly congenital) bilateral conductive hearing loss. Other advan-
tages of bilateral rehabilitation (usage of head-shadow in noise and binaural summation 
amongst others) are not included. Nonetheless, these important benefits are available in 
bilaterally rehabilitated children. In conclusion, given the known advantages of bilateral 
rehabilitation and the current results on directional hearing, bilateral application of BCDs 
in children with BCHL is advocated.
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Objective To compare implant stability, survival and soft tissue reactions for a 
novel (test) and previous generation (control) percutaneous auditory 
osseointegrated implant for bone conduction hearing at long-term 
follow-up of 5 years.
Study design Single follow-up visit of a previously completed multicenter, random-
ized, controlled trial.
Patients Fifty-seven of the 77 participants of a completed randomized con-
trolled trial on a new auditory osseointegrated implant underwent a 
single follow-up visit five years after implantation, which comprised 
implant stability measurements and collection of Holgers scores. Ad-
ditionally, implant survival was recorded for all 77 patients from the 
original trial.
Results The test implant showed significantly higher implant stability quotient 
(ISQ) values compared to the control implant throughout the 5-year 
follow-up. Mean area under the curve of ISQ high from baseline 
to 5 years was 71.6 (SD ±2.0) and 66.7 (SD ±3.4) for the test 
and control implant, respectively (p<0.0001). For both implants, 
the mean ISQ value recorded at 5 years was higher compared to 
implantation (test group +2.03 (SD ±2.55, within group p<0.0001) 
and control group +2.25 (SD ±4.95, within group p=0.12)). No 
difference was noticed in increase from baseline between groups 
(p=0.64). Furthermore, evaluation of soft tissue reactions continued to 
show superiority of the test implant. At the 5-year follow-up visit, one 
patient (2.5%) presented with a Holgers grade 2 in the test group, 
compared to four patients (23.5%) in the control group (p=0.048); 
no patient presented with more severe soft tissue reactions. Excluding 
explantations, the survival rate was 95.8% for the test group and 
95.0% for the control group. The corresponding rates including 
explantations were 93.9 % and 90.0 %.
Conclusion The test implant showed superiority in terms of higher mean ISQ 
values and less adverse soft tissue reactions, both at the single 5-year 
follow-up visit and during the complete follow-up. In addition, both 
implants showed an equally high implant survival.
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Introduction
Since Tjellström reported on the fitting of the first patient with a bone-anchored hearing de-
vice using a temporal bone implant in 1977 1, many improvements have been made to au-
ditory osseointegrated implant systems (also referred to as bone conduction hearing implant 
systems). Hearing rehabilitation through direct bone conduction via an implant anchored in 
the temporal bone is nowadays an established method to overcome pure conductive hear-
ing loss and also for mixed hearing loss as well as single-sided sensorineural deafness 2. 
The original auditory osseointegrated implant was a titanium implant with an as-machined 
surface, designed by Brånemark in the late 70’s and later made commercially available 
as the Cochlearä Bahaâ flange fixture. In 2009, a new implant design was introduced, 
with a wider diameter aimed to increase implant stability 3 and a moderately roughened 
surface to increase bone response (i.e. remodeling) after implantation 4. Moreover, a new 
rounded shape and conical connection that provides a tighter seal to the percutaneous 
abutment were chosen to reduce soft tissue reactions. Previously, Dun et al. and Nelissen 
et al. reported 6 month and 3-year results from a randomized controlled trial of this new 
(test) implant and previous generation (control) implant 5,6. Implant stability measurements 
showed higher mean implant stability quotient (ISQ) values during the complete follow-up 
period for the test implant compared to the control implant. An initial decrease in stability 
was recorded 10 days after surgery in both study groups, while ISQ values remained 
relatively stable above baseline scores across the 6, 12 and 24 months visits. However, a 
statistically significant decrease towards baseline was noticed for both implants at the last 
follow-up visit at three years. Better soft tissue outcomes were observed with the test implant, 
while implant survival after three years was comparably high for both implants.
While formally a separate study, the current clinical investigation is a continuation of 
the previously completed and reported trial with a single follow-up visit five years after 
implantation 5,6. The aim of the current study was to measure long-term implant stability and 
explore the development of the decreasing ISQ values seen at the 3-year follow-up visit, 
and to confirm good implant survival and abutment tolerability at long-term follow-up. The 
current results comprise the first 5-year clinical data collected prospectively on percutane-
ous auditory osseointegrated implants.
Methods
Study design and participants
The aim of the current study was to show superiority of the test implant compared to a 
control implant in terms of implant stability (primary outcome measure), and to evaluate 
long-term implant survival and soft tissue reactions (secondary outcome measures).
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The study was designed as a single prospective follow-up visit five years after implanta-
tion for the patients who participated in the completed 3-year multicenter, randomized, 
controlled trial conducted at Radboud University Medical Centre Nijmegen (Nijmegen, 
The Netherlands), Salford Royal Hospital (Salford, UK), Sahlgrenska University Hospital 
(Göteborg, Sweden) and Manchester Royal Infirmary (Manchester, UK). All patients who 
participated in the original trial were invited to participate in the current study. To be included 
in the original trial, the patients had to be at least 18 years old, have a bone thickness at 
the implant site of at least 4mm, and no disease or treatment known to compromise the 
bone quality at the implant site. Exclusion criteria for the current study were inability to follow 
investigational procedure and any factor, at the discretion of the investigator, that was con-
sidered to contraindicate participation, e.g. mental or physical disability or travelling plans 
not compliant with the study protocol. For patients who had lost or removed the implant 
placed in the original trial, only time to implant loss was recorded. Patients who for other 
reasons did not attend the 5-year visit were also included in the implant survival analysis; the 
last available information regarding implant survival was obtained verbally from the patient, 
from medical records or from information captured in the original investigation.
Randomization for the original investigation was fixed in proportions 2:1 (test:control), 
stratified for each site, and was realized by means of numbered blinded envelopes. Both 
patients and surgeons were blinded until implantation, but because of differences in implant 
design, no blinding could be applied thereafter. Surgery was performed between April 
and December 2009. A single-stage surgical procedure with reduction of subcutaneous 
soft tissue was applied in all centers; a linear incision technique was used in Nijmegen, 
the flap technique in Manchester and Salford, and the dermatome technique in Göteborg. 
At each site, the same technique was used for test and control implants. Loading of the 
implants with sound processors was performed from 6 weeks after implantation. Follow-up 
visits in the previous study were completed at 10 days, at 4, 6, 8, and 12 weeks, and at 
6, 12, 24 and 36 months.
Implants
The test implant was the novel titanium implant (diameter 4.5 mm; length 4mm) with a 6 mm 
rounded, apically converging titanium abutment developed by Cochlear Bone Anchored 
Solutions AB (Mölnlycke, Sweden). This system was later commercialized under the name 
Cochlearä Bahaâ BIA300 Implant with Abutment with an additional minor change to the 
internal abutment connection design. The control implant was the previous generation 
as-machined titanium flange fixture (diameter 3.75 mm; length 4mm) with a 6 mm coni-
cally shaped abutment from the same manufacturer. Aside from the difference in abutment 
shape, the test implant incorporates a wider diameter, small-sized threads at the implant 
neck, and the moderately rough TiOblastä (Dentsply, Mölndal, Sweden) surface on the 
intraosseous part of the implant (Figure 1).
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Outcomes of the 5-year follow-up visit
For all patients who attended the single visit, demographics, baseline variables (date of 
birth, gender, ethnical background, use of nicotine) and relevant medical history since the 
previous study were recorded. Implant stability quotient (ISQ) values were measured using 
resonance frequency analysis (RFA) at the abutment level with the Osstell Mentor or Osstell 
ISQ and a SmartPeg (type 43) (Osstell AB, Göteborg, Sweden). The ISQ score ranges 
from 1 to 100, with increasing scores presenting a more rigid implant-bone interface. 
As this score is also a representation of other implant variables, assessment of changes 
over time is consequently more sensible than evaluation of absolute values at a given time 
point 7,8. The highest (ISQ high) and lowest value (ISQ low) obtained from perpendicular 
measurements were recorded. Soft tissue status was assessed according to the Holgers 
soft tissue classification on a 5-point scale from 0, no signs of soft tissue reaction, to 4, 
an infection requiring implant removal 9. Holgers grade 2 or higher is considered an 
adverse soft tissue reaction in need of (local) treatment and the distinction is consequently of 
clinical importance. Furthermore, implant survival/loss was recorded, including the reason 
of implant loss or explantation (active removal of the implant).
Statistical analysis and data management
No new sample size calculations were performed; all patients from the previous investiga-
tion were asked to participate. For the original study a power calculation was conducted 
on the primary outcome variable ISQ 6. For comparisons between test and control groups, 
Mann-Whitney U test was used for all continuous variables, Mantel-Haenszel chi-square 
test for all ordered categorical variables, and Fisher exact test for dichotomous variables. 
Wilcoxon Signed Rank test was used for change within groups for continuous variables. 
A weighted average of ISQ during the entire study period was obtained by mean area 
under the curve (AUC) calculations. Implant survival probability was analyzed using a 
Figure 1. Control (A) and test (B) implants with abutments
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Kaplan-Meier survival curve with log-rank test; the last available information regarding 
implant survival was used as the censoring date for the implant survival analysis.
A significance level of 0.05 was adopted and all tests were two-tailed. No correc-
tions were made for multiple comparisons. For the primary outcome variable, in case of 
missing baseline value the value at the second visit was used as baseline value instead; 
furthermore, no imputation with last observation carried forward was used.
Data management was performed by external data managers (dSharp, Göteborg, 
Sweden, and Statistiska Konsultgruppen, Göteborg, Sweden), and statistical analysis was 
realized by external biostatisticians (Statistiska Konsultgruppen, Göteborg, Sweden) ac-
cording to a predefined statistical analysis plan using SASâ v9.4 (Cary, NC, USA).
Ethical consideration
The investigation was conducted in accordance with the Declaration of Helsinki and the 
international standard for ‘Clinical investigation of medical devices for human subjects 
- Good clinical practice (ISO 14155:2011). Local ethics committees and competent 
authorities in all participating countries gave approval or a declaration of no objection for 
this single follow-up visit after 5 years.
The current study was registered at ClinicalTrials.gov and assigned the identifier 
NCT02092610.
Results
Patient characteristics
Out of the 77 patients in the original study, 57 patients (37 in Nijmegen, 11 in Salford 
and 9 in Göteborg) signed the informed consent to participate in this follow-up trial and 
attended the five-year follow-up visit. While the study protocol indicated a visit window of 
60 ± 3 months, the actual visit dates ranged from 60 to 71 months post implantation. The 
patients from Manchester Royal Infirmary (Manchester, UK) could not visit the clinic, but 
were included in the implant survival population.
Twenty patients were lost to follow-up, had lost their implant or were not able to visit the 
clinic. The baseline characteristics of the 57 patients who attended the study visit (‘five-year 
follow-up population’) and the 77 patients in the original trial (who constituted the ‘implant 
survival population’ in the current investigation) are shown in Table 1. A slightly older 
patient population was seen for the control implant, which was more evident in the five-year 
follow-up population. There were no other significant or important differences in baseline 
characteristics between the two study groups.
87
ISQ
The ISQ values for the test implant were significantly higher compared to those of the 
control implant at all visits. The mean AUC for ISQ high between baseline and 5 years 
was 71.6 (SD ±2.0) and 66.7 (SD ±3.4) for the test and control implant, respectively 
(p<0.0001) (Figure 2). The corresponding values for ISQ low were 69.9 (SD ±2.0) and 
64.9 (SD ±3.3) (p<0.0001).
Mean ISQ high at 5 years was 72.1 (SD ±2.2) for the test implant compared to 67.4 
(SD ±4.0) for the control implant (p<0.0001). ISQ low resulted in similar results, with 
absolute numbers on average 1 to 2 points lower. An increase in ISQ values was recorded 
between the last visit at 3 years in the original trial and the 5-year visit in the current study 
for both implants. The change in ISQ high from baseline to 5 years was 2.03 (SD ±2.55, 
within group p<0.0001) for the test implant and 2.25 (SD ±4.95, within group p=0.12) 
for the control implant. No difference was noticed in increase from baseline between 
groups (p=0.64). All outcome variables are shown in more detail in Table 2.
Table 1. Baseline characteristics
Characteristics
Five-year follow-up 
population (n=57)*
Implant survival population 
(n=77)*
Test group 
(n=40)
Control group 
(n=17)
Test group 
(n=52)
Control group 
(n=25)
Sex Male 19 (47.5 %) 10 (58.8 %) 23 (44.2 %) 15 (60.0 %)
Female 21 (52.5 %) 7 (41.2 %) 29 (55.8 %) 10 (40.0 %)
Age at 
baseline**
Years 55.4 (SD 12.8; 
range 22.1-78.8)
64.2 (SD 9.4; 
range 43.2-83.3)
55.5 (SD 13.8; 
range 22.1-80.1)
61.7 (SD 13.5; 
range 25.4-84.2)
Smoking at 
baseline
No 36 (90.0 %) 16 (94.1 %) 46 (88.5 %) 22 (88.0 %)
Yes 4 (10.0 %) 1 (5.9 %) 6 (11.5 %) 3 (12.0 %)
Indication Conductive 12 (30.0 %) 5 (29.4 %) 14 (26.9 %) 7 (28.0 %)
Mixed 14 (35.0 %) 9 (52.9 %) 20 (38.5 %) 13 (52.0 %)
SSD 13 (32.5 %) 2 (11.8 %) 17 (32.7 %) 4 (16.0 %)
Other 1 (2.5 %) 1 (5.9 %) 1 (1.9 %) 1 (4.0 %)
Study site Nijmegen 26 (65.0 %) 11 (64.7 %) 28 (53.8 %) 14 (56.0 %)
Salford 7 (17.5 %) 4 (23.5 %) 12 (23.1 %) 6 (24.0 %)
Göteborg 7 (17.5 %) 2 (11.8 %) 9 (17.3 %) 4 (16.0 %)
Manchester - - 3 (5.8 %) 1 (4.0 %)
* ‘Five-year follow-up population’ includes all patients who were able to visit the clinic 5 years after implan-
tation. ‘Implant survival population’ includes all patients from the original trial and was used to determine the 
implant survival/loss during the complete follow-up.
**The age at baseline was significantly different between the two treatment groups within the Five-year 
follow-up population (p=0.03). There were no other significant or important differences between groups.
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Soft tissue reactions
The classification of soft-tissue reactions using Holgers’ index showed continued improvement 
for the test implant compared to the control implant, with less type 1 and type 2 soft-tissue 
reactions, as shown in Figure 4. At the 5-year follow-up visit, one patient (2.5 %) presented 
with a Holgers grade 2 in the test group, compared to four patients (23.5 %) in the control 
group (p=0.048). No patients presented with Holgers grade 3 or 4. The distribution of 
soft-tissue reactions over all Holgers grades (i.e. grade 0 to grade 4) was also significantly 
different between groups (p=0.0013). When comparing the maximum severity of soft tissue 
reactions per patient across all visits (i.e. highest Holgers grade during complete study), a 
significant difference in favor of the test implant was also recorded (p=0.015) (Table 2).
Implant survival
In the test group, during the first three years of the study, one implant was explanted 
(chronic pain around abutment) and one implant was lost (eight weeks after surgery, at 
time of sound processor fitting, attributed to failure of osseointegration); in the control group 
no implants were explanted or lost during this period. Between the 3- and 5-year visits, 
another implant was lost in the test group (51 months after implantation). In the control 
group, one implant was explanted after 60 months and one implant was lost after 58 
months (possibly related to radiotherapy at the implant site in the months prior to implant 
loss). Excluding explantations, the implant survival rate was 95.8 % and 95.0 % for the test 
and control group, respectively (Figure 3). The corresponding rates including explantations 
were 93.9 % and 90.0 %.
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Figure 2. Box-and-whisker plot of ISQ high – Lines represent ISQ high for patients who attended the 5-year 
follow-up. Mean (cross) and median (horizontal line) are defined within the boxplot. The box represents the 
interquartile range, the whiskers the 95 % confidence interval and the single dots the outliers.
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Figure 3. Implant survival, excluding explantations – Lines represent the survival curve for both study 
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Figure 4. Soft tissue reactions according to Holger classification – Bars represent the percentage of pa-
tients with a soft tissue reaction in patients who attended the 5 year follow-up visit
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Discussion
Principal findings
The aim of the current study was to compare clinical outcomes of a novel and a previ-
ous generation auditory osseointegrated implant system at long-term follow-up. The study 
showed superiority of the test implant compared to the control implant regarding ISQ mea-
surements during the complete follow-up. The decrease in ISQ values recorded between 
2 and 3 years of follow-up returned to higher ISQ values at the 5-year follow-up. The test 
implant continued to show superior soft tissue outcomes at 5 years, with less adverse soft 
tissue reactions in the test group. Implant survival of both study groups was slightly lower at 
5 years of follow-up, however, still at high levels compared to previously reported numbers 
10-12.
Strengths and limitations
The current investigation provides the first 5-year evidence on novel, wide implants in 
bone conduction hearing in a controlled approach. The original randomized controlled 
trial with multiple participating centers already provided very strong evidence for a high 
implant survival and good soft tissue outcome at 3-year follow-up. With the additional 
long-term follow-up in a prospective manner and with the original multicenter set-up, we 
were able confirm these good outcomes and showed reassuring results for future follow-up 
with increasing ISQ scores since last follow-up, continued high implant survival and good 
soft tissue outcomes for the test group.
One of the limitations of the current study is the loss to follow-up of some patients for the 
5-year visit compared to the original study sample. Twenty patients, including five patients 
who had lost their implant or were explanted during the past five years and five patients 
who were already lost to follow-up/withdrew consent during the original trial, could not 
be included in the 5-year follow-up analysis of implant stability and soft tissue reactions. 
Consequently, a selection bias for this last follow-up visit cannot be excluded, even more 
since the current visit was a distinct investigation for which patients had to give separate 
informed consent. However, mostly minor differences in baseline characteristics between 
the five-year follow-up population and original study sample were observed. A difference 
in inclusion proportion between centers compared to the original trial and a small dif-
ference in age at baseline was noticed. All 77 patients of the original study population 
were included in the implant survival analysis; however, for the patients who could not be 
contacted, survival information was censored from a date prior to the 5-year follow-up and 
was based on patient files and/or information collected in the original investigation. The 
non-blinded follow-up and analysis is another limitation, as was already discussed in the 
previous reports 5,6.
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Interpretation and comparison with other studies
The available literature reporting on the same type of implant generally shows good results 
in terms of implant stability and soft tissue outcomes; however, the majority of the investiga-
tions are retrospective cohort studies without a control group or small pilot studies 13,14,15-18. 
For other wide auditory osseointegrated implants, similarly higher ISQ values compared 
to smaller diameter implants have been reported in short term follow-up 19. To obtain more 
evidence on clinically important outcomes like implant survival, it would be highly desirable 
to have additional well-designed studies on wider implants in bone conduction hearing. 
Long-term follow-up, which was one of the major strengths of the current investigation, 
would be expedient for these studies.
Nelissen et al. previously hypothesized that the dip in mean ISQ between 2 and 3 years 
(for both types of implants) could be the result of marginal bone loss around the implant 6. 
With the current results showing increasing values at the 5-year follow-up (with ISQ values 
comparable to the 2-year results), and with another investigation of the same implant 
showing no stability dip at 3 years any biological explanation of the previous decrease in 
stability seems unlikely 6. An alternative reason for the dip could be a measurement error. 
Studies in dental implantology show conflicting results on intra-rater and inter-rater reliability 
of RFA 20-22. Importantly, the small decrease detected by the stability measurements did not 
translate into clinical instability.
Implant stability as measured by RFA was chosen as the main outcome measure of the 
current study. This outcome measure should be interpreted with caution, as it is influenced 
by many factors in implant, abutment design and surgery 8. It should additionally be 
emphasized that implant stability measures are a surrogate measure for implant survival, 
which is ultimately the most important for patients. Implant survival rates were shown to be 
high and equal for both study groups.
The implants in the present investigation were loaded with the sound processor from 6 
weeks after surgery, which at the time of study initiation was not common practice. At that 
time, mostly loading protocols allowing 3 months of unloaded implants were reported. 
With the high implant survival rate and good soft tissue outcomes at 5 years, earlier load-
ing seems to be safe at long-term follow-up. Nowadays even earlier loading is frequently 
reported and considered to be safe 23,24. These early loading protocols allow patients to 
use their device as soon as possible with an improved patient satisfaction as a result.
Regarding one of the other secondary outcome measures, the decrease in soft tissue 
reactions is an important advantage of the new implant-abutment system. Percentages of 
adverse soft tissue reactions were reduced to 20 % for the new implant versus 58.8 % for 
the previous generation implant during the complete follow-up, representing an essential 
reduced need for post-operative treatment. Both the rounded shape of the abutment and 
the conical connection between the new implant and abutment that provides a tighter seal, 
have been proposed as explanations for this reduction 5, 6.
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Conclusion
The new auditory osseointegrated implant design showed superiority compared to the 
previous implant design in terms of long-term implant stability as measured by resonance 
frequency analysis. Furthermore, although auditory osseointegrated implant surgery is 
a relatively safe procedure already, an important and persistent reduction in soft tissue 
reactions was noticed for the new implant. These good outcomes at longest follow-up 
reported to date in a prospective controlled study, support the replacement of the previous 
generation implants by the new BIA300 implant with abutment.
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Objective To compare the stability, survival, and tolerability of two percutane-
ous osseointegrated titanium implants for bone conduction hearing: 
a 4.5-mm-diameter implant (test) and a 3.75-mm-diameter implant 
(control).
Methods Fifty-seven adult patients were included in this randomized controlled 
clinical trial. Sixty implants were allocated in a 2:1 (test–control) ratio. 
Follow-up visits were scheduled at 7, 14, 21, and 28 days; 6 and 
12 weeks; and 6 months. At every visit, implant stability quotient 
(ISQ) values were recorded by means of resonance frequency analy-
sis (RFA) and skin reactions were evaluated according to the Holgers 
classification. Implants were loaded with the bone conduction device 
at three weeks. Hearing-related quality of life was evaluated using 
the Abbreviated Profile of Hearing Aid Benefit (APHAB), the Glasgow 
Benefit Inventory (GBI), and the Glasgow Health Status Inventory 
(GHSI).
Results ISQ values were statistically significantly higher for the test implant 
compared to the control implant. No implants were lost and soft tissue 
reactions were comparable for both implants. Positive results were 
reported in the hearing-related quality of life questionnaires.
Conclusion These six-month results indicate that both implants and their corre-
sponding hearing devices are safe options for hearing rehabilitation 
in patients with the appropriate indications. Loading at three weeks 
did not affect the stability of either implant.
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Introduction
Percutaneous osseointegrated titanium implants have been used to attach vibrating bone 
conduction devices to the temporal bone since 1977 1. Both implants and devices, as well 
as the indications for application, have been studied extensively 2,3. The clinical outcomes 
of these implants have been reported in large populations: long-term implant survival rates 
vary between 81.5% and 98.4%, while complications generally involve soft tissue inflam-
mation 4-6. Severe complications are rare 4,5.
Recently, the designs of these bone-anchored hearing implants have evolved to include 
wider diameters, based on the known advantages of wider implants in dentistry 7. These 
4.5-mm-diameter implants provide a larger contact surface between the implant and the 
bone compared to the 3.75-mm-diameter implants of the previous generation, which 
results in higher reported implant stability quotients (ISQ) and high implant survival rates 
8,9. Moreover, wider implants appear to have higher levels of initial stability, which allows 
for early loading of the implant with the device. Loading of these wider implants has been 
reported to be safe at three weeks after surgery 10.
The current randomized controlled clinical trial investigated ISQ, implant survival, and 
soft tissue tolerability of a new wider diameter implant in comparison to a previous genera-
tion implant in the first six months after implantation. Early loading of both implants was 
studied, with all implants loaded at three weeks. Subjective benefits of the bone conduction 
system were investigated using quality of life questionnaires.
Methods
Implants and patients
The test implant was the wide Ponto implant (diameter 4.5 mm, length 4 mm) and the con-
trol implant was the previous generation Ponto implant (diameter 3.75 mm, length 4 mm). 
Both implants used the same 6-mm abutment. The implants and abutments are developed 
and manufactured by Oticon Medical AB (Askim, Sweden) and are displayed in Figure 1.
Out of all of the patients indicated for a percutaneous bone conduction device, 57 
adult patients with a total of 60 implants were consecutively included. Eligibility criteria 
were as follows: indication for a percutaneous implant; age of 18 years or older; bone 
thickness of at least 4 mm at the implant site; written informed consent given; abutment of 
6 mm required (not longer); ability to participate in follow-up visits; no history of psychiatric 
diseases; no mental disabilities; no presumed doubt, for any reason, that the patient would 
not be able to attend all follow-up visits; no presence of diseases or use of treatments 
known to compromise bone quality at the implant site (e.g., radiotherapy, osteoporosis, 
diabetes mellitus).
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Study design
The current study was designed as an open randomized controlled clinical trial in our 
tertiary referral center. The primary outcome parameter was implant stability measured 
as ISQ Low values in the first six months after implantation. Secondary objectives were to 
compare ISQ High values in the same period, ISQ Low and High values at all visits, time 
to stability dip (in ISQ Low) if applicable, implant survival, soft tissue reactions during all 
visits, and quality of life outcomes.
The sample size was based on the primary efficacy variable. A weighted average of 
ISQ Low values during the six-month follow-up period was obtained by the mean area 
under the curve (AUC) calculation using the trapezoid rule with all ISQ low measurements 
over the first six months. Data from a similarly designed previous study 11 were used for 
the sample size calculation. An expected difference of 4.5 in the mean AUC of the ISQ 
Low values of the test and the control groups, with unequal standard deviations (SDs) of ± 
2.8 and ± 5.5, respectively, were used for determining the sample size. A two-sided t-test 
with Satterthwaite’s correction for unequal variances was performed. For a power of 90%, 
significance level of 0.05, and randomization ratio of 2:1, a total of 60 implants needed 
to be included.
Randomization was performed in a 2:1 ratio (test-control). A computer-generated list 
of random allocations was used. The group assignments were enclosed in sequentially 
numbered opaque sealed envelopes. The randomization was blinded to the patients and 
investigators until the surgery was performed. Patients were allocated in consecutive order. 
Blinding of the investigators after the group assignments were made was not feasible 
because the appearances of the implants and instruments used during surgery were clearly 
different. Because most patients were operated under local anesthesia, the patients were 
also not blinded.
Implants and abutments were placed in a single-stage surgical procedure. The linear 
incision technique with subcutaneous tissue reduction was applied in all cases 12. Implants 
were alternately placed within or posterior to the incision line. In accordance with the study 
Figure 1. Control (a) and test (b) implants with 
abutments
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protocol, follow-up visits were scheduled at 7, 14, 21, and 28 days, 6 and 12 weeks, 
and 6 months. At each visit, resonance frequency analysis (RFA) was used to establish the 
ISQ. RFA uses magnetic pulses generated by the Osstell ISQ device (Osstell AB, Göteborg, 
Sweden) to excite the SmartPeg (type 55) that is connected to the abutment, which leads 
to vibration of the implant-abutment system. The intensity of these vibrations is analyzed by 
the device that computes the ISQ, which is an indication of the rigidity of the implant-bone 
link 13. Perpendicular measurements result in an ISQ High value and an ISQ Low value. 
At each visit, the skin status was also assessed according to the Holgers classification 14. 
Three weeks after surgery, the patients were fitted with the bone conduction device. The 
benefit of the bone conduction system was assessed using three questionnaires: the Ab-
breviated Profile of Hearing Aid Benefit (APHAB) 15, the Glasgow Benefit Inventory (GBI), 
and the Glasgow Health Status Inventory (GHSI)16. The APHAB and GHSI outcomes were 
only included in the analysis when both the baseline screening before implantation and 
the six-month evaluation had been completed. In cases where patients used hearing aids 
at the baseline evaluation, they were asked to complete the baseline questionnaire both 
for the aided and unaided conditions. The unaided condition was used as the baseline 
measurement for analyzing the benefit of the bone conduction system at six months.
Statistical analysis
Data management and statistical analyses were performed by external data managers and 
biostatisticians (Statistiska Konsultgruppen, Göteborg, Sweden) according to a predefined 
statistical analysis plan.
For comparisons between the test and control groups, Mann-Whitney U tests were used 
for all continuous variables, Mantel-Haenszel χ2 tests were used for all ordered categorical 
variables, Fisher’s exact test was used for all dichotomous variables, and χ2 tests were 
used for all non-ordered categorical variables. For changes over time, Wilcoxon signed 
rank tests (continuous variables) and Sign tests (order categorical variables, dichotomous 
variables) were used. Groups were compared according to the intention-to-treat principle. 
For subjects lost to follow-up, last-observation-carried forward was used for ISQ measure-
ments in the AUC calculations.
For implant variables, bilaterally implanted patients who received both a control and a 
test implant were included in both analyses. Patients who received two test or two control 
implants were represented by the mean of the two measurements for continuous variables 
or the worst value for categorical variables. For patient variables, bilaterally implanted 
patients who received both control and test implants were included in descriptive statistics 
but excluded in formal analyses on the patient level.
All tests were two-tailed with significance levels of 0.05 and were executed using SAS 
v9.2 and v9.3 software (SAS Institute Inc., Cary, NC, USA).
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Ethical considerations
The clinical investigation was performed in accordance with the current version of the Dec-
laration of Helsinki (Washington 2002, ISO 14155), Good Clinical Practice (International 
Conference on Harmonization Good Clinical Practice) and was approved by the local 
ethical committee.
Results
Patients
Fifty-seven patients with a total of 60 bone-anchored hearing implants (40 test and 20 
control) were included in the randomization. Surgeries were performed between June 
2012 and January 2014. Three patients received bilateral implants; two of these patients 
were randomized for both a test and a control implant, and one patient received two 
test implants. The baseline demographic information is shown in Table 1. No significant 
differences were found between the test and control populations. All randomized patients 
received their allocated treatment and could be included in the final six-month analysis.
Implant stability quotient
The mean AUC for ISQ Low was 64.4 (SD ± 2.9; range 55.5–70.1) for the test popula-
tion (n = 39) and 59.3 (SD ± 2.1; range 55.5–62.5) for the control population (n = 20). 
The difference between groups of 5.1 ISQ points (95% CI 3.6–6.6; p < 0.0001) was 
statistically significant. For ISQ High, a difference of 3.3 (95% CI 1.8–4.7; p < 0.0001) 
was observed during the six-month follow-up, with a mean AUC of 65.8 (SD ± 2.7; range 
57.0–70.5) for the test population and 62.5 (SD ± 2.8; range 56.9–66.8) for the control 
Table 1. Patient demographics and baseline characteristics
Variable Test (n=39) Control (n=20) p-value
Sex, n (%)
Male 15 (38.5) 9 (45.0)
Female 24 (61.5) 11 (55.0) 0.8554
Age in years, mean (SD) 53.7 (12.0) 53.0 (16.4) 0.4950
Smoking at baseline, n (%) 6 (15.4) 6 (30.0) 0.2750
Body mass index, mean (SD) 25.9 (4.2) 25.3 (4.1) 0.6029
Skin disease, n (%) 4 (10.5) 3 (14.3) 0.9176
Indication for bone-anchored hearing implant, n (%)
Acquired conductive/mixed hearing loss 26 (66.7) 16 (80.0) 0.3657
Congenital conductive hearing loss 1 (2.6) 1 (5.0) 1.0000
Single-sided deafness 13 (33.3) 3 (15.0) 0.2704
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population. At all follow-up visits, statistically significant differences in mean ISQs between 
both groups were recorded. The results are displayed in Figure 2. The mean increase 
in ISQ from baseline is statistically significant in both groups; however, the increase in 
ISQ from baseline for the test implant is statistically significantly stronger compared to 
the increase for the control implant. The ISQ dip at 42 days for the test implant can be 
ascribed to a single implant that displayed a very low ISQ (ISQ Low 46, ISQ High 52) 
but remained clinically stable and presented with an ISQ within the normal range at the 
next follow-up appointment.
No dip in mean ISQs was observed, as the ISQ High and ISQ Low values were higher 
than the baseline ISQ values (at surgery) at all follow-up visits.
Implants were loaded three weeks after surgery (with a two-day range) in all but one 
patient (loaded at 24 days). This early loading moment did not seem to influence ISQ 
values, as these progressed positively in both implants.
At six months, a mean increase in the ISQ Low from the time of surgery of 4.5 (SD ± 
4.6; range –4–29) was observed for the total group (n = 59), which was significantly 
different from the ISQ low at the time of surgery (p < 0.0001). The mean increase was 
5.1 (SD ± 4.9; range –4–29) in the test group and 3.3 (SD ± 3.8; range –3–13) in the 
control group. The mean difference in the increase in ISQ Low between both groups was 
statistically significant (95% CI –0.7–4.4; p = 0.046).
Figure 2. Box-and-whisker plots of ISQ 
low and ISQ high measurements.The mean 
(cross) and median (horizontal line) are de-
fined within each box plot. Dots represent 
outlier values
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Survival and tolerability
No implants were lost during the follow-up period. In each study group, one implant 
required surgical revision of the soft tissue. One patient who suffered from psoriasis pre-
sented with insufficient skin healing after surgery and the other patient presented with 
skin partially overgrowing the abutment. Three implants (7.7%) in the test group and two 
implants (10.0%) in the control group developed adverse skin reactions (Holgers grade 
2–4). Results related to soft tissue reactions are displayed in Figure 3. The analysis of 
soft tissue statuses throughout the follow-up period revealed findings of Holgers grade 0 
in 87.1 % (test) and 88.4 % (control) of visits, Holgers grade 1 in 11.8 % (test) and 9.5 
% (control) of visits, Holgers grade 2 in 1.1 % (test) and 1.4 % (control) of visits, Holgers 
grade 3 in 0.0 % (test) and 0.7 % (control) of visits, and no Holgers grade 4 cases over all 
of the visits. Two out of the five patients who presented with adverse skin reactions suffered 
from skin diseases. Furthermore, no statistically significant differences were noted in other 
postoperative complications: bleeding or hematoma (one (2.6%) test patients versus one 
(4.8%) control patient), pain or numbness (four (10.5%) test patients versus two (9.5%) 
control patients), and wound dehiscence (three (7.7%) test patients versus two (10.0%) 
control patients). Additionally, skin height did not differ between the two groups.
Quality of life
The GBI questionnaire was completed 12 weeks after surgery. Eight patients completed the 
questionnaire outside of the defined visit window (mean of 22 days after the planned visit 
date). These results were still included in the final analysis. No differences were observed 
in the outcomes between the test and control groups. The results are shown in Table 2.
Figure 3. Soft tissue tolerability for test and control groups as a percentage of all visits according to 
the Holgers classification. Note that only Holgers grade 0–3 are depicted, as no Holgers grade 4 was 
observed
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All patients completed the APHAB and GHSI questionnaires six months after surgery. 
However, five patients did not complete baseline questionnaires and were consequently 
excluded from the benefit analysis. One additional patient did not complete the baseline 
APHAB, while another three patients were excluded from the benefit analysis using the 
GHSI because of incomplete data on the six-month questionnaire. The outcomes of these 
questionnaires are displayed in Figure 4. For the GHSI, significant improvement was ob-
served for the total and general scores, but not for the social and physical subscales. The 
APHAB indicated that there was statistically significant improvement on all of the subscales 
in the aided condition compared to the unaided condition.
Figure 4. Subjective benefit as mea-
sured by the APHAB and GHSI question-
naires, completed before surgery and af-
ter 6 months of follow-up. The subscales 
of the APHAB are represented by the 
abbreviations on the x axis: EC ease of 
communication, BN background noise, 
RV reverberation, and AV aversiveness 
of sounds
Table 2. Subjective benefit as measured by the GBI
Variables (SD) Test (n=39) Control (n=20) p-value
Total score 33.1 (20.0) 36.5 (14.1) 0.4889
General subscale 46.9 (25.5) 50.7 (21.2) 0.5715
Social subscale 11.0 (20.6) 10.0 (18.6) 0.9199
Physical subscale 1.28 (18.9) 6.67 (14.7) 0.0371
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Discussion
The current randomized controlled clinical trial compared outcomes of two percutaneous 
bone-anchored hearing implants for bone conduction devices with six months of follow-
up. These implants, a new 4.5-mm-diameter implant (test) and the 3.75-mm previous 
generation implant (control), were both loaded with the bone conduction device at three 
weeks. The test implant exhibited significantly higher ISQ values than the control implant. 
All other clinical outcomes were comparable between the implants. Quality of life generally 
improved in the aided condition compared to before implantation.
The strengths of the current study include the absence of cases lost to follow-up and the 
conscientiously followed prospective study protocol. The tightly spaced follow-up visits al-
low for a detailed analysis of the development of the implant’s stability. Therefore, the study 
design yielded useful information on short-term clinical results for both implants. The study’s 
strength lies also in the fact that only a single parameter, the implant width/design, was 
varied. A limitation of the current study was the non-blinded follow-up for the investigators 
and patients.
Both implants exhibited positive trends in ISQ measurements that generally increased 
from baseline until the final follow-up at six months. These positive trends are an indication 
of a progression in implant stability over time. RFA application in bone anchored hear-
ing implants has gained increasing interest in recent years. However, to date, reporting 
standards vary widely. Therefore, comparisons between different studies should be made 
very carefully. Foghsgaard and Caye-Thomasen 9 also studied the test implant and found 
an increasing trend in ISQ in the first year after surgery; however, they noted a slight 
decrease at the second follow-up visit (mean 7.3 weeks), when loading was applied. In 
our results, the ISQ was never lower than at surgery. It is worth noting not only that the test 
implant gave higher ISQ values on average, as expected, but also that the increase in 
ISQ over time was significantly higher for the test implant than the control implant. Although 
the present investigation was limited to adult patients with normal bone quality, it might be 
anticipated that the positive outcomes of the test implant could improve treatment outcomes 
in pediatric patients and patients with compromised bone quality. In comparable prospec-
tive studies on another wide implant type, increasing ISQ trends were reported in the first 
six months as well, with a dip in the ISQ at the first follow-up visit after surgery (ten days) 
10,11. A three-year follow-up on those implants revealed somewhat decreasing trends in 
ISQs beginning two years after implantation 8. It will be interesting to extend the follow-up 
period of the current study to observe ISQ trends in comparison.
At this moment, the clinical implications of absolute ISQ values are not yet understood, so 
only trends should be evaluated. Additionally, in dental implantology, there is still a lack of 
studies documenting clear clinical benefits from therapeutic decisions based on RFA 13. The 
large number of different implant designs in dental implantology might also influence this.
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The implant survival rate was 100% for both implants. The same percentage was also 
reported for the current test implant in another one-year follow-up prospective case series 
9. An implant survival rate of 96.8% was reported on the current control implant in a 
retrospective case series with a mean follow-up period of 16.9 months (range 12.1–25.2 
months) 17. These survival rates are slightly higher than those reported in two other prospec-
tive studies on a different wide implant type 10,11. Although all of these are short-term results, 
the first year after surgery has been reported to be critical, as more than half of implant 
losses occur in that year 4. The current study will be extended to compare the results to 
long-term survival figures from retrospective analyses. Varying survival rates of 81.5% to 
98.4% with maximum follow-up periods of up to 32.5 years have been reported on 
previous generation implants (3.75-mm diameter flange fixtures with a design comparable 
to that of the current control implant) 4-6.
Soft tissue tolerability was comparably good in both the test and control implants, with 
incidental adverse Holgers grade 2 and 3 skin reactions. This was expected because the 
abutment, which is believed to mainly influence the skin outcomes, was the same for both 
the test and control groups. The current adverse soft tissue events are comparable or even 
slightly better than rates reported from this center in the studies of another type of wide 
implant 10,11, also installed with skin thinning techniques. A remarkable fact is that two 
out of five patients who presented with adverse skin reactions suffered from skin diseases, 
which is a higher incidence than in the study population as a whole. This is in agreement 
with earlier observations 18,19 and the more recent identification of skin diseases as risk 
factors for skin reactions around bone-anchored hearing implants in a large retrospective 
cohort study 20.
As both implants were loaded at three weeks after implantation, the current study es-
tablished that early loading did not affect the positive ISQ trend and shortterm clinical 
outcomes. This is confirmed by another study of the current control implant that reported 
on a loading time as early as two weeks after implantation 21. Early loading of two, three 
and four weeks has also been studied on another type of wide implant with promising 
short-term results 10,22,23.
Hearing-related quality of life improved due to the system as a whole, as patients re-
ported improvements on both the APHAB and GHSI questionnaires from pre-implantation 
to six months later. The aided APHAB outcome is comparable to a similar sized population 
with single-sided deafness fitted with bone conduction devices 24 and better than a larger 
population of elderly patients fitted with bone conduction devices for mixed indications 
25. The APHAB outcome can be strongly influenced by the sound processor used, with 
modern sound processors producing significantly better aided APHAB scores than older 
technologies 26. To our knowledge, the GHSI has not been used to evaluate quality of life 
improvements with percutaneous bone conduction devices. GBI scores were also positive 
and comparable between groups. The current GBI outcome compares positively to other 
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studies that used the GBI to establish benefit from bone conduction systems (see Table 3 
in Faber et al. 10). It should be emphasized that indications and patient characteristics 
influence quality of life, so comparisons with these other studies should be made carefully. 
Intra-study comparisons of aided versus unaided conditions are therefore more important 
than inter-study comparisons.
Conclusion
After six months of follow-up, outcomes of a new 4.5-mm-diameter implant for bone con-
duction devices compared to the previous generation 3.75-mm-diameter implant exhibited 
higher ISQ values and similarly promising clinical characteristics. No implants were lost, 
and soft tissue tolerability was good. Loading both implants at three weeks appeared to be 
safe and hearing-related quality of life improved. These positive short-term results indicate 
that the new implant and its corresponding hearing devices loaded at three weeks is a safe 
option for hearing rehabilitation.
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Objective To compare the clinical and audiological outcome after linear 
incision with soft-tissue preservation and standard linear incision with 
soft-tissue reduction for placement of percutaneous bone-anchored 
hearing implants.
Study design Clinical trial with historical control-group from a prior randomized 
controlled trial.
Setting Tertiary referral center.
Patients and 
interventions
Twenty-five patients were enrolled in a prospective cohort of bone-
anchored hearing implant placement with linear incision and tissue 
preservation with a follow-up of 6 months. The control-group consisted 
of 25 patients from a prior randomized controlled trial in the same 
tertiary referral center. All sound processors were fitted 3 weeks after 
surgery.
Main outcome 
measures
Numbness around the abutment, length of surgery, soft-tissue reac-
tions according to Holgers’ classification, Patient and Observer Scar 
Assessment Scale (POSAS), implant loss, Implant Stability Quotient 
(ISQ) and audiological outcome.
Results issue preservation resulted in better results on sensibility (mean 
percentage correct responses 98% (SD 4.4) versus 89% (SD 15.0), 
p=0.003), on the POSAS (mean observer score 15.3 (SD 4.3) ver-
sus 19.4 (SD 6.3), p=0.006), and shorter total surgery time (mean 
24.6 minutes (SD 6.2) versus 31.9 minutes (SD 6.5), p<0.001). 
More adverse soft-tissue reactions as measured by the Holgers clas-
sification were observed in the test-group (n=7 (28%) versus n=1 
(4%), p=0.049). For ISQ and audiology the study did not provide 
evidence that tissue preservation is better or worse compared to tissue 
reduction.
Conclusions Tissue preservation compared to tissue reduction leads to a generally 
favorable clinical outcome, comparable audiology results and signifi-
cantly shorter surgery time. Longer follow-up is warranted to conclude 
on the increased adverse soft-tissue reactions after 6 months.
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Introduction
The surgical procedure for percutaneous titanium implants for bone conduction hearing 
has been modified several times since its introduction. During the last two decades there 
has been a tendency to less invasive surgery. When reviewing several frequently used 
techniques, the linear incision has been shown to be superior in several studies 1-3. With 
the linear incision technique, as well as new implant and abutment designs, complications 
like implant loss and adverse soft-tissue reactions have decreased to 0-4% and 8-15% 
respectively per implant in the adult population 4,5.
In 2011 Hultcrantz described a modification of the linear technique, without soft-tissue 
reduction 6. The rationale of soft-tissue preservation is less scar tissue formation, resulting 
in less numbness, cosmetic advantages and faster wound healing. Furthermore, tissue 
preservation results in shorter surgery times. This technique was shown superior on these 
matters in this study and consequently the preservation technique was adopted by many 
surgeons. However, most comparative studies use no or a less ideal control-group, includ-
ing dermatome technique, or test-groups with a variation on the preservation technique, 
like a (modified) punch technique 6-13. Additionally, audiological outcomes have not been 
reported thus far, while it has been mentioned that leaving the subcutaneous tissue around 
the abutment might dampen the vibrations to the skull 14.
The objective of the current study is to compare the aforementioned clinical and audio-
logical outcomes uniformly after linear incision with soft-tissue preservation and a standard 
linear incision with soft-tissue reduction.
Methods
Study design and participants
The current study was set up as a clinical trial on soft-tissue preservation with a histori-
cal control-group in which soft-tissue reduction was applied. Twenty-five patients were 
consecutively included in the test-group. Patients were eligible to participate if they had 
an indication for a bone-anchored hearing implant, were 18 years or older and had no 
mental disability or psychiatric disease in medical history. We excluded patients with a 
bone thickness at implant site of less than 4mm, soft-tissue thickness of more than 10mm or 
inability to show up on all follow-up visits. We additionally excluded patients with diseases 
or treatments known to compromise bone quality at the implant site (e.g. radiotherapy, 
osteoporosis, diabetes mellitus).
The last 25 patients implanted with a wide implant using the linear incision technique with 
tissue reduction in a randomized controlled trial comparing wide implants with previous 
generation implants were asked to participate as controls in the current study 5. Identical 
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implants and abutments were used in both groups and surgeries were performed by the 
same surgeons. Additionally, the same eligibility criteria were adhered to, with exception 
of the maximum soft-tissue thickness criterion.
Surgical techniques and follow-up
All patients were implanted with the Ponto wide implant (diameter 4.5mm, length 4mm, 
Oticon Medical AB, Askin, Sweden) during single-staged surgery. Abutment length was 
determined on soft-tissue thickness for the test-group (0.5-3mm: 6mm abutment, 3-6mm: 
9mm abutment, 6-10mm: 12mm abutment). Follow-up visits were scheduled at 7 days, 21 
days (sound processor fitting), 12 weeks, and 6 months. In the control-group, the standard 
linear incision technique, including tissue reduction and placement of a 6mm abutment, 
was applied in all cases 1. Follow-up visits were scheduled at the same time points as 
the tissue preservation cohort, with additional follow-up at 14 days, 28 days, 6 weeks, 
and 12 months. Extra assessments, intended for the current study, were included at the 
12-month follow-up visit for control patients.
Outcome measures
Primary outcome
The primary outcome measure was numbness around the abutment. Numbness was as-
sessed with a broken wooden cotton swab; gnostic (cotton side) and vital (broken, sharp 
wooden side) sensibility were determined at 6 selected locations (Figure 1a) and percent-
ages of correct answers were calculated. Subjective sensibility was additionally measured 
with a Visual Analogue Scale (VAS) from 0, no complaints, to 10, maximum numbness. 
Patients reported the area of subjective numbness as the diameter (centimeter) of skin with 
sensibility loss around the implant. Superiority of the tissue preservation technique was 
expected for the primary outcome variable.
Secondary outcomes
Secondary outcomes included length of surgery measured from start of incision to end of 
surgery collected from the electronic patient file. Surgery times were excluded when start 
or end of surgery was missing, or when a bilateral procedure or an additional procedure 
was executed in same setting.
Soft-tissue reactions were recorded according to Holgers’ classification 15. The Holgers’ 
soft classification is scored on a 5-point scale from 0, no signs of soft-tissue reaction, to 4, an 
infection for which removal of implant is needed. Holgers grade 2 or higher was considered 
an adverse soft-tissue reaction in need of (local) treatment. Revision surgery (soft-tissue revision 
or abutment replacement) was recorded and skin height was assessed during follow-up. Skin 
height was related to the abutment using four different categories as shown in Figure 1b.
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Scar assessment with the Patient and Observer Scar Assessment Scale (POSAS) v2.0 
was conducted 16. The POSAS consists of a patient and an observer scale. Both scales 
contain 6 items with response options 1 to 10. Response option 1 corresponds to normal 
skin and 10 to worst imaginable. The total score range is from 6 to 60 for both scales. 
The patient and the observer additionally score their overall opinion (not included in the 
total scores).
Implant loss was recorded during follow-up and Implant Stability Quotient (ISQ) was 
measured at all visits using resonance frequency analysis (RFA) with the Osstell Mentor and 
a SmartPeg (type 55) (Osstell AB, Göteborg, Sweden). ISQ scores range from 0 to 100, 
with increasing scores displaying a more rigid implant-bone interface, but the score is also 
an representation of implant variables like implant diameter and abutment length 17. Longer 
abutments will result in lower absolute ISQ scores at baseline, so in the current study, trends 
are compared between different abutment lengths 18. Perpendicular measurements of the 
implant resulted in an ISQ high and an ISQ low value.
Furthermore, audiometric thresholds were collected. Bone conduction (BC) in situ thresh-
olds were measured with the patients’ sound processor on abutment and on a softband, 
additionally, BC thresholds were measured with a B71 transducer and audiometer (all 
measurements at a position 2cm cranial of the abutment).
Figure 1a. Sensibility measurement locations, at 
all locations both gnostic (cotton side of wooden 
cotton swab) and vital sensibility (broken, sharp 
wooden side) will be tested randomly, the percent-
age correct answers was calculated for both as well 
as an overall percentage.
Figure 1b. Soft-tissue height relative to abutment 
(A under the shoulder of the abutment, B above the 
shoulder of the abutment, C partial overgrowth, D 
complete overgrowth).
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Subjective benefit was measured by the Glasgow Benefit Inventory (GBI), the Glasgow 
Health Status Inventory (GHSI), the Abbreviated Profile of Hearing Aid Benefit (APHAB) ques-
tionnaires 19,20. The GBI is an 18-item questionnaire, which evaluates the patients’ perceived 
benefit from an otorhinolaryngology intervention 19. Response options are on a 5-point Likert 
scale ranging from large improvement to large deterioration in health status. Total scores 
range from -100 (maximal adverse effect), 0 (no effect), to 100 (maximal positive effect). The 
GHSI measures the effect of a health problem on the quality of life of a person at the time 
the questionnaire is completed. The questionnaire contains 18 items and response options 
on a 5-point Likert scale. Total scoring is from 0 to +100, with higher scores indicating better 
health status. The APHAB is a 24-item inventory, scored in four 6-item subscales on com-
munication abilities or perception of sound in daily life situations 20. All items are scored on a 
7-point scale indicating frequency of problems experienced. An average unaided an aided 
score is calculated ranging from 1 to 99, with higher scores indicating more problems.
The numbness assessment, POSAS scale and audiometric thresholds were collected 
in the test-group at 6 months and in the control-group at 12 months. This was required 
because control patients already passed their 6 months visit before start of the current 
study. All other outcome measures were collected at same time points in the test and the 
control-group. Outcome assessment was not blinded.
Sample size and statistical analysis
No sample size calculations were made; investigators’ experience and practically feasible 
number of patients determined the sample size. For comparison between test-group and 
the control-group Fishers nonparametric permutation test was used for numbness variables, 
Mann-Whitney U-test was used for other continuous variables, Mantel-Haenszel chi-square 
test for ordered categorical variables and Fisher’s exact test for dichotomous variables. 
For analysis over time Wilcoxon Signed rank test was used for continuous variables. Non-
parametric methods were chosen on non-normality assumptions and small sample sizes. 
Missing values were not imputed and no adjustments were made for multiple testing. 
In addition to the intention to treat analysis, we also performed a post-hoc per-protocol 
analysis on numbness and POSAS, excluding a patient in the control-group who had previ-
ous bone-implant surgery with tissue reduction. The test and control-groups had a different 
number of visits, thus for analysis including visit-based data, only data from follow-up visits 
available for both groups were included, for cumulative variables all visits including extra 
visits were included. All tests were two-tailed with significance levels of 0.05. Analyses 
were performed using SAS v9.4 (Cary, NC). Data management and statistical analysis 
were performed by external data managers and biostatisticians (Statistiska Konsultgruppen, 
Göteborg, Sweden) according to a predefined statistical analysis plan.
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Ethical considerations
The clinical investigation was performed in accordance with the current version of the 
declaration of Helsinki (Washington 2002, ISO 14155) and was approved by the local 
ethical committee. The current study was registered with ClinicalTrials.gov and assigned 
the identifier NCT02064478.
Results
Patient and surgery characteristics
All surgeries were performed between February 2014 and August 2014 in the test-group, 
and between March 2013 and January 2014 in the control-group. No patients were 
excluded in the test-group because of the additional skin thickness criterion. Baseline 
characteristics were similar between the two study groups (Table 1).
Numbness assessment
The cotton swab numbness assessment resulted in a mean percentage of correct responses 
of 98% (SD 4.4) and 89% (SD 15.0) in the test and control group respectively (p=0.003). 
The subjective numbness assessment with the VAS score resulted in a mean VAS of 0.4 (SD 
1.1) in the test-group and 1.7 (SD 2.4) in the control-group (p=0.051). The per protocol 
analysis showed similar results for all comparisons (Table 2).
Table 1. Baseline characteristics
Characteristics Preservation group (n=25) Reduction group (n=25)
Sex, - n (%)
Male 15 (60%) 10 (40%)
Female 10 (40%) 15 (60.0)
Age, yr - mean (SD) 51.5 (13.4) 53.9 (12.2)
Smoking at baseline, - n (%) 4 (16%) 4 (16%)
BMI at baseline, kg/m2 - mean (SD) 26.0 (3.9) 26.5 (4.2)
Skin disease at baseline, - n (%) 1 (4%) 3 (12%)
Indication, - n (%)
Acquired conductive/mixed 21 (84%) 18 (72%)
Congenital conductive 1 (4%) 0 (0%)
SSD 3 (12%) 7 (28%)
Abutment length selected, - n (%)
6mm 0 (0%) 25 (100%)
9mm 17 (68%) 0 (0%)
12mm 8 (32%) 0 (0%)
* There were no significant differences in baseline characteristics between the two study groups
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Table 2. Primary and secondary outcome measures
Outcome
Preservation
group (n=25)
mean (SD)
Reduction
group (n=25)
mean (SD)
p-value
Numbness at 
6/12 months 
*
Gnostic sensibility, % 96.7 (8.3) 88.7 (18.5) p=0.053
Vital sensibility, % 99.3 (3.3) 89.3 (17.9) p=0.007
Total sensibility , % 98.0 (4.4) 89.0 (15.0) p=0.003
Subjective numbness, VAS 0.36 (1.10) 1.69 (2.44) p=0.051
Area of subjective numbness, cm 0.24 (0.83) 0.89 (1.39) p=0.021
Length of 
surgery, min
Electronic patient file** 24.6 (6.2) 31.9 (6.5) p<0.001
Knife time 20.8 (4.3)
Maximum 
Holgers 
across all 
visits 0-6m, – 
n (%)
Grade 0 11 (44%) 12 (48%)
Grade 1 7 (28%) 12 (48%)
Grade 2 4 (16%) 1 (4%)
Grade 3 3 (12%) 0 (0%)
Grade 4 0 (0%) 0 (0%) P=0.14
Mild versus 
adverse 
soft tissue 
reactions
Grade 0-1 18 (72%) 24 (96%)
Grade 2-4 7 (28%) 1 (4%) P=0.049
Skin height 
at 6 months
A – under shoulder 18 (72%) 17 (68%)
B – above shoulder 7 (28%) 8 (32%)
C – partial overgrowth 0 (0%) 0 (0%)
D – complete overgrowth 0 (0%) 0 (0%) P=1.00
POSAS at 
6/12 months 
***
P – Pain 2.72 (1.77) 2.44 (1.96) p=0.41
P – Itching 2.48 (2.10) 2.84 (2.53) p=0.79
P – Color 2.88 (2.15) 3.88 (2.51) p=0.14
P – Stiffness 2.64 (2.08) 2.60 (1.80) p=0.98
P – Thickness 2.76 (2.70) 3.48 (2.20) p=0.067
P – Irregularity 2.36 (2.25) 3.64 (2.20) p=0.017
P– Total score 15.8 (10.8) 18.9 (9.7) P=0.11
P– Overall opinion 2.44 (2.31) 3.36 (1.87) p=0.014
O – Vascularity 2.88 (1.30) 3.64 (1.25) p=0.010
O – Pigmentation 2.16 (0.55) 2.76 (1.16) p=0.048
O– Thickness 2.92 (1.63) 3.32 (1.63) p=0.26
O – Relief 2.84 (1.28) 3.56 (1.53) p=0.048
O – Pliability 2.20 (0.50) 2.76 (1.23) p=0.092
O – Surface 2.28 (0.68) 3.32 (1.31) p<0.001
O – Total score 15.3 (4.3) 19.4 (6.3) p=0.006
O – Overall opinion 2.84 (1.21) 3.76 (1.30) p=0.006
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Length of surgery
The mean surgical time as registered in the electronic patient file was 24.6 minutes (SD 
6.2; range 13-39) in the test-group and 31.9 minutes (SD 6.5; range 20-44) for the 
control-group (p<0.001). In the test-group the length of surgery was also recorded as knife 
time only (measured by the investigator), resulting in 20.8 minutes (SD 4.3; range 13-29).
Adverse events
In the test-group device/surgery-related adverse events included one patient with fever in the 
first days postoperative without any local signs of infection, one patient with persistent itch 
around the abutment and one patient with ongoing pain around the abutment (not able to 
get sound processor on abutment, different sound processor selected). In the control-group 
related events included two patients with a wound dehiscence at 7 days, two patients with 
mild pain around the abutment, one patient with scar hypertrophy and one patient with an 
abscess next to the abutment (required recurrent incision and antibiotic treatment).
For the test-group 7 patients required one additional unplanned visit, in the control-group 
two patients required one unplanned visit and one patient required 4 unplanned visits 
(patient with abscess).
Table 2. Primary and secondary outcome measures (continued)
Outcome
Preservation
group (n=25)
mean (SD)
Reduction
group (n=25)
mean (SD)
p-value
ISQ low Baseline 54.4 (3.5) 61.0 (3.4) p<0.001
AUC 0-6 months 57.0 (4.1) 64.2 (3.1) p<0.001
Change in ISQ 0-6mo +4.6 (2.0) +4.4 (3.2) p=0.86
BC in situ at 
6/12 months, 
dB
Abutment, 250Hz-8kHz 25.5 (12.8) 25.0 (11.8) p=0.93
Testband, 250Hz-8kHz 37.8 (11.3) 35.5 (10.0) P=0.53
B71, 250 – 4kHz 22.4 (11.2) 20.9 (11.7) P=0.79
Abutment – testband, 250Hz-8kHz -12.2 (7.0) -10.5 (4.7) p=0.10
Abutment - B71, 250 – 4kHz -0.99 (4.86) -0.48 (4.72) p=0.79
*Intention to treat analysis is presented. Slightly different results are shown for per protocol analysis in the 
control group. Gnostic: mean control group 88.2 (SD 18.7), p=0.044. Vital: 88.9(18.2), p=0.003. Total: 
88.5 (15.1), p=0.002. Subjective: 1.76 (2.47), p=0.039. Area of subjective: 0.93 (1.41), p=0.016.
** n=20 for test group and n=22 for control group
***Intention to treat analysis is presented. Slightly different results are shown for per protocol analysis in 
the control group. Largest differences were seen for the patient scale on stiffness (mean 2.46 (SD 1.69), 
p=0.87), and for the observer scale on pliability (2.63 (1.06), p=0.14), surface (3.21 (1.22), p=0.002) 
and relief (3.46 (1.47), p=0.071). On total scores this resulted in 18.5(9.6) for the patient scale and 19.0 
(6.2) for the observer scale
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Other soft-tissue outcomes
Soft-tissue reactions
In both groups no Holgers grade 4 reactions were recorded. Comparing all Holgers 
grades as maximum per implant across all visits between groups, no significant difference 
was found (p=0.14). When comparing clinically relevant adverse reactions (Holgers ≥2), 
28% (n=7) adverse reactions in the test-group versus 4% (n=1) in the control-group were 
observed (p =0.049). The rate of adverse soft-tissue reactions per visit was 7.5% (n=8 in 
282 visits, one patient with two adverse soft-tissue reactions) and 0.6% (n=1 in 356 visits). 
All adverse soft-tissue reactions resolved after one or two local treatment regimens.
Revision surgery & skin height
One revision surgery was performed in the control-group one month after initial surgery 
because of high skin. No partial or complete soft-tissue overgrowth was observed, and no 
differences between groups were noticed in skin height during first 6 months.
POSAS
On the patient scale highest values were scored for color, thickness and irregularity. Dif-
ferences between groups were noted on irregularity and on overall opinion. The mean 
total score for the patient scale was 15.8 (SD 10.8) for the test-group versus 18.9 (SD 
9.7) for the control-group (p=0.11). On the observer scale highest values were scored for 
vascularity, thickness and relief. Differences between groups were noticed in vascularity, 
pigmentation, surface and overall opinion. The mean total observer score was 15.3 (SD 
4.3) for the test-group versus 19.4 (SD 6.3) for the control-group (p=0.006). The per 
protocol analysis showed similar results (Table 2).
Implant loss and ISQ
No implants were lost in either group. ISQ low was higher at baseline (surgery) in the 
control-group (p<0.001), as was expected with longer abutments in the test-group, and 
remained higher during follow-up (AUC ISQ low 0-6 months, p<0.001). Nevertheless, 
no difference between groups was recorded in the change of ISQ from surgery. ISQ low 
showed a mean increase of +4.6 (SD 2.0) in the test-group and +4.4 (SD 3.2) in the 
control-group (change within groups p<0.001; difference between groups p=0.86). ISQ 
high showed similar results, with absolute numbers 1 to 2 points higher on average and 
slightly less increase over time (Figure 2b).
Audiology
The overall thresholds at 250Hz to 8kHz on testband and at 250Hz to 4kHz on B71 
showed no differences between groups, indicating similar hearing thresholds. The overall 
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thresholds on abutment, which are clinically most relevant given similar hearing thresholds, 
showed no difference between groups (mean 25.5 (SD 12.8) versus 25.0 (SD 11.8), 
p=0.93). Additionally, the overall difference between abutment and testband (250Hz to 
8kHz) showed no difference between test and control-group (mean -12.2 (SD 7.0) versus 
-10.5 (SD 4.7), (p=0.10).
Figure 2a. Soft-tissue reactions according to Holgers’ classification, as a percentage per visit per study 
group, not including extra visits.
Figure 2b. Box-and-whisker plots of ISQ 
low and ISQ high measurements over time. 
The mean (cross) and median (horizontal 
bar) are defined within each plot, boxes 
represent interquartile range, whiskers 
represent 95% range and dots represent 
outlier values.
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Comparing individual frequency thresholds between the two study groups for the abut-
ment and for the B71 conditions, no significant differences where noticed. In the testband 
condition a difference was noted at the 1 kHz frequency (mean 30.2 (SD 12.9) versus 
20.8 (SD 14.0), p=0.028). Additionally, comparisons between different conditions on 
individual frequencies were performed. For comparison between test and control-group 
when looking at the difference between abutment and testband, a significant difference 
was noticed at 1kHz (mean -14.4 (SD 7.8) versus -5.0 (SD 7.2), p<0.001) and 1.5kHz 
frequency (mean -9.6 (SD 7.1) versus -5.4 (SD 6.8), p=0.037). When comparing abut-
ment to B71 conditions, a difference was observed on the 1.5kHz situation (mean -5.8 
(SD 5.5) versus -2.0 (SD 7.8), p=0.044). All mean thresholds per frequency are shown 
in Table 3.
Health related quality of life
The GBI was completed 12 weeks after surgery. The GBI showed a positive result (>0) 
in 98% of all 50 patients on the total score (mean total score 32.3, SD 19.9, range 
-6.3 to 88.9). On the general subscale 96% of patients scored positively. The social and 
physical subscale showed a neutral effect in most patients, 75% respectively 74%, and a 
considerable proportion with a positive result, 25% resp.18%.
The GHSI and APHAB were both assessed at 6 months. For the GHSI total score base-
line (best score, either aided or unaided) to visit at month 6 (aided) a significant mean 
Table 3. BC direct thresholds on abutment, testband and B71 – mean (SD), preservation n=25, reduction 
n=25.
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P= Preservation group, R=Reduction group.
Selected sound processor for the test group: Ponto pro n=0, Ponto pro power n=2, Ponto plus n=5, Ponto 
plus power n=18.
For the control group: Ponto pro n=4, Ponto pro power n=16, Ponto plus n=2, Ponto plus power n=3.
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improvement of +12.4 (SD 10.5; p<0.0001) was observed. For the general score also 
an improvement was observed, the social and physical scores did not show a improvement 
or deterioration. For the APHAB questionnaire an improvement was noted on the mean 
total score at 6 months compared to best baseline score of -24.3 (SD 23.1; p<0.0001). 
This difference was observed on all subscales with exception of the aversiveness scale 
(Figure 3).
No significant differences were found between test and control-group in GBI results or 
benefit on the GHSI and APHAB.
Discussion
Key findings
Tissue preservation surgery resulted in better results on sensibility and POSAS scar as-
sessment scale and shorter surgery time. However, significantly more adverse soft-tissue 
reactions according to the Holgers score were observed. For ISQ and audiology the study 
did not provide evidence that tissue preservation is better or worse compared to tissue 
reduction.
Figure 3. Health related quality of life measured 
by the GHSI and APHAB questionnaires, com-
pleted before surgery (best score, either aided or 
unaided) and after 6 months (aided) (EC ease of 
communication, BN background noise, RV rever-
beration, AV aversiveness). The mean (cross) and 
median (horizontal bar) are defined within each 
plot, boxes represent interquartile range, whiskers 
represent 95% range and dots represent outlier 
values.
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Strengths and limitations
One of the important strengths of the current study is the selection of the control-group with 
a standard linear incision with tissue reduction. All studies performed so far use no or a 
less ideal control-group, consequently superiority of the new technique over the current gold 
standard could not be concluded on these studies 6-9,12. Aside from the selection of the 
control-group, the current study adds important results on audiological outcomes.
By taking the control patients from a previous trial, the interventions could not be random-
ized and follow-up visits were separated in time for the two study groups. The 12-month 
evaluation of the control-group was, however, expected to result in better outcomes on 
sensibility and POSAS for the control-group, since healing of soft-tissue would be more 
complete at longer follow-up. We feel that the benefit of fewer patients needed for par-
ticipation and earlier availability of results outweigh the drawbacks of the selected study 
design. Moreover, both groups were included with the same eligibility criteria and had 
comparable baseline characteristics.
Follow-up visits were more tightly spaced in the control-group. It might be possible that 
more frequent visits to the out-patient clinic result in better soft-tissue care. Conversely, more 
than half of adverse soft-tissue reactions were noticed at 6 months and the more tightly 
spaced visits were completed in the first 6 weeks.
Another limitation could be the non-blinded follow-up. However, since both surgical 
techniques result in different appearance of implant sites and abutment lengths, with ac-
companying ISQ values, blinding of observers and patients would not be feasible.
Interpretation
For the primary outcome variable numbness, we recorded significant differences in favor of 
the tissue preservation technique, though in most patients treated with standard linear inci-
sion technique also good sensibility scores of > 90%, and low VAS scores with small areas 
of subjective numbness were observed. Additionally, several patients reported difficulties 
answering the questions on this scale due to limited visibility, especially on the color and 
overall question. Moreover, patients reported limited importance of both VAS and area of 
numbness and appearance of the scar behind the ear during evaluation with the POSAS. 
This might though be biased by the short follow-up and dominated patients’ perspectives 
by the good outcomes on hearing improvement.
The difference in absolute ISQ scores at baseline and during follow-up can be explained 
by different abutment lengths 18. Since trends in ISQ during follow-up showed a similar 
development, no evidence of stability differences is suggested by these data. The increased 
soft tissue reactions should be interpreted with care, and further follow-up is needed to draw 
conclusions. The number of adverse soft-tissue reactions in the control-group (n=1, 4%), was 
lower compared to the percentage of adverse soft-tissue reactions in the complete study 
group from which the current control-group was a subset 5. A pathophysiological hypothesis 
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for the increased soft-tissue reactions could be the result of more free movement of soft-tissue 
surrounding the abutment, as was described previously by Brånemark and Albrektsson 21.
All implants were loaded with a sound processor 3 weeks after surgery. The current good 
results suggest that loading at 3 weeks seems to be safe at short-term follow-up, also when 
using tissue preservation and longer abutments. The literature supports these early loading 
protocols with even longer follow-up and similar good outcomes in the standard linear 
incision technique 22,23.
Comparing audiological outcomes by BC in situ measurements, we noticed only minor 
differences in thresholds between both groups, except for testband at 1kHz and difference 
between abutment-B71 at 1.5kHz and abutment-testband on 1kHz and 1.5kHz. The 
significantly poorer results on these frequencies for the test-group may be due to changes in 
resonance frequency of the sound processor in the transcutaneous conditions, resulting in 
less output in the mid frequencies 14. This effect is most strongly present in cases with tissue 
preservation. Nevertheless, it seems that surrounding skin around abutments and longer 
abutments did not affect the transmission of sound at 6 months follow-up with current set-up.
Generalizability and conclusions
This study adds knowledge in the rapidly evolving tissue preservation trend in bone an-
chored hearing implant surgery. Since we noticed some conflicting results compared to the 
existing literature, like the increase in soft-tissue reactions according to Holgers, this study 
emphasizes the need for a more elaborate evaluation of new surgical techniques before 
complete substitution of currently applied methods is sensible.
Based on the current 6 months results, the overall difference between these surgical 
techniques from a patient’s perspective might not be evidently in favor of either tissue 
preservation or tissue reduction: comparable results on audiology, less numbness and better 
POSAS scores, yet more soft-tissue reactions according to Holgers were recorded in the first 
6 months. However, since adverse soft-tissue reactions in the study completely recovered 
after one or two local treatment regimens, the burden for patients might be relatively minor. 
An additional important gain is the reduction of surgery times.
Longer follow-up of the current study will be needed to draw firm conclusions, especially 
regarding soft-tissue reactions. Data on 36 months results will be reported for this study 
later.
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Objectives To compare the hearing performance of patients with conductive and 
mild mixed hearing loss and single-sided sensorineural deafness pro-
vided with a new transcutaneous bone conduction hearing implant 
(the Baha Attract System) with unaided hearing as well as aided with 
a sound processor on a softband. Furthermore, to evaluate safety and 
subjective benefit before and after implantation of the test device.
Participants Fifty-four adult patients in five participating centres were enrolled in 
this prospective study. Baseline data were collected during a pre-
operative visit and after a softband trial all patients were implanted 
unilaterally. Follow-up visits were scheduled at 10 days, 4 weeks, 6 
weeks, 12 weeks, and 6 months.
Main outcome 
measures
Free-field hearing thresholds (PTA4 in dB HL; mean threshold at 500, 
1000, 2000, 4000Hz) (primary outcome measure). Individual free-
field hearing thresholds, speech recognition in quiet and in noise, soft 
tissue status during follow-up and subjective benefit as measured with 
the APHAB, SSQ and HUI questionnaires.
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Results Implantation of the Baha Attract System resulted in favourable 
audiological outcomes compared to unaided conditions. On the 
primary outcome parameter, a statistically significant improvement 
was observed compared to unaided hearing for the patients with 
conductive/mixed hearing loss (mean PTA4 difference -20.8dB HL, 
SD 9.8; p<0.0001), and for the patients with single-sided sensori-
neural deafness (SSD) (mean PTA4 difference -21.6dB HL, SD 12.2; 
p<0.0001). During all audiology tests, the non-test ear was blocked. 
Statistically significant improvements were also recorded in speech 
tests in quiet and noise compared to unaided hearing for the conduc-
tive/mixed hearing loss group and for speech in quiet in the SSD 
group. Compared to the preoperative measurement with softband, 
no significant differences were recorded in the PTA4 free-field hearing 
threshold or the other audiological outcomes in either of the groups 
(p>0.05). Soft tissue related issues observed during follow-up included 
numbness, pain/discomfort at the implant site and to a lesser extent 
pressure related skin complications. A declining trend was noted 
in the rate of these complications during follow-up. Approximately 
20% of patients reported some degree of numbness and 38% (slight) 
pain/discomfort at final follow-up of 6 months. Good results on the 
subjective benefit questionnaires were observed, with statistically 
significant improvements on APHAB and SSQ questionnaires, and on 
the hearing attribute of HUI3.
Conclusions The Baha Attract System provided a significant improvement in hear-
ing performance and subjective benefit compared to the preoperative 
unaided condition (with the non-test ear blocked). Hearing perfor-
mance of the Baha Attract was similar to a test situation with the same 
sound processor on a softband. A proportion of the patients reported 
numbness and pain/discomfort at the implant site during follow-up, 
especially during the first postoperative weeks. Based on the results of 
the current multicentre study, the Baha Attract can be considered as a 
treatment option for patients with the aforementioned hearing losses. 
Especially in the SSD patients a careful selection procedure is war-
ranted. Therefore a pre-operative trial should be part of the decision 
making process before fitting a patient with the Baha Attract System.
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Introduction
Bone conduction hearing implant systems (also referred to as auditory osseointegrated 
implant systems) have been used for over 40 years as an effective method for hearing 
rehabilitation in patients with conductive and mixed hearing loss who could not be reha-
bilitated with conventional hearing aids or surgery, as well as for single-sided sensorineural 
deafness (SSD) in more recent years. Traditional systems include an osseointegrated tita-
nium implant with a percutaneous (skin-penetrating) abutment on which a bone conduction 
sound processor can be coupled. While the percutaneous system provides good results 
in terms of hearing and clinical outcomes as well as patient satisfaction, it still has some 
disadvantages due to the percutaneous coupling. Potential complications include loss of 
the titanium implant, recurrent soft tissue problems around the abutment (particularly when 
daily care poses problems), and potential aesthetic issues related to the percutaneous 
abutment 1, with some patients declining a percutaneous solution. In 1986, a transcutane-
ous (non skin-penetrating) bone conduction system, the Xomed Audiant, was introduced 
that had the potential to overcome these problems; however, disappointing output and 
skin complications resulted in withdrawal from the market 2-3. Over the past few years, 
new transcutaneous bone conduction implants were introduced, including the Baha Attract 
System 4. The Baha Attract System consists of a subcutaneous part, including a regular 
titanium implant on which an internal magnet is attached. Externally, a sound processor 
is attached to a second magnet and a soft pad, intended to distribute the pressure evenly 
over the underlying intact skin surface and thereby preventing pressure-related issues. Since 
initiation of the current study, several clinical studies have reported good results with this 
system, with favourable clinical outcomes and significant improvement in audiological 
outcomes compared to unaided conditions 5-12. The current study was intended to add 
data on efficacy in terms of hearing performance and to evaluate safety of the Baha Attract 
System in a multicentre setting in the largest study on this new device to date. The present 
paper reports the results from the primary analysis after 6 months of follow-up. The patients 
will continue to be followed up for a total of 24 months.
Materials And Methods
Study design and participants
The aim of the current multicentre study was to compare the hearing performance of a 
transcutaneous bone conduction hearing implant system, the Baha Attract System (test 
device) manufactured by Cochlear Bone Anchored Solutions AB (Mölnlycke, Sweden), 
with unaided hearing and with the hearing performance of the same sound processor on a 
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Baha softband. Additionally, the study aimed to evaluate changes in subjective benefit and 
clinical outcomes with the test device compared to the preoperative situation.
Fifty-four adult patients with an indication for a bone conduction hearing implant were 
consecutively included in one of five participating centres starting May 2014: Queen Eliza-
beth Hospital Birmingham (Birmingham, UK), World Hearing Center Institute of Physiology 
and Pathology of Hearing (Warsaw, Poland), Manchester Royal Infirmary (Manchester, 
UK), Medical College of Wisconsin (Milwaukee, USA), and Radboud University Medical 
Center Nijmegen (Nijmegen, the Netherlands). Eligibility criteria for participation in the 
study are shown in Figure 1.
Surgery and follow-up
During the preoperative visit baseline characteristics were collected, and audiological 
and subjective hearing assessments were performed. During this visit a suitable sound 
processor was selected by the audiologist and the patient. Audiological outcomes, as 
exemplified below, were determined in an unaided condition and with the selected sound 
processor on a softband. All patients underwent a home trial of approximately one week 
(small variations depending on local clinical practice) with the sound processor on softband 
before consent for surgery.
A single-stage surgical procedure with placement of a 4mm BI300 Implant and a BIM400 
Implant Magnet was applied in all centres (Figure 2a). The surgical technique involves an 
anterior based C-shaped flap 15 mm away from the edge of the implanted magnet (Figure 
2b). Soft tissue thinning was advocated in case of >6 mm soft tissue thickness measured 
preoperatively and confirmed with a soft tissue gauge during surgery. Bone polishing was 
advocated in case of an uneven bone surface underneath the implant magnet. During 
implantation the Implant Stability Quotient (ISQ) was measured using resonance frequency 
analysis (RFA) at the implant level with the Osstell ISQ instrument and SmartPeg type 30 
Adult subject, i.e. ≥ 18 years of age 
Conductive or mixed hearing loss: bone conduction thresholds with a pure tone average PTA4* of <30 dB 
hearing level in the ear to be implanted 
OR 
Single-sided sensorineural deafness (SSD): bone conduction thresholds with a PTA4* of ≤ 30 dB hearing level 
in the good ear** 
No previous bone conduction implant on the side of the skull to be implanted 
Patients that are scheduled for unilateral implant surgery 
At least 3mm soft tissue thickness at the planned implant site 
Condition that could jeopardize osseointegration and/or wound healing should not be present (e.g. 
osteoporosis, psoriasis, use of corticosteroids, uncontrolled diabetes, radiation therapy at the same side of the 
skull as the planned implant) 
Able to follow investigational procedures (e.g. to complete quality of life scales) 
*mean of 500, 1000, 2000, 4000 Hz 
** for US ≤ 20 dB hearing level AC in the good ear or indication for an AC CROS but cannot or will not use an AC 
CROS 
 Figure 1. Eligibility criteria
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(Osstell, Göteborg, Sweden). The ISQ score ranges from 1 to 100, with increasing scores 
suggesting a more rigid implant-bone interface. Perpendicular measurements resulted in an 
ISQ low and ISQ high value 13. Surgery time was measured as the time from first incision 
until last suture.
Follow-up visits were scheduled at 10 days (±5 days; wound inspection and removal of 
sutures), 4 weeks (±1 week; sound processor fitting), 6 weeks (±1 week), 12 weeks (±2 
weeks), and 6 months (±4 weeks). During all follow-up visits the selected sound proces-
sor, the selected sound processor magnet (SPM) and the sound processor settings were 
evaluated. The sound processors that were available for use in the investigation were 
the Cochlear Baha 4 and BP110 sound processors. During the study, the Baha 5 Sound 
Processor became available and was used in two cases. The SPM is available in six 
different strengths, with SPM1 being the weakest and SPM6 the strongest. The sound 
processor magnet is selected based on subjective evaluation of the SPM retention and 
patient preferences. In case of an SPM change or when patient reported suboptimal fitting, 
re-fitting of the sound processor settings was performed, using BC Direct and feedback 
measurements (part of the fitting software).
Outcome measures
Primary outcome
Free-field threshold audiometry with the Baha Attract versus unaided preoperative assess-
ment was chosen as primary outcome measure. From individual thresholds, the pure-tone 
average (PTA4, mean of 500, 1000, 2000, and 4000Hz) was calculated. Narrow-band 
noise was presented through a speaker in front position (0 degrees azimuth) according 
to the ascending or modified Hughson-Westlake method 14. During the tests, the sound 
processor was set to omnidirectional mode and the non-test ear was blocked with an ear 
plug, in 2 centres additionally an ear muff was applied (Nijmegen, Kajetany).
Figure 2a. Baha® Attract System Figure 2b. Surgical incision, in two of the centres 
an anterior based flap was used
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Secondary outcomes
Secondary outcomes included free-field thresholds at individual frequencies (250, 500, 
1000, 2000, 3000, 4000, and 6000Hz), speech perception in quiet and in noise. 
Speech in quiet was tested with monosyllables presented from the front (0 degrees azi-
muth). The percentage correct words at each presentation level (50, 65 and 80dB SPL) 
was recorded. Speech perception in noise was evaluated with sentences from the front 
(0 degrees azimuth) and with noise from the back (180 degrees azimuth). Noise was 
presented at a fixed level of 65 dB SPL while the speech level was adapted in 2dB steps 
to establish the level of 50% correct responses (SRT). The difference between the SRT and 
the noise level is the speech-to-noise ratio (SNR). During both tests, the sound processor was 
set to omnidirectional mode and the non-test ear was blocked. Due to differences in native 
languages, different speech materials and tests were used at the test sites (Birmingham and 
Manchester: QuickSIN test 15 and AB word lists 16; Warsaw: Matrix test 17 and monosyl-
labic word test according to Pruszewicz 18; Milwaukee: HINT 19 and CNC lists 20; Ni-
jmegen: Plomp&Mimpen 21 and NVA-Bosmanlijsten 22). Absolute SNR scores were related 
to reference values for normal hearing patients for each specific test (Milwaukee -2.92dB 
19, Nijmegen -5.4dB 21, Kajetany -9.6dB 17) to enable comparison of data across sites; for 
evaluation of within-patient change in SNR the reference value is not required.
Clinical parameters comprised daily use of the sound processor in hours, number of 
episodes of insufficient retention per week, number of changes of the soft pad per week, 
and implant loss/removal. Pain was measured using a 4-point Likert scale; from no pain/
discomfort to excessive pain/discomfort. Numbness was tested at randomly picked loca-
tions around the implant area with a pin and a cotton swab and was indicated as no 
numbness, numbness within 2 cm of the centre of the magnet or numbness (within and) 
beyond 2 cm of the centre of the magnet. Additionally, soft tissue status was scored 
as signs of infection, inflammation, skin necrosis or scar hypertrophy. Furthermore, any 
adverse events or device deficiencies were reported.
Magnetic retention force (MRF) was measured using a dynamometer (Baha Attract Force 
Gauge, Cochlear Bone Anchored Solutions AB), which measures the force in Newton 
(N) required to remove the external magnet from the skin overlying the internal magnet. 
The SPM soft pads used in the study showed a slight variation in thickness, resulting in 
approximately 0.1 Newton variability in MRF measurements.
Subjective benefit was measured by the Health Utilities Index (HUI3) 23, Abbreviated 
Profile of Hearing Aid Benefit (APHAB) 24, and Speech, Spatial and Qualities of Hearing 
Scale (SSQ) 25 questionnaires. The HUI3 is a generic preference based measure composed 
of 15 individual questions on 8 health-related quality of life dimensions: vision, hearing, 
speech, ambulation, dexterity, emotion, cognition, and pain. Each dimension is scored 
according to the utility approach from 0.00 for the lowest (highest degree of impairment or 
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disability) to 1.00 for the highest level (no impairment). Additionally, from these separate 
dimensions a comprehensive health state attribute is calculated.
The APHAB is a 24-item inventory, which is scored in four subscales on communication 
abilities or perception of sound in daily life situations (ease of communication, reverbera-
tion, background noise, aversiveness) and a global score. All items are scored on a 7-point 
scale indicating frequency of problems experienced, ranging from 1 to 99%, with higher 
scores indicating more problems.
The SSQ is composed of 49 items that are scored on a visual analogue scale with 0 
representing complete inability and 10 representing complete ability or complete presence 
of a quality (or absence of need for effort). The questionnaire measures auditory disability 
across three subscales: hearing speech in a variety of contexts; directional, distance and 
movement components of spatial hearing and the ability to segregate sounds; and qualities 
of hearing including ease of listening, naturalness, clarity and identifiability of different 
sounds. For all subscales a mean score is calculated.
Sample size and statistical analysis
Sample size calculations were conducted to include enough power to detect a change 
on the primary outcome measure, PTA4 for unaided hearing versus hearing with the Baha 
Attract, as well as on the secondary outcome measure PTA4 softband versus Baha Attract. 
The power was set to 90% with a two-sided test with a significance level of 0.05. A 
within subject standard deviation of 3dB was assumed based on a previous internal study 
performed by the study sponsor. To compensate for a 10% dropout rate, a minimum of 52 
patients needed to be included to detect a change of 1.5dB in free-field hearing thresholds 
on the secondary outcome measure. Sample size calculation was based on the full study 
population; due to the essentially different applications in conductive/mixed hearing loss 
(n=39) and SSD (n=15), results were analysed per type of indication. However, total 
group results are presented for the parameters that were used for the power calculation. 
Statistical analyses were performed by paired non-parametric tests based on non-normality 
assumptions. Paired measurements of audiometry and questionnaires were analysed us-
ing Fisher’s non-parametric permutation test in an intention to treat analysis (ITT) (which 
included all patients that underwent surgery). Additionally, a per protocol population (PP) 
was defined which excluded patients with hearing tests performed significantly outside a 
visit window or not performed during the selected visit, and patients who did not have a 
refitting after a magnet change. All tests were two-tailed with significance levels of 0.05. 
Missing values were not imputed and no adjustments were made for multiple testing.
Monitoring at the European sites was performed by external monitors (Factory-CRO, 
Bilthoven, The Netherlands); monitoring at the US site was performed by monitors at Co-
chlear Americas (Denver, CO, USA). Data management was performed by external data 
managers (Factory CRO, Bilthoven, The Netherlands), and statistical analysis was realized 
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by external biostatisticians (Statistiska Konsultgruppen, Göteborg, Sweden) according to a 
predefined statistical analysis plan and using SASâ v9.4 (Cary, NC, USA).
Ethical considerations
The study was approved by all local ethics committees/institutional review boards and 
registered with ClinicalTrials.gov and assigned the identifier NCT02022085.
RESULTS
Patients and surgery characteristics
Results are presented for the intention to treat (ITT) population (n=54, all patients who 
underwent surgery). Similar outcomes were recorded for the per protocol (PP) population 
(n=49).
Sixty-one patients were screened for participation in the study, 7 patients were with-
drawn from the study before surgery. Reasons for discontinuation before surgery were either 
eligibility failure (n=2) or withdrawal of consent (n=5). Three of the patients that withdrew 
consent opted for a percutaneous bone conduction hearing implant. Fifty-four patients were 
included in the study and underwent surgery between May 2014 and July 2015. Per 
centre, 12 patients in Birmingham, 14 patients in Warsaw, 4 patients in Manchester, 1 
patient in Milwaukee and 23 patients in Nijmegen were included. Baseline characteristics 
are shown in Table 1. Thirty-nine patients were eligible for a bone conduction hearing 
implant because of a conductive or mixed hearing loss (mean PTA4 BC Baha side 11.4dB 
HL, SD 6.0, range 2.5-28.8), and 15 patients because of SSD (mean PTA4 BC good ear 
8.1dB HL, SD 7.4, range -2.5-23.8 , mean PTA4 AC good ear 11.8dB HL, SD 10.4, 
range 1.3-42.5) (Figure 3). Mean surgery time was 38.7 minutes (SD 10.7; range 17-68 
minutes). Soft tissue thinning was performed in 22.2% (n=12) and bone polishing was nec-
essary in 20.4% (n=11) of the patients. ISQ measurements at implant level resulted in ISQ 
low 73.5 (SD 9.4; range 41.0-85.0) and ISQ high 77.3 (SD 9.0; range 41.0-90.0).
One patient discontinued the study after surgery; explantation of the implant magnet was 
required because of infection at the implant site appearing shortly after implantation. All 
other patients completed 6 months of follow-up.
Audiology
Free-field thresholds
On the primary outcome parameter, average free-field hearing threshold PTA4 with the non-
test ear blocked, a significant improvement with the Baha Attract was observed compared 
to preoperative unaided hearing was observed at 6 months for the group of patients 
with conductive/mixed hearing loss (mean PTA4 difference -20.8dB, SD 9.8; p<0.0001) 
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(Table 2a). For all individual frequencies, this significant improvement was observed (Figure 
4a). Audiological results were similar at fitting as seen at 6 months follow-up.
Results with the test device at 6 months, were not statistically significantly different from 
the results with the same processor on a softband for the group of patients with conductive/
mixed hearing loss (mean PTA4 difference – 0.3dB, SD 5.2; p=0.73). When comparing 
individual frequencies, the results for the test device were statistically significantly better 
at 500Hz (mean difference -3.97dB, SD 7.6; p=0.0026) while more favourable results 
were obtained with the softband at 3kHz, 4kHz and 6kHz (mean difference at 3kHz: 
3.46, SD 10.2, p=0.027; at 4kHz: 3.85dB, SD 9.1, p=0.012; at 6kHz: 6.0dB, SD 
10.0, p=0.0007).
For the subgroup of patients with SSD, similar results were observed both compared 
to the unaided situation (mean PTA4 difference -21.6dB; SD 12.2, p=<0.0001) and 
compared to softband (mean PTA4 difference -1.5dB, SD 5.1, p=0.27).
Consequently, the total study population (presented for trial publishing obligations) 
showed similar outcomes compared to unaided hearing (mean PTA4 difference –21.0dB; 
Table 1. Baseline characteristics
Characteristics Study group n=54
Gender Male 21 (38.9%)
Female 33 (61.1%)
Age at baseline Years 42.1 (SD 13.6; range 18.3-70.3)
Smoking at baseline Yes 14 (25.9%)
No 40 (74.1%)
Indication Conductive/mixed 39 (72.2%)
SSD 15 (27.8%)
Bone conduction PTA*, 
mean (SD) dB
Baha side (conductive/mixed) 11.4 (SD 6.0)
Good ear (SSD) 8.1 (SD 7.4)
Currently using a hearing 
aid
Yes 7 (13.0%)
No 47 (87.0%)
Sound processor BP100 1 (1.9%)
BP110 23 (42.6%)
Baha 4 28 (51.9%)
Baha 5 2 (3.7%)
Study site Birmingham 12 (22.2%)
Warsaw 14 (25.9%)
Manchester 4 (7.4%)
Milwaukee 1 (1.9%)
Nijmegen 23 (42.6%)
* 500, 1000, 2000, 4000 Hz
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SD 10.4, p=<0.0001) and compared to softband (mean PTA4 difference –0.6dB; SD 
5.1, p=0.38). Note that the non-test ear was blocked.
Speech in quiet and noise
Additional audiological measures in the conductive/mixed hearing loss group demon-
strated statistically signifi cant improvements in speech recognition in noise and in quiet for 
the Baha Attract as compared to the preoperative unaided condition (Table 2b). When 
comparing results of the (preoperative) softband application to the 6 months follow-up data 
with the test device, no differences were observed. There was a 5.0dB improvement in 
speech to noise ratio (SNR) compared to unaided and a 1.2dB improvement compared 
to softband. The difference in percentage correctly perceived words at 65dB in quiet was 
44.5% more correct words compared to unaided and 3.0% less correct words compared 
to the device on softband. For the SSD group similar results were noted, however smaller 
differences in SNR were recorded compared to unaided (2.6dB improvement compared 
to unaided and 1.3dB less favourable compared to softband). The speech test in quiet at 
65dB resulted in 40.7% more correct words compared to unaided and 0.2% more correct 
words compared to softband. The non-test ear was blocked in all the measurements.
In Table 2b absolute SNR values are presented adjusted to reference values for normal 
hearing listeners. It should be noted that by using reference values, negative values imply 
a. Conductive/mixed hearing loss b. Single-sided deafness
Figure 3. Audiogram preoperative (conductive hearing loss and SSD)
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that the results are worse than those of normal hearing listeners. Reference values were 
used in order to deal with different test characteristics. Nevertheless, even when reference 
values are being used, variability of test results between sites is not completely eliminated. 
SNR data from the site in Birmingham and Manchester were excluded from the analysis, 
due to invalid results for this specific test (incl. incorrect speaker set-up and presentation 
level of speech below patients’ hearing thresholds). As a result the ITT population only for 
the SNR data included 27 patients in the conductive/mixed hearing loss group and 11 
patients in the SSD group.
Clinical parameters
SP magnet selection and daily use
Choice of sound processor and sound processor magnets is presented in Table 2b. At 
first fitting, the most frequently selected magnets were the SPM5 or SPM6 (70%). During 
follow-up, a general decrease in magnet strength was noted, with SPM3 and SPM4 
being most frequently selected at 6 months follow-up (57%). Sound processor magnets 
were adjusted according to patient preferences, including presence of pain/discomfort, 
insufficient retention, or clinical signs of increasing/decreasing soft tissue compression. As 
shown in Table 2b, many patients needed a magnet change at all follow-up visits, even at 
6-months follow-up 75% of all patients required a decrease or increase in magnet strength. 
Mean magnetic retention force was stable over time, with a mean of 1.0-1.2 Newton at 
the different follow-up visits. However, the retention force varied between patients (range 
at 6 months visit: 0.3-2.2 Newton). In nine patients, the sound processor was replaced 
during the study period. Reasons for change of the initially selected sound processor 
mostly included availability of a newer sound processor and for one patient a change was 
needed because of magnetic retention difficulties (a smaller and lighter sound processor 
was selected). During the first weeks after initial fitting the sound processor was reported 
to fall off 4.5 times a week on average (SD 14.7); in the following weeks/months this 
number decreased to 1.8-1.9 per week. In the total group, average daily use was constant 
during follow-up, with a mean of 7.8 hours/day at 6 months (SD 4.6; range 0.5-18.0 
hours/day).
Soft tissue problems and adverse events
During the study, four patients indicated excessive discomfort or pain at the implant site, 
which resolved spontaneously before final follow-up at 6 months. Some degree of discom-
fort/pain was stated by 60.4% of patients at 6 weeks; this number decreased to 37.7% 
of patients at 6 months (28.3% only slight discomfort/pain). No evident effect of soft 
tissue thinning on pain or numbness outcomes was observed. Numbness, reported by the 
patients during tests with either the pin, cotton swab or both, at the implant site was present 
for 64.2% of patients at the 6-week postoperative visit. At final follow-up this number 
148
Ta
b
le
 2
a
. 
A
ud
io
lo
gy
 o
ut
co
m
es
, i
nt
en
tio
n-
to
-tr
ea
t a
na
ly
sis
O
u
tc
o
m
e
C
o
n
d
u
ct
iv
e/
m
ix
ed
 h
ea
ri
n
g
 lo
ss
 (
n
=
3
9
)
P
re
-o
p
er
a
ti
ve
 
u
n
a
id
ed
(S
D
; 
ra
n
g
e)
P
re
-o
p
er
a
ti
ve
 
so
ft
b
a
n
d
(S
D
; 
ra
n
g
e)
Fi
tt
in
g
 T
es
t 
d
ev
ic
e
(S
D
; 
ra
n
g
e)
6
 m
o
n
th
s 
Te
st
 d
ev
ic
e
(S
D
; 
ra
n
g
e)
C
h
a
n
g
e 
p
re
-
o
p
er
a
ti
ve
 u
n
a
id
ed
 
to
 6
 m
o
n
th
s 
a
id
ed
(S
D
; 
ra
n
g
e)
C
h
a
n
g
e 
p
re
-
o
p
er
a
ti
ve
 a
id
ed
 t
o
 
6
 m
o
n
th
s 
a
id
ed
(S
D
; 
ra
n
g
e)
M
ea
n
 f
re
e 
fi
el
d
 h
ea
ri
n
g
 
te
st
s:
 t
h
re
sh
o
ld
 a
u
d
io
m
et
ry
 
P
TA
4
*,
 d
B
51
.8
 (S
D
 9
.4
; 
36
.3
 to
 5
4.
9)
31
.3
 (S
D
 6
.2
; 
16
.3
 to
 4
3.
8)
30
.5
 (S
D
 7
.9
; 
18
.8
-5
5.
0)
31
.1
 (S
D
 7
.0
; 
18
.8
-5
2.
5)
-2
0.
8 
(S
D
 9
.8
; -
38
.8
-
5.
0)
 p
<0
.0
00
1
-0
.2
9 
(S
D
 5
.1
9;
 -1
0.
0-
13
.7
5)
 p
=0
.7
3
A
d
a
p
ti
ve
 s
p
ee
ch
 
re
co
g
n
it
io
n
 in
 n
o
is
e 
(5
0
%
, 
si
g
n
a
l t
o
 n
o
is
e 
ra
ti
o
),
 d
B
**
9.
3 
(S
D
 7
.1
; 1
.3
 
to
 3
2.
1)
 (n
=2
5)
5.
9 
(S
D
 5
.5
; -
1.
4 
to
 1
9.
6)
 (n
=2
7)
5.
4 
(S
D
 4
.6
; 
-3
.9
 to
 1
3.
4)
 
(n
=2
7)
4.
7 
(S
D
 3
.9
; 
-1
.8
 to
 1
1.
4)
 
(n
=2
7)
-5
.0
 (S
D
 6
.2
; -
23
.9
 to
 
5.
1 
) p
<0
.0
00
1 
(n
=2
5)
-1
.2
 (S
D
 4
.0
; -
8.
2 
to
 
6.
8)
 p
 =
0.
13
 (n
=2
7)
Sp
ee
ch
 in
 q
u
ie
t,
 %
 c
o
rr
ec
tl
y
 
p
er
ce
iv
ed
 w
o
rd
s
5
0
d
B
7.
4 
(S
D
 1
6.
5;
 0
 
to
 6
0)
56
.6
 (S
D
 2
6.
9;
 
20
 to
 1
00
)
53
.5
 (S
D
 3
0.
5;
 
0 
to
 1
00
) 
(n
=3
7)
61
.2
 (S
D
 2
2.
8;
 
0 
to
 1
00
)
53
.8
 (S
D
 2
7.
6;
 -2
4 
to
 
10
0)
 p
<0
.0
00
1
4.
67
 (S
D
 2
7.
3;
 -4
7 
to
 
60
) p
=0
.2
9
6
5
d
B
44
.4
 (S
D
 3
2.
4;
 
0 
to
 9
6)
91
.8
 (S
D
 9
.2
; 7
0 
to
 1
00
)
89
.6
 (S
D
 1
2.
4;
 
45
 to
 1
00
) 
(n
=3
7)
88
.8
 (S
D
 1
4.
6;
 
30
 to
 1
00
)
44
.5
 (S
D
 3
1.
7;
 -3
 to
 
10
0)
 p
<0
.0
00
1
-3
.0
 (S
D
 1
1.
7;
 -4
5 
to
 
20
) p
=0
.1
2
8
0
d
B
82
.4
 (S
D
 2
3.
5;
 
10
 to
 1
00
)
96
.9
 (S
D
 5
.7
; 7
0 
to
 1
00
)
96
.6
 (S
D
 4
.9
; 
80
 to
 1
00
) 
(n
=3
7)
96
.3
 (S
D
 5
.7
; 
70
 to
 1
00
)
13
.8
 (S
D
 2
2.
2;
 -2
0 
to
 
80
) p
<0
.0
00
1
-0
.6
7 
(S
D
 4
.7
; -
10
 to
 
10
) p
=0
.4
* 
50
0,
 1
00
0,
 2
00
0,
 4
00
0 
H
z
**
 a
dj
us
te
d 
to
 re
fe
re
nc
e 
va
lu
es
 fo
r n
or
m
al
 h
ea
rin
g 
M
ilw
au
ke
e 
-2
.9
2 
dB
, N
ijm
eg
en
 -5
.4
 d
B,
 K
aj
et
an
y 
-9
.6
 d
B
149
Ta
b
le
 2
a
. 
A
ud
io
lo
gy
 o
ut
co
m
es
, i
nt
en
tio
n-
to
-tr
ea
t a
na
ly
sis
O
u
tc
o
m
e
SS
D
 (
n
=
1
5
)
P
re
-o
p
er
a
ti
ve
 
u
n
a
id
ed
(S
D
; 
ra
n
g
e)
P
re
-o
p
er
a
ti
ve
 
so
ft
b
a
n
d
(S
D
; 
ra
n
g
e)
Fi
tt
in
g
 T
es
t 
d
ev
ic
e
(S
D
; 
ra
n
g
e)
6
 m
o
n
th
s 
Te
st
 d
ev
ic
e
(S
D
; 
ra
n
g
e)
C
h
a
n
g
e 
p
re
-
o
p
er
a
ti
ve
 u
n
a
id
ed
 
to
 6
 m
o
n
th
s 
a
id
ed
(S
D
; 
ra
n
g
e)
C
h
a
n
g
e 
p
re
-
o
p
er
a
ti
ve
 a
id
ed
 t
o
 
6
 m
o
n
th
s 
a
id
ed
(S
D
; 
ra
n
g
e)
M
ea
n
 f
re
e 
fi
el
d
 h
ea
ri
n
g
 
te
st
s:
 t
h
re
sh
o
ld
 a
u
d
io
m
et
ry
 
P
TA
4
*,
 d
B
52
.3
 (S
D
 1
3.
2;
 
23
.8
 to
 8
1.
3)
32
.3
 (S
D
 4
.9
; 
21
.3
 to
 3
8.
8)
29
.2
 (S
D
 5
.1
; 
17
.5
 to
 3
6.
3)
30
.8
 (S
D
 4
.0
; 
23
.8
 to
 3
7.
5)
-2
1.
6 
(S
D
 1
2.
2;
 -5
0.
0 
to
 
0.
0)
 p
<0
.0
00
1
-1
.5
 (S
D
 5
.1
; -
11
.3
 to
 
5.
0)
 p
<0
.0
00
1
A
d
a
p
ti
ve
 s
p
ee
ch
 
re
co
g
n
it
io
n
 in
 n
o
is
e 
(5
0
%
, 
si
g
n
a
l t
o
 n
o
is
e 
ra
ti
o
),
 d
B
**
6.
9 
(S
D
 3
.4
; 0
.3
 
to
 1
1.
8)
 (n
=1
1)
2.
99
 (S
D
 3
.1
; 
-4
.3
 to
 8
.0
) 
(n
=1
1)
4.
3 
(S
D
 2
.4
; 
1.
0 
to
 7
.7
) 
(n
=1
1)
4.
3 
(S
D
 3
.4
; 
-1
.8
 to
 1
0.
3)
 
(n
=1
1)
-2
.5
7 
(S
D
 3
.9
; -
7.
2 
to
 
3.
8)
 p
 =
0.
05
1 
(n
=1
1)
1.
3 
(S
D
 4
.2
; -
5.
1 
to
 
8.
4)
 p
 =
0.
34
 (n
=1
1)
Sp
ee
ch
 in
 q
u
ie
t,
 %
 c
o
rr
ec
tl
y
 
p
er
ce
iv
ed
 w
o
rd
s
5
0
d
B
22
.0
 (S
D
 3
9.
0;
 
0 
to
 1
00
)
71
.8
 (S
D
 1
7.
5;
 
48
 to
 1
00
)
70
.8
 (S
D
 2
0.
6;
 
30
 to
 1
00
) 
(n
=1
4)
69
.5
 (S
D
 1
7.
9;
 
40
 to
 9
5)
47
.5
 (S
D
 3
3.
6;
 -2
0 
to
 
90
) p
=0
.0
00
5
-2
.3
 (S
D
 1
7.
1;
 -5
0 
to
 
27
) p
=0
.6
7
6
5
d
B
52
.9
 (S
D
 3
3.
5;
 
0 
to
 1
00
)
93
.3
 (S
D
 1
1.
1;
 
60
 to
 1
00
)
94
.4
 (S
D
 6
.7
; 
78
 to
 1
00
) 
(n
=1
4)
93
.5
 (S
D
 6
.1
; 
80
 to
 1
00
)
40
.7
 (S
D
 3
1.
8;
 0
 to
 9
6)
 
p=
0.
00
05
0.
2 
(S
D
 7
.1
; -
10
 to
 2
0)
 
p=
0.
94
8
0
d
B
85
.2
 (S
D
 1
5.
0;
 
57
 to
 1
00
)
96
.7
 (S
D
 5
.4
; 8
0 
to
 1
00
)
97
.8
 (S
D
 3
.0
 
; 9
0 
to
 1
00
) 
(n
=1
4)
97
.2
 (S
D
 4
.1
; 
90
 to
 1
00
)
12
.0
 (S
D
 1
4.
6;
 -1
0 
to
 
43
) p
=0
.0
05
9
0.
5 
(S
D
 5
.7
; -
10
 to
 1
0)
 
p=
0.
78
* 
50
0,
 1
00
0,
 2
00
0,
 4
00
0 
H
z
**
 a
dj
us
te
d 
to
 re
fe
re
nc
e 
va
lu
es
 fo
r n
or
m
al
 h
ea
rin
g 
M
ilw
au
ke
e 
-2
.9
2 
dB
, N
ijm
eg
en
 -5
.4
 d
B,
 K
aj
et
an
y 
-9
.6
 d
B
150
Ta
b
le
 2
b
. 
C
lin
ic
al
 o
ut
co
m
es
, i
nt
en
tio
n-
to
-tr
ea
t a
na
ly
sis
O
u
tc
o
m
e
1
0
D
 -
 S
u
tu
re
 
re
m
o
va
l (
n
=
5
4
)
4
W
 –
 F
it
ti
n
g
 
(n
=
5
4
)
6
W
 (
n
=
5
3
)
1
2
W
 (
n
=
5
3
)
6
M
 (
n
=
5
3
)
SP
 M
a
g
n
et
SP
M
1
-
0 
(0
.0
%
)
1 
(1
.9
%
)
0 
(0
.0
%
)
0 
(0
.0
%
)
SP
M
2
-
1 
(1
.9
%
)
2 
(3
.8
%
)
9 
(1
7.
0%
)
9 
(1
7.
0%
)
SP
M
3
-
6 
(1
1.
1%
)
13
 (2
4.
5%
)
15
 (2
8.
3%
)
18
 (3
4.
0%
)
SP
M
4
-
9 
(1
6.
7%
)
16
 (3
0.
2%
)
11
 (2
0.
8%
)
12
 (2
2.
6%
)
SP
M
5
-
19
 (3
5.
2%
)
10
 (1
8.
9%
)
12
 (2
2.
6%
)
9 
(1
7.
0%
)
SP
M
6
-
19
 (3
5.
2%
)
11
 (2
0.
8%
)
6 
11
.3
%
)
5 
(9
.4
%
)
M
a
g
n
et
ic
 r
et
en
ti
o
n
 f
o
rc
e,
 
N
ew
to
n
-
1.
0 
(S
D
 0
.4
; 
ra
ng
e 
0.
3-
1.
7)
1.
1 
(S
D
 0
.3
; 
ra
ng
e 
0.
4-
1.
8)
1.
2 
(S
D
 0
.4
; 
ra
ng
e 
0.
3-
1.
9)
1.
2 
(S
D
 0
.4
; 
ra
ng
e 
0.
3-
2.
2)
C
h
a
n
g
e 
o
f 
m
a
g
n
et
N
o
-
-
23
(4
3,
4%
)
14
(2
6.
4%
)
13
(2
4.
5%
)
D
ec
re
a
se
-
-
27
(5
0.
9%
)
36
(6
7.
9%
)
39
(7
3.
6%
)
In
cr
ea
se
-
-
3(
5.
7%
)
3(
5.
7%
)
1(
1.
9%
)
C
h
a
n
g
e 
o
f 
so
u
n
d
 p
ro
ce
ss
o
r
N
o
-
49
(9
0.
7%
)
51
(9
6.
2%
)
52
(9
8.
1)
51
(9
6.
2%
)
Ye
s
-
5(
9.
3%
)
2(
3.
8%
)
1(
1.
9%
)
2(
3.
8)
D
a
ily
 u
se
 a
ve
ra
g
e,
 h
o
u
rs
/
d
a
y
-
-
7.
2 
(S
D
 4
.1
; 
ra
ng
e 
0-
18
)
8.
3 
(S
D
 4
.7
; 
ra
ng
e 
1-
18
)
7.
8 
(S
D
 4
.6
; 
ra
ng
e 
0.
5-
18
)
N
u
m
b
er
 o
f 
ti
m
es
 s
o
u
n
d
 
p
ro
ce
ss
o
r 
fe
ll 
o
ff
 la
st
 w
ee
k
-
-
4.
5 
(S
D
 1
4.
7;
 
ra
ng
e 
0-
80
)
1.
8 
(S
D
 5
.2
; 
ra
ng
e 
0-
30
)
1.
9 
(S
D
 7
.1
; 
ra
ng
e 
0-
50
)
N
u
m
b
er
 o
f 
so
ft
 p
a
d
 c
h
a
n
g
es
 
p
er
 w
ee
k
-
-
0.
2 
(S
D
 0
.4
; 
ra
ng
e 
0.
0-
2.
0)
0.
2 
(S
D
 0
.2
; 
ra
ng
e 
0.
0-
0.
9)
0.
2 
(S
D
 0
.2
; 
ra
ng
e 
0.
0-
0.
5)
P
a
in
/d
is
co
m
fo
rt
N
o
 d
is
co
m
fo
rt
/p
a
in
-
-
21
 (3
9.
6%
)
24
 (4
5.
3%
)
33
 (6
2.
3%
)
Sl
ig
h
t 
d
is
co
m
fo
rt
/
p
a
in
-
-
15
 (2
8.
3%
)
16
 (3
0.
2%
)
15
 (2
8.
3%
)
D
is
co
m
fo
rt
/p
a
in
-
-
15
 (2
8.
3%
)
11
 (2
0.
8%
)
5 
(9
.4
%
)
151
Ta
b
le
 2
b
. 
C
lin
ic
al
 o
ut
co
m
es
, i
nt
en
tio
n-
to
-tr
ea
t a
na
ly
sis
 (c
on
tin
ue
d)
O
u
tc
o
m
e
1
0
D
 -
 S
u
tu
re
 
re
m
o
va
l (
n
=
5
4
)
4
W
 –
 F
it
ti
n
g
 
(n
=
5
4
)
6
W
 (
n
=
5
3
)
1
2
W
 (
n
=
5
3
)
6
M
 (
n
=
5
3
)
Ex
ce
ss
iv
e 
d
is
co
m
fo
rt
/p
a
in
-
-
2 
(3
.8
%
)
2 
(3
.8
%
)
0 
(0
.0
%
)
N
u
m
b
n
es
s 
w
it
h
 p
in
N
o
 n
u
m
b
n
es
s
12
 (2
2.
2%
)
15
 (2
7.
8%
)
21
 (3
9.
6%
)
33
 (6
2.
3%
)
42
 (8
0.
8%
)
N
u
m
b
n
es
s 
w
it
h
in
 
2
cm
9 
(1
6.
7%
)
7 
(1
3.
0%
)
3 
(5
.7
%
)
5 
(9
.4
%
)
3 
(5
.8
%
)
N
u
m
b
n
es
s 
w
it
h
in
/
b
ey
o
n
d
 2
cm
33
 (6
1.
1%
)
32
 (5
9.
3%
)
29
 (5
4.
7%
)
15
 (2
8.
3%
)
7 
(1
3.
5%
)
N
u
m
b
n
es
s 
w
it
h
 c
o
tt
o
n
 s
w
a
b
N
o
 n
u
m
b
n
es
s
13
 (2
4.
1%
)
18
 (3
3.
3%
)
23
 (4
3.
4%
)
31
 (5
8.
5%
)
43
 (8
2.
7%
)
N
u
m
b
n
es
s 
w
it
h
in
 
2
cm
9 
(1
6.
7%
)
6 
(1
1.
1%
)
2 
(3
.8
%
)
6 
(1
1.
3%
)
2 
(3
.8
%
)
N
u
m
b
n
es
s 
w
it
h
in
/
b
ey
o
n
d
 2
cm
32
 (5
9.
3%
)
30
 (5
5.
6%
)
28
 (5
2.
8%
)
16
 (3
0.
2%
)
7 
(1
3.
5%
)
P
ro
b
le
m
s 
so
ft
 t
is
su
e 
st
a
tu
s*
N
o
54
 (1
00
%
)
52
 (9
6.
3%
)
51
 (9
6.
2%
)
49
 (9
2.
5%
)
51
 (9
6.
2%
)
Ye
s
0 
(0
%
)
2 
(3
.7
%
)
2 
(3
.8
%
)
4 
(7
.5
%
)
2 
(3
.8
%
)
* 
w
er
e 
th
er
e 
an
y 
sig
ns
 o
f i
nf
ec
tio
n,
 in
fla
m
m
at
io
n,
 s
ki
n 
ne
cr
os
is 
an
d/
or
 s
ca
r h
yp
er
tro
ph
y?
152
Ta
b
le
 2
c.
 S
ub
je
ct
iv
e 
be
ne
fit
 q
ue
sti
on
na
ire
s,
 in
te
nt
io
n-
to
-tr
ea
t a
na
ly
sis
O
u
tc
o
m
e
C
o
n
d
u
ct
iv
e/
m
ix
ed
 h
ea
ri
n
g
 lo
ss
 (
n
=
3
9
)
SS
D
 g
ro
u
p
 (
n
=
1
5
)
P
re
o
p
er
a
ti
ve
(S
D
; 
ra
n
g
e)
6
 m
o
n
th
s
(S
D
; 
ra
n
g
e)
C
h
a
n
g
e
P
re
o
p
er
a
ti
ve
(S
D
; 
ra
n
g
e)
6
 m
o
n
th
s
(S
D
; 
ra
n
g
e)
C
h
a
n
g
e
H
U
I
V
is
io
n
0.
97
 (S
D
 0
.0
3;
 r0
.9
5 
to
 1
.0
0)
0.
97
 (S
D
 0
.0
3;
 0
.9
5 
to
 1
.0
0)
p=
1.
00
0.
97
 (S
D
 0
.0
3;
 
0.
95
 to
 1
.0
0)
0.
97
 (S
D
 0
.0
7;
 0
.7
3 
to
 
1.
00
) (
n=
14
)
p=
1.
00
(n
=1
4)
H
ea
ri
n
g
0.
62
 (S
D
 0
.3
3;
 0
.0
0 
to
 1
.0
0)
 (n
=3
8)
0.
77
 (S
D
 0
.1
2;
 0
.3
2 
to
 1
.0
0)
 (n
=3
7)
p=
0.
02
(n
=3
6)
0.
73
 (S
D
 0
.3
3;
 
0.
00
 to
 1
.0
0)
0.
76
 (S
D
 0
.0
7;
 0
.3
2 
to
 
1.
00
) (
n=
13
)
p=
0.
68
(n
=1
3)
Sp
ee
ch
0.
93
 (S
D
 0
.1
4;
 0
.4
1 
to
 1
.0
0)
 (n
=3
8)
0.
98
 (S
D
 0
.0
6;
 0
.8
2 
to
 1
.0
0)
p=
0.
04
(n
=3
8)
0.
94
 (S
D
 0
.1
7;
 
0.
41
 to
 1
.0
0)
0.
98
 (S
D
 0
.0
9;
 0
.6
7 
to
 
1.
00
) (
n=
14
)
p=
0.
75
(n
=1
4)
A
m
b
u
la
ti
o
n
0.
98
 (S
D
 0
.0
7;
 0
.6
7 
to
 1
.0
0)
0.
96
 (S
D
 0
.1
0;
 0
.6
7 
to
 1
.0
0)
p=
0.
25
1.
00
 (S
D
 0
.0
0;
 
1.
00
 to
 1
.0
0)
1.
00
 (S
D
 0
.0
0;
 1
.0
0 
to
 
1.
00
) (
n=
14
)
p=
 1
.0
0
(n
=1
4)
D
ex
te
ri
ty
0.
99
 (S
D
 0
.0
3;
 0
.8
8 
to
 1
.0
0)
0.
98
 (S
D
 0
.0
9 
; 0
.4
5 
to
 1
.0
0)
p=
1.
00
1.
00
 (S
D
 0
.0
0;
 
1.
00
 to
 1
.0
0)
0.
95
 (S
D
 0
.1
5;
 0
.4
5 
to
 
1.
00
) (
n=
14
)
p=
0.
50
(n
=1
4)
Em
o
ti
o
n
0.
93
 (S
D
 0
.1
2;
 0
.3
3 
to
 1
.0
0)
0.
95
 (S
D
 0
.1
3;
 0
.3
3 
to
 1
.0
0)
p=
0.
55
0.
89
 (S
D
 0
.1
8;
 
0.
33
 to
 1
.0
0)
0.
91
 (S
D
 0
.1
8;
 0
.3
3 
to
 
1.
00
) (
n=
14
)
p=
0.
70
(n
=1
4)
C
o
g
n
it
io
n
0.
99
 (S
D
 0
.0
5;
 0
.7
0 
to
 1
.0
0)
0.
98
 (S
D
 0
.0
7;
 0
.7
0 
to
 1
.0
0)
 (n
=3
8)
p=
0.
47
(n
=3
8)
0.
87
 (S
D
 0
.2
3;
 
0.
32
 to
 1
.0
0)
0.
91
 (S
D
 0
.1
9;
 0
.3
2 
to
 
1.
00
) (
n=
14
)
p=
0.
50
(n
=1
4)
P
a
in
0.
91
 (S
D
 0
.1
4;
 0
.4
8 
to
 1
.0
0)
0.
92
 (S
D
 0
.1
3;
 0
.4
8 
to
 1
.0
0)
p=
0.
65
0.
89
 (S
D
 0
.1
1;
 
0.
77
 to
 1
.0
0)
0.
93
 (S
D
 0
.0
8;
 0
.7
7 
to
 
1.
00
) (
n=
14
)
p=
0.
18
(n
=1
4)
C
o
m
p
re
h
en
si
ve
 h
ea
lt
h
 s
ta
te
0.
67
 (S
D
 0
.2
1;
 0
.3
2 
to
 1
.0
0)
 (n
=3
7)
0.
74
 (S
D
 0
.1
99
; 0
.2
8 
to
 0
.9
7)
 (n
=3
6)
p=
0.
11
(n
=3
4)
0.
65
 (S
D
 0
.3
2;
 
-0
.1
4 
to
 0
.9
7)
0.
70
 (S
D
 0
.2
9;
 -0
.0
6 
to
 
0.
93
) (
n=
13
)
p=
0.
49
(n
=1
3)
153
Ta
b
le
 2
c.
 S
ub
je
ct
iv
e 
be
ne
fit
 q
ue
sti
on
na
ire
s,
 in
te
nt
io
n-
to
-tr
ea
t a
na
ly
sis
 (c
on
tin
ue
d)
O
u
tc
o
m
e
C
o
n
d
u
ct
iv
e/
m
ix
ed
 h
ea
ri
n
g
 lo
ss
 (
n
=
3
9
)
SS
D
 g
ro
u
p
 (
n
=
1
5
)
P
re
o
p
er
a
ti
ve
(S
D
; 
ra
n
g
e)
6
 m
o
n
th
s
(S
D
; 
ra
n
g
e)
C
h
a
n
g
e
P
re
o
p
er
a
ti
ve
(S
D
; 
ra
n
g
e)
6
 m
o
n
th
s
(S
D
; 
ra
n
g
e)
C
h
a
n
g
e
A
P
H
A
B
Ea
se
 o
f 
co
m
m
u
n
ic
a
ti
o
n
41
.9
 (S
D
 2
4.
3;
 2
.8
 
to
 9
9.
0)
16
.9
 (S
D
 1
4.
9;
 1
.0
 
to
 6
6.
7)
p<
0.
00
01
27
.8
 (S
D
 1
6.
2;
 
10
.5
 to
 7
6.
5)
20
.5
 (S
D
 1
9.
8;
 1
.0
 to
 
64
.2
) (
n=
14
)
P=
0.
09
(n
=1
4)
B
a
ck
g
ro
u
n
d
 n
o
is
e
56
.7
 (S
D
 2
0.
2;
 1
8.
8 
to
 9
9.
0)
28
.3
 (S
D
 1
6.
8;
 8
.3
 
to
 6
8.
5)
p<
0.
00
01
68
.2
 (S
D
 1
5.
3;
 
45
.7
 to
 9
3.
0)
48
.6
 (S
D
 2
2.
0;
 1
4.
7 
to
 
87
.0
) (
n=
14
)
P=
0.
00
06
(n
=1
4)
R
ev
er
b
er
a
ti
o
n
52
.1
 (S
D
 1
8.
7;
 1
2.
3 
to
 9
9.
0)
25
.9
 (S
D
 1
4.
6;
 2
.8
 
to
 6
2.
5)
p<
0.
00
01
49
.7
 (S
D
 1
9.
4;
 
24
.7
 to
 9
7.
0)
39
.5
 (S
D
 2
4.
6;
 2
.8
 to
 
93
.0
) (
n=
14
)
P=
0.
03
(n
=1
4)
A
ve
rs
iv
en
es
s
31
.6
 (S
D
 2
0.
9;
 1
.0
 
to
 7
6.
7)
32
.9
 (S
D
 1
9.
0;
 1
.0
 
to
 7
4.
5)
p=
0.
71
37
.4
 (S
D
 2
4.
6;
 
2.
8 
to
 9
3.
0)
29
.2
 (S
D
 2
4.
1;
 1
.0
 to
 
68
.3
) (
n=
14
)
p=
0.
25
(n
=1
4)
G
lo
b
a
l
50
.2
 (S
D
 1
8.
1;
 1
5.
2 
to
 9
9.
0)
23
.7
 (S
D
 1
3.
2;
 5
.3
 
to
 5
9.
7)
p<
0.
00
01
48
.6
 (S
D
 1
3.
5;
 
28
.2
 to
 8
8.
8)
36
.2
 (S
D
 1
7.
1;
 1
0.
9 
to
 
74
.6
) (
n=
14
)
P=
0.
00
08
(n
=1
4)
SS
Q
Sp
ee
ch
4.
4 
(S
D
 1
.5
; 0
.8
 to
 
7.
2)
7.
1 
(S
D
 1
.4
; 4
.5
 to
 
9.
4)
p<
0.
00
01
3.
96
 (S
D
 1
.2
; 
1.
8 
to
 5
.6
)
5.
95
 (S
D
 1
.7
; 2
.7
 to
 
8.
5)
 (n
=1
4)
p<
0.
00
01
(n
=1
4)
Sp
a
ti
a
l
4.
3 
(S
D
 1
.8
; 0
.7
 to
 
8.
3)
6.
4 
(S
D
 1
.6
; 2
.2
 to
 
9.
2)
p<
0.
00
01
2.
7 
(S
D
 1
.3
; 0
.9
 
to
 4
.6
)
3.
9 
(S
D
 1
.8
; 1
.3
 to
 6
.3
) 
(n
=1
3)
p=
0.
04
(n
=1
3)
Q
u
a
lit
ie
s
5.
8 
(S
D
 1
.4
; 2
.6
 to
 
8.
7)
7.
6 
(S
D
 1
.4
; 4
.3
 to
 
9.
7)
p<
0.
00
01
5.
7 
(S
D
 1
.3
; 3
.0
 
to
 7
.9
7)
7.
2 
(S
D
 1
.3
; 4
.7
 to
 9
.1
) 
(n
=1
4)
P=
0.
00
02
(n
=1
4)
154
decreased to 20.8%. Soft tissue problems recorded as a predefined standard evaluation 
at each visit, i.e. infection, inflammation, skin necrosis and/or scar hypertrophy, occurred 
with a prevalence of 3.7, 3.8, 7.5 and 3.8% at fitting, week 6, week 12 and month 
6, respectively. These included one patient with minor skin pressure problems/necrosis, 
all other events were minor soft tissue infections or inflammations which resolved by local 
treatment.
A total of 43 patients presented with adverse events during the study of which 27 
patients experienced 36 device related events, mostly recorded as pain/discomfort (n=25 
events in 18 patients). Four reports in four patients were made of pressure related skin com-
plications and one report was made of magnetic retention difficulty. One device related 
serious adverse event was reported; a patient with infection at the implant site that required 
surgical removal of the implant magnet shortly after implantation. The related adverse 
events were partially overlapping with the abovementioned predefined study parameters 
collected at each visit.
Questionnaires
In the HUI3 questionnaire most attributes were scored high during the preoperative measure 
and no further improvement was noted during the study. In the conductive/mixed hearing 
loss group, however, for the hearing attribute a statistically significant improvement was 
recorded (mean +0.14, p=0.02). Additionally, an improvement was observed for the 
speech attribute, albeit smaller and with a high initial score (mean +0.05, p=0.04). For 
the comprehensive health state a non-significant improvement was noted (mean +0.06, 
p=0.11) (Table 2c). In the SSD group, smaller and non-significant differences were ob-
served (comprehensive health state mean +0.06, p=0.49).
The APHAB questionnaire showed significant improvement in terms of the global score in 
the conductive/mixed hearing loss group (mean global improvement 26.5%, p<0.0001). 
Furthermore, statistically significant improvements for all subscales except for the aversive-
ness score were recorded. In the SSD-subgroup less improvement on the global rating was 
noted (global mean improvement 12.9 %, p=0.0008).
The SSQ questionnaire showed improvements for all subscales in both subgroups of pa-
tients with conductive/mixed hearing loss and those with SSD, though not all improvements 
were statistically significant. The SSD patients showed slightly lower pre- and postoperative 
scores and less improvement compared to the conductive/mixed patients, with lowest 
scores and least improvement on the spatial domain (Table 2c).
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Discussion
Key findings
The results of the present investigation showed in general favourable audiological outcomes 
and subjective benefit on the questionnaires with the Baha Attract compared to unaided 
conditions. For patients with conductive or mixed hearing loss significant improvements 
were observed in free-field hearing thresholds and speech perception in quiet and noise 
   
1. Conductive/mixed hearing loss 2. Single-sided deafness
Figure 4a. Free-field threshold audiometry on individual frequencies
Figure 4b. Subjective benefit as measured by the HUI, APHAB and SSQ questionnaires.
Completed before surgery and after 6 months, change in scores is depicted for both indications. The mean 
(cross) and median (horizontal bar) are defined within each plot, boxes represent interquartile range, whis-
kers represent 95% range and dots represent outlier values.
AV = aversiveness, EC = ease of communication , RV = reverberation, BN = background noise
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compared to unaided hearing. For patients with SSD, significant improvements were ob-
served in free-field hearing thresholds and speech understanding in quiet and non-significant 
improvement for speech understanding in noise. However, compared to the preoperative 
measurement with softband, no differences were found in free-field hearing thresholds, 
speech in quiet and speech in noise in both groups. All audiology tests, including the 
unaided test, were executed with the non-test ear blocked. The most important soft tissue 
problems observed during follow-up included numbness, pain/discomfort at the implant 
site and to a lesser extent pressure related skin complications. A declining trend was noted 
in the rate of these complications at 3-6 months.
Strengths and limitations
The current study presents the largest multicentre prospective data on the Baha Attract System 
to date. Evidence is provided on all aspects of outcome measures relevant for device evalu-
ation. Hearing related outcomes and clinical parameters, as well as questionnaire data is 
provided according to a predefined study protocol. A consideration in the selected design 
might be the within-patient control. Choosing a within subject design reduces the amount 
of error arising from natural variance, which is especially important in outcomes with a 
high variance like hearing thresholds, hence the choice of the design. The comparison to 
unaided hearing could provide a good measure of experienced benefit achieved with the 
Baha Attract. However, a comparison with the current gold standard, the percutaneous 
solution, would make a stronger case for the test device. Thus far, no prospective studies 
have been reported with a percutaneous control, only a single retrospective case series 8. 
All other reports use the same within-patient design or compare the Baha Attract with other 
transcutaneous devices and generally show adequate results on clinical and audiological 
outcomes 5-7,9-11,26. For patients with SSD, some studies, showed slightly less favourable 
audiology data and higher non-usage 12,26.
Other consideration deals with the study design. Looking back, the predefined pooling 
of the data of both indications (conductive/mixed hearing loss and SSD), was not optimal. 
Therefore, the choice was made to present the data separately. Furthermore, to fully assess 
the benefit of the Baha Attract in SSD patients, a distinct set-up for the speech in noise 
test, with noise presented from the side instead of the back, might have been preferred. 
Additionally, the choice to block the non-test ear during the audiology tests is likely to have 
resulted in an overestimation of the effect of the test device compared to the normal un-
blocked situation, especially in SSD patients. At last, for the speech in noise tests the fixed 
noise level of 65dB SPL might not have been audible to all patients in the preoperative 
unaided situation. Therefore, regarding the speech in noise performance the comparison 
with the softband is more informative.
Last but not least, the current results are from the mid-term evaluation; the long-term 
outcomes have to be awaited and will be presented after 24 months of follow-up.
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Interpretation
All previously published studies report good results on soft tissue status post implantation 
with the test device, with few problems regarding pain at the implant site (most of which 
resolved with a reduction of magnet strength) and resolving numbness scores during follow-
up. The only study reporting relatively high prevalence of numbness is a small case series 
by Carr et al., where eight out of ten patients reported presence of numbness at some point 
during follow-up 10. Furthermore, Dimitriadis et al. reported mostly minor skin issues (redness 
and tenderness) in pediatric patients implanted with the Baha Attract, while two patients 
presented with a skin dehiscence over the magnet 27. Skin necrosis is reported by two other 
case reports, and it was suggested that a strict post-fitting monitoring is critical in avoiding 
these complications 28,29. Since the results of the current study, showing approximately 
20% of patients with any degree of numbness and 38% with (slight) pain/discomfort at 6 
months of follow-up, deviate slightly from the other available evidence with better results on 
these clinical outcomes, it should be concluded that further and long-term research on these 
issues is needed. Numbness is also observed with the use of traditional percutaneous bone 
conduction hearing implants placed using soft tissue reduction surgery, yet few clinical 
investigations have evaluated and reported on numbness in a systematic way. Despite it 
being difficult to compare these numbers to available studies on percutaneous implants, 
from a clinical perspective it would be desirable to improve these numbers. A possibility 
to accomplish this reduction might be to modify the surgical incision and minimize trauma 
to nerves and vessels, e.g. by using a less invasive, shorter and more superior curved or 
linear incision 30. The clinical outcomes after 24 months of follow-up of the patients in this 
clinical investigation will be of particular interest, in order to understand if the continuous 
improvement in numbness and discomfort/pain seen during the first 6 months continues 
over the longer term. The ISQ measurements at surgery varied widely, though no os-
seointegration problems were noticed. The measurements in the current study were done 
at implant level, consequently the numbers are not comparable to previous reports at 
abutment level in literature 13; these measurements have their own merits, amongst others 
in creating reference values.
Results on hearing amplification are comparable to previous reports with outcomes 
comparable to those with a sound processor on softband or other transcutaneous devices. 
Compared to percutaneous bone conduction implants, transcutaneous systems provide 
less efficient sound transmission (especially at high frequencies) due to dampening by 
the intervening soft tissue layer. Early reports have shown that application of a passive 
transcutaneous device via a headband or testband result in dampening of 15-20dB for the 
frequency range from 1 to 4kHz 31,32. More recent studies indicate similar slightly inferior 
hearing thresholds with the use of a magnetic transcutaneous system as compared to a 
percutaneous abutment 33. With respect to different frequencies, a less favourable result 
of the Baha Attract was noticed in the high frequencies, which are especially important 
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for speech understanding. While transcutaneous systems suffer from less efficient sound 
transmission compared to percutaneous devices, they obviously have some important other 
advantages. These advantages include no need for daily care of the skin around the skin 
penetrating abutment, less risk of implant loss and infection, and potentially improved 
cosmetics, which might explain the recent increased interest for transcutaneous options. For 
patients that require a powerful solution, e.g. due to a significant (high-frequency) senso-
rineural component in their hearing loss, percutaneous devices remain the gold standard. 
In patients with SSD, free-field hearing thresholds with the Baha Attract that were equal or 
worse compared to the expected attenuation by the head-shadow effect were recorded 
in the majority of patients (aided thresholds >10-20dB poorer than the preoperatively 
measured AC thresholds in the good ear). This suggests that, to ensure good outcomes in 
this population, the patient should have normal or near-normal hearing in the good ear. 
While the sample size in the SSD group was too small to draw statistically supported 
conclusions, our clinical experience and the individual data of the SSD patients supports 
this recommendation. An important aspect to include in the candidacy selection for bone 
conduction implants is longevity, i.e. taking into account the deterioration of sensorineural 
hearing loss owing to ageing or progressive cochlear disease (www.snikimplants.nl). With 
the Baha Attract, the option remains to change to a percutaneous solution as the implanted 
magnet is attached to the same titanium implant as the abutment in percutaneous applica-
tion. More recently, more powerful sound processors have become available, enabling 
potentially more patients to benefit from transcutaneous systems in the future.
Generalizability
The results of the current multicentre prospective study adds important data on a still rela-
tively new and infrequently studied magnetic transcutaneous implant system. Since hearing 
results were generally comparable to a condition with a sound processor on a softband, 
a preoperative trial seems of vital importance in a clinical context for preoperative evalu-
ation of patients. When discussing different bone conduction options, the slightly more 
invasive surgery and less favourable MRI-compatibility compared to percutaneous devices 
should be taken into consideration. Furthermore, audiological indications still have to be 
determined. Up to now, restrictions to bone conduction thresholds better then 30-35dB HL 
or even more conservative limits have been mentioned in the literature 4,34, however, the 
recent availability of more powerful sound processors might affect this restriction.
Further research is warranted, including an appraisal of all available options. This ac-
counts to the audiology criteria but also clinical parameters like soft tissue problems. A 
direct and objective comparison on numbness and pain/discomfort problems, but also on 
other issues more likely for percutaneous implants like peri-implant disease and implant loss, 
for all different available systems are not available in the literature to date. Recent sugges-
tions on a new scale to evaluate the skin at the implant site usable for both percutaneous 
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and transcutaneous systems might make it possible to obtain a good comparison between 
systems 35.
Conclusions
The present multicentre study showed that the Baha Attract System provides improvement 
in hearing performance and subjective benefit compared to the preoperative unaided 
condition (with the non-test ear blocked). Hearing performance of the Baha Attract was 
similar to that obtained with the same sound processor on a softband. Based on the results 
of the current study, the Baha Attract system could be considered as a treatment option 
for patients with conductive/mixed hearing loss with relatively favourable bone conduc-
tion thresholds. For patients with SSD a more careful selection procedure is suggested. A 
pre-operative softband trial provides the patients with a representative experience of the 
post-operative hearing outcomes and should be part of the decision making process before 
fitting a patient with the Baha Attract System. Since these clinical results are still mid-term 
and not stabilized at the end of follow-up, the results of 24 months have to be awaited 
to present more definitive conclusions. The current results, in combination with increasing 
options in bone conduction implants, emphasize the importance of a well-informed patient 
and shared decision-making.
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General discussion
Since the first implantation of a bone conduction hearing implant in 1977 1, emphasis 
in research has been on the clinical evaluation of the system, in terms of implant stabil-
ity, soft-tissue outcomes and audiological results, for different patient groups and various 
indications. In the past decade, the rapidly evolving availability of new designs in implant 
systems and subsequent new surgical techniques has had its influence on the scope of 
research 2. In this chapter, evaluation of clinical and audiological outcomes, and the 
effectiveness of new implants and surgical techniques in bone implant research are further 
discussed.
Effectiveness and safety of implants in current practice
In Part 1 of this thesis several clinical outcomes were evaluated within various domains. 
Chapter 2 describes a large patient cohort, in which the association between several 
comorbidity risk factors and complications of bone conduction hearing implants was evalu-
ated. The study included 581 adult patients with a total follow-up time of 7120 years, 
the longest follow-up on bone implant complications reported thus far. Implant loss was 
observed in 7.5% of implants and adverse soft tissue reactions in 18.4% of implants. 
Several factors could be identified as a risk factor for complications. Firstly, for soft tissue 
reactions, skin disease was the only statistically significant risk factor in both univariate and 
multivariable analysis. Female gender showed a trend to a negative risk factor. Secondly, 
concerning revision surgery, both smoking and female gender appeared to be indepen-
dent negative risk factors. Thirdly, for implant loss, smoking could be identified as a risk 
factor. The possible pathophysiological mechanisms behind these associative factors are 
discussed in the manuscript and supportive evidence was reported 3-11. Other previously 
reported risk factors like BMI 12-14 and diabetes mellitus 15 could not be confirmed in this 
study. Remarkably, the complication rate was relatively high compared to more recently 
reported complication rates 16,17. The length of the follow-up might explain this higher rate. 
However, it was primarily assigned to the inclusion of previous generation implants and 
previous surgical procedures, which were more prone to complications (See Part II). This 
study could therefore serve as a historical control in future comparisons or a reference, 
since large cohort studies have previously proven their value as a reference within the field 
10,18-21. Additionally, it was suggested to include the identified risk factors in counselling 
patients. Up to date, no comparably large studies on comorbidity influences are available 
neither for new implants, nor for recently introduced surgical techniques.
In chapter 3 the clinical results of the Cochlear™ BI300® implant were retrospectively 
reviewed in 79 children, who were treated since the introduction of this new implant type 
in the Radboudumc Nijmegen and Birmingham Children’s Hospital. This study was initiated 
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to gain more insight into an observed increase in soft-tissue complications in our paediatric 
patient population since the introduction of this new implant. The study confirmed good 
implant survival for the new implant type (96,5% survival during a mean follow-up 11.7 
months), noticeably, this percentage is higher compared to what was reported for previous 
generation implants 10,12,22-24. The number of adverse soft tissue reactions appeared to 
resemble numbers reported on previous generation implants in children. Relatively more soft 
tissue overgrowth was noted. The resultant was an increased number of revision surgeries 
since the introduction of the BI300; in 28.7% of implants one or multiple revision surgeries 
were required, much higher compared to what was reported earlier 22,24. This increase in 
complications involves more visits to the outpatient clinic and (temporarily) non-use of the 
sound processor. An observed disparity in clinical results between the two participating 
centres (relatively more soft tissue problems in the Birmingham cohort), was attributed to dif-
ferences in case mix, treatment protocols, data collection and documentation. The greatest 
limitation however, was the lack of a control population, precluding a direct comparison 
with the results of the previous generation implants and identification of possible confound-
ing factors. Nevertheless, the study is of importance for its observation of less favourable 
clinical results in the paediatric population. As a result, treatment policy has changed 
considerably. At present longer abutments are implemented, since in previous studies it 
has been observed that longer abutments can reduce soft tissue problems 25. These longer 
abutments either replace the shorter one as an outpatient clinic procedure in the children 
of the study (who are old enough to undergo an abutment change in outpatient clinic), or 
are used at primary implantation, combined with tissue preservation technique, for newly 
treated children. The study emphasizes the relevance of prospectively collected clinical 
data at introduction of any newly designed implant or implant system, not only in adults, 
but also (and maybe especially) in children and other more vulnerable patient populations 
who are generally excluded from the first clinical trials.
Aside from clinical outcomes, like implant survival and soft tissue outcomes, evaluation on 
audiology measures was included in the current thesis. In Chapter 4 directional hearing 
was studied in children with bilateral conductive hearing loss using bilateral bone conduc-
tion devices. Spatial discrimination, (whether sound is heard on the left or right side) was 
evaluated with the minimum audible angle test. True sound localization (the accuracy of 
processing binaural cues), was tested with a sound localization test 26. By presenting 
the stimuli at randomly selected locations in a dark environment and by roving of the 
presentation level, we attempted to exclude previously described limitations and therefore 
being able to objectively study the binaural hearing with bilateral bone conduction de-
vices 27-31. Eleven children participated in the study. Ten out of these eleven participants 
were children with bilateral atresia, with accompanying congenital conductive hearing 
loss. Both tests were conducted in a condition with bilateral BCDs and in a unilateral left 
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and right condition, in randomized order. Bilateral application resulted in better spatial 
discrimination, as well as better sound localization. However, while spatial discrimination 
showed good results in nearly all children, the localization test showed that most children 
in this study demonstrated lateralization behaviour rather than actual sound localization, 
implicating that these children can distinguish sounds coming from the left or the right side, 
without being able to indicate the exact sound source location. Interesting differences 
were noticed between the children with congenital conductive hearing loss and the only 
child with acquired conductive hearing loss. In the bilateral BCD condition the child with 
acquired conductive hearing loss was able to localize sounds close to the ability of normal 
hearing subjects. Good localisation in patients with acquired conductive hearing loss was 
previously noticed in a study by Bosman et al 28 and could be matter of further research. It 
is suggested that early experience with binaural hearing might be essential for good sound 
localization. Despite the fact that the patients with bilateral congenital conductive hearing 
loss were not able to localize sounds accurately, they were able to lateralize sounds, which 
is important in daily life situations; for example in the determination the direction of sound in 
a classroom or outdoors. This potential benefit of bilateral fitting can be used in counselling 
patients and/or parents.
Optimizing patient indications for a bone conduction hearing implant is a valuable de-
velopment. The currently developed Dutch national guideline, as well as other national 
guidelines, and consensus or quality standards for bone conduction implants, are expected 
to help selecting the right patients for bone conduction hearing implants, and providing 
optimal personalized healthcare by including guidelines for minimum diagnostic processes, 
surgery and audiological follow-up and organization of care 32-34. Future studies on bone 
conduction device non-use might identify pre-operative predictive parameters to aid indi-
vidualized (i.e. patient centered) care. Good patient selection is not only of importance for 
patients, but also in a societal perspective. Increasing costs of bone conduction hearing 
implants, including costs of sound processor replacements every five years, are a growing 
burden on hospital budgets in the Netherlands. Dedicated outpatient teams, in which 
medical specialist and audiological teams work together and are able to provide the 
full-set of rehabilitation and surgical options (or at least are able to advice on all options), 
remain of crucial importance in this respect 32. Especially in low-volume patient care, like 
paediatric bone conduction implants or patients with craniofacial abnormalities, dedicated 
teams are important in diagnostic and therapeutic challenges. Chapters 3 and 4 highlight 
the importance of outcome evaluation in these groups. Chapter 3 additionally highlights 
the value of (inter)national collaboration and the value of uniform outcome evaluation and 
reporting. Another initiative that is expected to aid uniform outcome evaluation in the near 
future is Auronet. Auronet is an international group of dedicated professionals developing 
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a core set of patient-centered outcome measures to guide individual practice and act as a 
standard of reporting in clinical trials 35.
New implants and surgical techniques
In the second part of this thesis, the evolving availability of new implants and subsequent 
surgical techniques during the past decade is discussed. Before 2009 a single implant-
abutment system was available; the flange fixture from Cochlear™. In 2009 the company 
Oticon Medical™ introduced the Ponto® system with a classic Ponto® implant-abutment, 
with a different design compared to the already available system from Cochlear™. The 
novel shoulder shaped abutment resulted in adequate soft tissue outcomes and the standard 
diameter implant showed good implant survival in the first reports 36. At the same time a 
multicentre randomized controlled trial was initiated to study a new wider implant from 
Cochlear™. This new implant was designed with an altered surface technology (moder-
ately rough TiOblast®) and a wider diameter implant. These alterations were intended 
to increase stability and reduce implant loss. The abutment was rounded and apically 
converging, intended to decrease adverse soft tissue reactions. This system became com-
mercially available afterwards as the BI300® implant-abutment system. The results from a 
three-year randomized controlled trial were very promising (both at 6-months and 3-year 
follow-up), with a reduction in soft tissue reactions and higher ISQ (implant stability quotient) 
values 37,38. These results were also noted in other studies on the same implant 39-43. 
Subsequently, the previous generation implant was completely replaced by the BI300 over 
the next few years. However, given the importance of long-term follow-up (bone conduction 
hearing implants remain in situ during several decades), the results on outcome measures 
of the initial trial participants were once more assessed at a five-year follow-up visit. In 
addition, the incentive to perform a five year post-implantation assessment was supported 
by an average drop in ISQ value in the last year of the original trial 37. In chapter 5 the 
results of this long term follow-up are described. The initial trial comprised 52 test implants 
and 25 control implants (all part of the implant survival analysis). The five-year follow-up 
visit included 40 test implants and 17 control implants. For both groups of implants, the 
ISQ values recovered from the previous drop and the mean ISQ values at 5 years were 
higher compared with values at implantation. However, no difference was noticed in ISQ 
increase from baseline between the two groups of implants. Implant survival was high in 
both groups (95% versus 95.8%). Furthermore, the results on soft tissue reactions were 
superior for the BI300 implant (2.5% versus 23.5%), confirming the positive results from 
the previous trial. It was concluded that the current results supported the replacement of 
the previous generation implant by the new BI300 implant for adult patients. The primary 
outcome parameter in the original trial, ISQ, has been has been subject to discussion in 
the past few years. Absolute ISQ values are difficult to interpret, due to previously reported 
heterogeneous data and the influence of implant and abutment type and length on absolute 
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values 44,45. Furthermore, the relation of ISQ and implant loss has not been confirmed up to 
now, which questions the clinical importance that can be assigned to absolute ISQ-values 
in current practice. Several suggestions were done by Nelissen et al. for future research 
and clinical use of this outcome 44. In the case of the BI300 system the positive soft tissue 
outcomes in adults have proven to be of clinical importance for these patients.
Since the initial randomized controlled trial on the BI300 versus the previous generation 
flange fixture, several initiatives for further improvement of implants and abutments have 
been undertaken. Most modifications are intended on increasing implant stability and 
reducing implant loss, like the Oticon™ wide implant (wider implant diameter). In chapter 
6 the results of a randomized controlled trial on this Oticon™ wide implant are discussed. 
Fifty-seven patients with 60 implants were included in this trial with a randomization ratio 
of 2:1 (test versus control). The new wider test implant showed a significantly higher ISQ 
value (ISQ high and low) compared to the control implant. Additionally, the increase in 
average ISQ was significantly more for the test implant. No implants were lost in either 
group. Other clinical outcomes like adverse soft tissue reactions were comparable between 
the test and control implant. Based on these outcomes the previous generation 3.75 mm 
wide implant was replaced by the new, wider implant. This study was continued to 3 years 
and the complete study shows similar results at final follow-up 46.
Other modifications on the implants and abutments are all still in clinical or preclinical 
trial phase, with consequently limited data available. One of these newer modifications is 
the Cochlear™ BI400®, with a hydroxyapatite coated abutment to achieve a tight skin-
implant connection, aiming to further reduce soft-tissue problems. The first case series on the 
BIA400 failed to show an evident positive effect on soft tissue outcomes 47,48, and results 
of a larger trial are awaited 49. Another implant modification intended to increase implant 
stability and reduce implant loss, is the Oticon™ BHX. This implant has a laser modification 
of implant surface and hereby, hypothetically, an improved biomechanical anchorage. 
The first results on this implant have recently been published 50. In this patient cohort of 34 
participants, one implant loss was reported. The ISQ values were comparable to previous 
reports on the Oticon™ wide implant.
It could be questioned whether all the present, and possible alterations in design of the 
percutaneous implant in the future are beneficial, since the complication rate is already 
low in the currently used implants in the adult patient population. Incremental costs of new 
designs are only warranted if it leads to significantly better patient care. The currently 
available percutaneous bone anchored hearing implants have low complication rates and 
good clinical results. If there is little room for improvement, it could be doubted whether 
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new designs are a cost-effective, and resources should perhaps be attributed to other 
aspects of bone implant research.
Introduction of new medical devices and current regulation has been of interest in scientific 
and policy discussions over some time now 51-57. Failures of metal-on-metal articulations in 
total hip replacements 58 and the PIP breast implant scandal 59,60, amongst others, have 
emphasized the need for more thorough and evidence based introduction of devices, and 
for timely evaluation.
Pharmaceutical approval processes pose considerably more methodological boundaries 
than those that apply for medical implants, where only evidence of safety needs to be 
shown before commercial availability 61,62. Moreover, after these safety trials, commonly 
so-called post-market trials are initiated. These trials not only serve the evaluation of safety 
and effectiveness to aid clinician and patient in device selection, but are also deployed 
as a marketing tool (and to support medical claims) 63,64. One may think that otological 
implants pose little risks to patients, a recall of highly magnetic stapes prosthesis in 1987 
and a cochlear implant positioner causing an increased incidence of bacterial meningitis 
in 2002, however, suggest otherwise 65,66. Therefore, approval should be based on 
prospective comparative effectiveness trials of high-quality and sufficient duration 51,54,67,68. 
Ideally these trials should either not be industry sponsored or without interference of the 
manufacturing company in trial design, result analysis and reporting, given the widely 
available evidence of bias by industry sponsorship 69-72. Furthermore, routine data is sug-
gested to be used to monitor newly introduced implants, for example in national and 
international registries 64,73. The scale of uncontrolled device introduction may not be fully 
recognized and consequences even less known 74. In other medical specialities, the device 
failures have resulted in implementation of (inter)national device registries. In the field of 
otology initiatives for national registries are currently also explored 34.
The problem of late evaluation of new developments is not merely a problem in medical 
device introduction. New surgical techniques are developed and widely applied in clinical 
practice before thorough evaluation, as surgical innovation is not subjected to any formal 
regulation. Despite the lack of mandatory guidelines, the importance of timely evalua-
tion of new techniques is recognized 55-57. In chapter 7 a new surgical technique within 
bone implant research, a modification of the standard linear incision technique 75,76, is 
presented. For many years a soft tissue reduction step was applied during the implantation 
of a percutaneous implant. It was assumed that a thin, and immobile skin around the 
abutment reduced the chance for soft-tissue infections and improved the sound transmission. 
Hultcrantz et al. introduced a simplified surgery without skin reduction and reasonable 
short-term results were reported 77. One of the grounds for this innovation was the recent 
availability of longer abutments, which is an important condition for the possibility of tissue 
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preservation, since previous 6mm abutments are generally not long enough to perforate the 
complete skin. The new tissue preservation technique was conducted in 25 patients in our 
centre, comparing them to 25 trial patients from a previous study with soft tissue reduction 
(discussed in chapter 6). Results on audiology outcomes were similar for both techniques 
and a significant shorter surgery time was recorded for the preservation technique. An 
increase in minor soft-tissue reactions after 6 months was observed (n=7 versus n=1, 
p=0.049). This increase in adverse soft-tissue reactions was not evident in the first study by 
Hultcrantz et al. or subsequent studies by the same or other authors 77-82. Based on these 
conflicting results, the need for a more elaborate evaluation and long-term follow-up was 
stated. The results of the three-year follow-up are expected in the near future. Meanwhile 
the bone implant surgery techniques have been adjusted in several centres already, with a 
minimally invasive punch technique being one of the latest developments for implantation 
of percutaneous implants. In our view, published results of this technique are still sparse 
49,83,84 and some restraint in adopting this technique seems appropriate. Especially since 
the punch technique involves less surgical exposition, which makes adequate visualisation 
and cooling less easy. Experience with implantation of bone conduction hearing implants 
in a standard technique seems advisable before using this technique. Given the good 
clinical results of the standard (linear) incision techniques, again, it could be questioned 
how much room for improvement there is with adjustments in the current surgical technique.
As already stated in the introduction, another development within the field is the revival 
of transcutaneous systems. These transcutaneous systems are introduced with the potential 
to overcome some of the remaining disadvantages of the percutaneous coupling. These 
include loss of the titanium implant, possible recurrent soft tissue problems around the 
abutment in specific patients (particularly when daily care poses problems), and potential 
aesthetic issues related to the percutaneous abutment. In chapter 8 the six-months results 
of a trial on the transcutaneous Cochlear™ Baha® Attract are presented. The multicentre 
trial included 5 centres and 54 patients, with either a conductive/mixed hearing loss 
or single-sided deafness (SSD). A significant proportion of the patients reported pain or 
numbness during the follow-up, especially during the first postoperative weeks. Most cases 
of pain resolved or reduced with changing the magnet to a less strong one, however, 
in several cases the device could (temporarily) not be worn as a result. Several patients 
presented with long term complaints of pain/discomfort (21% of patients at 6 months) 
and/or numbness (38% of patients at 6 months). No major soft tissue problems like soft 
tissue necrosis were noticed (which is reported in case reports, both after conversion from 
percutaneous to transcutaneous implants, and after initial transcutaneous fitting 85-87. Good 
results on the subjective benefit questionnaires at 6-months were observed compared to 
the preoperative (unaided) situation. For the free-field hearing thresholds in both groups 
(SSD and conductive/mixed hearing loss) an improvement was observed compared to 
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unaided hearing, however, not compared to the preoperative measurement with softband. 
It should be noted that all the audiological tests were all conducted with the non-test ear 
blocked, resulting in an overestimation of the effect of the test device compared to the 
normal unblocked situation, especially in SSD patients. Improvements were also recorded 
in speech tests in quiet and noise compared to unaided hearing for the conductive/mixed 
hearing loss group and for speech in quiet in the SSD group. Again, no improvements were 
noticed compared to the softband condition in these outcomes. In these results the limita-
tions regarding the blocking of the non-test ear apply as well. Furthermore, in the speech 
in noise tests the fixed noise level of 65dB SPL was probably not audible to all patients 
(in the preoperative situation). This resulted in an overestimation of the effect of the Baha® 
Attract compared to the ‘unaided’ condition. The comparison with the softband is deemed 
more informative. Since the softband provides a representative experience of the post-
operative hearing outcomes with the Baha® Attract, it was advised that a pre-operative 
softband trial should be part of the decisionmaking process before fitting a patient with the 
Baha® Attract System. For single-sided deafness patients and those patients that require 
more amplification, e.g. due to a significant (high-frequency) sensorineural component 
in their hearing loss, a restrained recommendation was suggested for the Baha® Attract 
based on a clinical perspective and individual patient data (free field hearing thresholds 
with the Attract worse compared to the expected attenuation by the head-shadow in the 
individual data of the majority of patients). As previously stated the skin dampening of 
transcutaneous devices results in a significant threshold decline of 5-20dB for frequencies 
1-4kHz compared to percutaneous solutions 88,89. Important to take into account in this 
respect is the deterioration of sensorineural hearing loss owing to ageing or progressive 
cochlear disease, i.e. the longevity of the bone implant (www.snikimplants.nl). Despite 
several challenges in analysis and interpretation of the data (underpowered results due to 
inability to combine the results of different indications, and different audiology tests with 
set-up restraints), a result of unfortunate choices in the trial design, the results of the study 
are important in determining the selection criteria for these new implants and for patient 
counselling during the preoperative decisionmaking processes. The trial will continue to 
a follow-up of two years. These results and direct comparisons with the percutaneous 
bone implant and other available options are awaited. Several clinics reported in verbal 
communications that up to more than half of their patients are implanted with a Baha® 
Attract nowadays. This market share of the Baha® Attract is remarkable in the light of 
its’ appearance only several years ago and the limited available literature. Audiological 
efficacy is reported in a limited number of studies, in which mostly moderate results are 
presented 90-98. Whether the market share of transcutaneous bone implants continues to 
grow within the field of bone implants will be dependent on upcoming developments of 
more powerful sound processors and advances in active transcutaneous options. Passive 
solutions, like the Baha® Attract and the Sophono®, present with audiological concerns 
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due to skin dampening as stated 99,100. Of these two options, the Baha® Attract has the 
advantage of the possibility of connection of (recently available) more powerful sound 
processors, which as long as no feedback issues arise, can expand the indications of the 
device. Next to this, with the Baha® Attract the option remains to change to a percutane-
ous solution, when warranted by the deterioration in bone conduction thresholds or by 
other issues, like pressure related skin problems. On the other hand, (expected) soft tissue 
problems with a percutaneous device in selected patients (or challenges in providing daily 
care), implant loss or aesthetic issues could be reasons to change a percutaneous implant 
to a transcutaneous solution or to choose a transcutaneous system at initial implantation. 
Given the good results of percutaneous implants in most patients, this might however apply 
to a limited number of patients. Active transcutaneous options might take away some of the 
audiology restrictions. For the Med-El™ Bonebridge®, a comparable audiological capac-
ity to the percutaneous implant with standard (non-super-power) bone conduction devices 
is reported 101,102. The preclinical and first clinical results on the Swedish Bone Conduction 
Implant were promising, with comparable results to those of the Bonebridge® 103-106. 
Further clinical results should be awaited for this device, which will be commercially avail-
able in the near future as the Sentio from Oticon™. Another active system, the Cochlear™ 
OSIA system, is currently evaluated in a first trial, from which no results are published yet.
Although active solutions and more powerful sound processors might expand the pos-
sibilities for transcutaneous systems, other advantages of percutaneous bone implant will 
remain. The straightforward surgical implantation of the percutaneous bone conduction 
hearing implants with good clinical results of minor and infrequent complications is a major 
advantage. The surgery for percutaneous implants (linear incision with tissue preserva-
tion) is shorter in duration and is easily done under local anaesthesia. The less invasive 
procedure of percutaneous devices has some additional advantages, like considerably less 
soft tissue damage that can be important in case of future auricular reconstruction (provided 
they are placed in the correct position), and a more simple removal of the system, which 
might be necessary for various reasons. MRI compatibility is another important aspect to 
consider. Percutaneous implants are MRI compatible, transcutaneous implants are generally 
MRI conditional only up to 1.5 Tesla 107,108. Moreover, scattering from the implant is far 
more extensive in the transcutaneous implants, up to 15 centimetres, compared to the 
scattering of percutaneous implants, up to 1 cm from the implant 107,109,110. Patients who 
are likely to need frequent MRI may be less suitable for a magnetic transcutaneous option 
111. Based upon these advantages, percutaneous bone implants are expected to remain 
an important part of bone conduction hearing solutions in the near future. The continuous 
expansion and improvement of options for bone conduction hearing, including the current 
introduction of new active transcutaneous devices, is deemed important considering the 
increased possibility of patient-centered and individualized care.
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Concluding remarks
This thesis emphasizes the importance of clinical evaluation of bone conduction hearing 
implants, for established percutaneous systems, as well as for new implants and surgical 
techniques. Preferably these innovations should be assessed on safety issues as well as 
on effectiveness and efficacy before widespread commercial implementation. Controlled 
trials, comparing new implants to the current gold standard, the percutaneous bone con-
duction hearing implant, are warranted. Newly available guidelines and the development 
of an (inter)national registry are expected to be of aid. Future research should include focus 
on prospective evaluation on specific indications and on preoperative identification of 
good candidates for bone implants in more detail. In this respect, separate evaluations of 
clinical outcome in paediatric populations are essential. The present focus on evaluation 
of new implant systems and more powerful sound processors is expected to remain a part 
of upcoming research. It is expected that for the foreseeable future, the percutaneous bone 
conduction hearing implant will remain an important addition to all available hearing 
rehabilitation options, and that current and new options contribute to more patient-centered 
and individualized care.
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Summary
After an introduction on bone conduction hearing and the bone conduction hearing im-
plant, the first part of this thesis (chapters 2-4) concentrates on the evaluation of several 
outcomes in clinical practice.
Chapter 2 presents the results of a study aiming to determine the relation between occur-
rence of complications of percutaneous implants and comorbidity factors. The rate of soft 
tissue reactions, revision surgery and implant loss is evaluated in light of the presence or 
absence of a variety of comorbidity factors. A large cohort of 581 adult patients with long 
term-follow-up (total of 7120 person years) was analysed with a proportional hazards 
regression model to identify associative factors for complications. For soft tissue reactions, 
skin disease could be identified as an independent risk factor. In a univariate analysis, 
fewer revisions were observed in the female gender and cardiovascular disease group. In 
multivariable analysis female gender and smoking were identified as negative risk factors 
for revision surgery. Smoking was identified as a risk factor for implant loss in both univari-
ate and multivariable analysis. Previously identified risk factors, as BMI (body mass index) 
and diabetes, could not be confirmed in the current study. Outcomes were evaluated in this 
historical cohort, however, it should be noted that the implant and surgical technique used 
are infrequently used nowadays.
In chapter 3 the results of a new type percutaneous implant are described, applied in 79 
children from two tertiary referral centers in Europe. This study was initiated because of a 
possible increased number of soft tissue reactions in the paediatric patient population. The 
mean follow-up was 11.7 months. The study could confirm a good implant survival (96.5% 
implant survival) and a rather stable rate of adverse soft tissue reactions over time was re-
corded. In contrast, soft-tissue reactions in adult patients using this same implant, decreased 
compared to previous generation implants (see Chapter 5). Additionally, an increase in 
revision surgery frequency was evident; in 28.7% of the implants one or multiple revision 
surgeries were required because of soft tissue problems (skin overgrowth). This increase 
resulted in more visits and a higher burden for the patients, family and health-care system. 
The study set-up (with missing control group) unfortunately hindered a firm conclusion on the 
cause for this increase. Additional studies are needed on this specific topic.
Chapter 4 focuses on an audiological outcome parameter, namely directional hearing in 
patients provided with bilateral bone implants. Children with bilateral conductive hearing 
loss were invited to take part in this study; eleven children participated. An outspoken 
effect of bilateral versus unilateral device use was seen, although this was mainly the result 
of (correct) lateralization of sounds rather than precise localization of the sound source in 
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the bilateral condition. In other words, these children can distinguish sounds coming from 
the left or the right side, without being able to indicate the exact sound source location. It 
should be noted that all children but one had congenital conductive hearing loss. The only 
child with acquired conductive hearing loss was by far the best performer, suggesting that 
previous ‘normal’ hearing experience during early childhood might be essential for good 
localization. From this study it was concluded that a second bone conduction device (BCD) 
is of importance to children with bilateral conductive hearing loss.
The second part of this thesis is composed of several chapters discussing new percutaneous 
implants, implant systems or new surgical techniques. In chapter 5, long-term data of a 
randomized controlled trial are presented, studying a new type of implant in adults. This 
new implant produced by Cochlear™ has a different shape of the abutment and wider 
diameter of the implant as compared to the older implant. A significant decrease in soft 
tissue reactions (2.5% versus 23.5% Holgers grade 2 reactions) and higher implant stability 
quotient (ISQ) was noticed with the new implant. However, no difference was noticed in 
increase in ISQ from baseline between the two implants. High implant survival rates were 
observed in both groups (96% versus 95%). Long-term evaluation after introduction of new 
implants is of importance. As an example, an unexplained drop in average ISQ values 
was recorded between 2 and 3 years follow-up, which was not reflected in the stability 
quotients of the implant in the current evaluation. The observed positive outcomes of this 
trial support the replacement of previous generation percutaneous implants by the new 
BI300 implant in adult patients.
In chapter 6 the results of an early post-market release study of another percutaneous im-
plant are presented. Six months results of the first wide implant from Oticon Medical™ are 
evaluated and discussed. This study focussed on the ISQ and on implant loss, comparing 
the new test implant with the previous generation control implant. Fifty-seven adult patients 
with 60 implants were included in the trial, with a randomization ratio of 2:1 (test versus 
control). The test implant showed a significantly higher ISQ value compared to the control 
implant. Furthermore, the mean change in ISQ low during the trial was significantly larger 
for the test implant. No implants were lost and other clinical outcomes like the number of 
complications and adverse soft tissue reactions were comparable between test and control 
implants. These short-term results suggest that the new implant is a safe and good option in 
hearing rehabilitation. This study was continued; 3 years follow-up data are gathered and 
will be published soon.
For many years, implantation of percutaneous implants included a reduction of soft tissue 
at the implant site. It was assumed that a thin, rather immobile skin around the abutment 
was essential to reduce soft tissue infections. However, one of the leading centers in bone 
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implant research had introduced a simplified surgical procedure without skin reduction. In 
chapter 7 this tissue preservation technique was studied comparing the results of newly 
treated patients with published data of patients using the tissue reduction technique (as 
the 6-month data discussed in chapter 6). The results of this new technique were generally 
adequate, including comparable audiological results and a shorter surgery time (mean 25 
minutes versus 32 minutes, p<0.001). However, during the first 6 months, an increase in 
soft-tissue reactions was observed in the soft tissue preservation group (n=7 versus n=1, 
p=0.049). The increase in adverse soft-tissue reactions was not evident in other studies, 
and the soft-tissue preservation technique is nowadays widely adopted as the new standard 
surgical method. Three-year results of our study are expected shortly.
Chapter 8 presents the results of a post market release study of a novel transcutaneous 
implant system. The system was evaluated in 54 patients regarding clinical outcomes, 
patients’ opinions and audiological data. The audiological results were compared to a 
condition with a BCD on softband and the unaided condition, in a within patient design. 
The studied transcutaneous system is a so-called passive system, which suffers from less 
efficient sound transmission compared to percutaneous devices. On the other hand, the 
advantages of the closed skin include no need for daily care and less risk of implant loss 
and infection. These theoretical (dis)advantages were evaluated in the current multicentre 
trial. Post-operative soft tissue problems, like numbness and pain/discomfort at implant 
site, were reported rather frequently by the patients (21% numbness and 38% (slight) 
pain/discomfort at 6 months). On the predefined primary outcome parameter, the mean 
free-field hearing thresholds at 500-1000-2000-4000Hz, an improvement was observed 
compared to unaided hearing for the patients with conductive/mixed hearing loss, and 
for the patients with single sided deafness. The audiological tests were performed with the 
non-test ear blocked. Improvements compared to unaided hearing were also observed for 
speech tests in quiet and noise for the conductive/mixed hearing loss group and for speech 
in quiet in the SSD group. Good results were reported on subjective benefit questionnaires. 
In both groups, hearing performance was similar to results with the same sound processor 
connected to a softband, suggesting that this new transcutaneous implant performed similar 
to a (non-surgically) transcutaneous temporary application. For patients that require more 
amplification, because of a significant (high-frequency) sensorineural component in their 
hearing loss or single-sided deafness, the less efficient sound transmission could pose prob-
lems, and a more restrained recommendation was suggested. The multicentre design and 
the pre-selected indications provided a challenge and resulted in deviations in the protocol 
and difficulty in interpreting some of the results. It was concluded that a softband trial is a 
good preoperative indicator. Long-term results need to be awaited for proper selection of 
patients for either a transcutaneous or a percutaneous bone conduction implant.
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In the current thesis a variety of topics within the field of bone conduction hearing implants 
were studied and discussed. Some of the recent developments in percutaneous and trans-
cutaneous bone implants, new surgical techniques and clinical outcomes were evaluated. 
This thesis contributes to the assessment of a diverse set of trends in the field. The trends 
discussed will evolve and undergo further evaluation in the coming years.
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Samenvatting
In hoofdstuk 1 wordt het concept beengeleiding en het beengeleidingsimplantaat toe-
gelicht. Hierna spitst het eerste deel van dit proefschrift zich toe op de evaluatie van 
verschillende uitkomsten in de klinische praktijk.
In hoofdstuk 2 worden de resultaten van een studie beschreven, die de relatie tussen 
het optreden van complicaties bij percutane beengeleidingsimplantaten en comorbidi-
teitsfactoren onderzoekt. Het aantal huidreacties, revisie-operaties en implantaat verlies 
worden gerelateerd aan de aan- of afwezigheid van comorbiditeitsfactoren. Een groot 
cohort met 581 patiënten met lange termijn follow-up (totaal 7120 persoonsjaren) werd 
geanalyseerd met een proportioneel risico regressie model, met als doel het opsporen van 
geassocieerde factoren voor complicaties. Voor huidreacties werd een voorgeschiedenis 
met huidziekte geïdentificeerd als een onafhankelijk voorspellende factor. In een univariate 
analyse werden hiernaast minder revisie-operaties gezien onder vrouwelijke patiënten, en 
bij patiënten met een voorgeschiedenis van hart- en vaatziekten. In multivariabele analyse 
bleken het vrouwelijk geslacht en roken een negatief voorspellende waarde te hebben 
voor latere revisie-operaties. Roken bleek een positief voorspellende factor voor implantaat 
verlies in beide analyses. In eerdere studies gevonden factoren van invloed, zoals BMI 
(body mass index) en diabetes mellitus, konden in deze studie niet worden bevestigd als 
geassocieerde factoren. De uitkomsten werden gevonden in een historisch cohort, hierbij 
moet worden aangetekend dat de implantaten en chirurgische techniek in dit historische 
cohort in de huidige klinische praktijk nog weinig gebruikt worden, maar grotendeels 
vervangen zijn door nieuwe implantaten en technieken met een gunstiger postoperatief 
beloop.
In hoofdstuk 3 worden de resultaten van een nieuwer type percutaan beengeleidingsim-
plantaat beschreven onder 79 kinderen geopereerd in twee tertiaire zorgcentra in Europa. 
De studie werd gestart naar aanleiding van een klinisch opmerkelijke toename van huidre-
acties in de pediatrische patiëntpopulatie, welke gepaard ging met de introductie van een 
nieuw implantaat. De gemiddelde follow-up was 11,7 maanden. De studie bevestigde 
een goede implantaat overleving (96,5%) en toonde een nagenoeg stabiel aantal klinisch 
relevante huidreacties. Deze laatste bevinding moet in perspectief gezien worden van 
een eerdere studie, waarbij onder volwassen patiënten een afname van huidreacties 
vergeleken met het vorige generatie implantaat werd waargenomen (zie hoofdstuk 5). 
In de huidige studie werd hiernaast een toename van revisie-operaties in de pediatrische 
populatie gezien; in 28,7% van de implantaten bleken er 1 of meerdere revisie-operaties 
nodig in verband met huidproblemen (huid overgroei). Deze toename resulteerde in meer 
ziekenhuisbezoek en toegenomen belasting voor patiënten, familie en het zorgsysteem. 
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De onderzoeksopzet (met ontbrekende controle groep) verhinderde harde conclusies over 
de achterliggende oorzaak van deze toename, hiervoor zijn aanvullende studies vereist.
Hoofdstuk 4 behandelt de uitkomsten aangaande richtinghoren in een groep van kinderen 
met tweezijdige aanpassing met beengeleidingsimplantaten. Kinderen met bilateraal 
conductief gehoorverlies werden uitgenodigd om mee te doen aan deze studie, en 11 
kinderen stemden in met deelname. Een uitgesproken voordeel van bilateraal versus uni-
laterale aanpassing werd gezien in de richtinghoren testen. Dit was echter gebaseerd op 
correcte lateralisatie van geluid en niet op basis van exacte lokalisatie van de geluidsbron 
in de bilaterale conditie. Met andere woorden, deze kinderen waren in staat een goed 
onderscheid te maken of geluiden van links of rechts werden aangeboden, zonder de 
precieze locatie van het geluid te identificeren. Hierbij moet nog worden aangetekend 
dat het bij 10 van de 11 kinderen een congenitaal bilateraal gehoorverlies betrof. De 
deelneemster met een verworven bilateraal conductief gehoorverlies was met afstand de 
beste in het exact lokaliseren van het geluid, waarbij het vermoeden zou kunnen ontstaan 
dat vroegtijdige bilaterale ervaring essentieel zou kunnen zijn voor goede lokalisatie van 
geluid. Uit de resultaten kan worden geconcludeerd dat een tweede beengeleidingsim-
plantaat van grote meerwaarde is voor kinderen met bilateraal conductief gehoorverlies.
Het tweede deel van dit proefschrift is een samenstelling van verschillende studies naar 
nieuwe implantaten en chirurgische technieken. In hoofdstuk 5 wordt lange termijn data 
van een gerandomiseerde studie beschreven, waarin een nieuw type implantaat van 
Cochlear™ wordt onderzocht onder volwassen patiënten. Dit nieuwe implantaat kent een 
andere vorm van het koppelstuk en grotere diameter van het implantaat vergeleken met 
het oude implantaat. Een significante afname in huidreacties (2,5% versus 23,5% Holgers 
graad 2 reacties) en hogere implantaat stabiliteits quotient (ISQ) werden gevonden. Er kon 
geen verschil worden gevonden in toename van deze ISQ ten opzichte van de uitgangs-
waarde tussen beide implantaten. Hoge overlevingspercentages werden genoteerd voor 
beide groepen (96% versus 95%). Het belang van lange termijn evaluatie na introductie 
van nieuwe implantaten werd duidelijk nadat er in deze studie op een eerder gevonden 
afname in ISQ tussen 2 en 3 jaar follow-up, geen verdere daling kon worden vastgesteld. 
De goede uitkomsten van deze trial ondersteunen de vervanging van de vorige generatie 
implantaten door het nieuwe BI300 implantaat in de volwassen patientenpopulatie.
In hoofdstuk 6 worden de eerste resultaten van een studie naar een ander percutaan 
implantaat gepresenteerd, namelijk de 6 maanden uitkomsten van het eerste bredere 
implantaat van Oticon Medical™. Deze studie richtte zich met name op ISQ en implan-
taatverlies, waarbij het nieuwe en bredere test implantaat vergeleken wordt met het vorige 
generatie implantaat van Oticon Medical™. Zevenenvijftig volwassen patiënten met 60 
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implantaten werden in de studie geïncludeerd, met een randomisatie ratio van 2:1 (test 
versus controle). Het testimplantaat toonde een significant hogere ISQ waarde vergeleken 
met het controle implantaat. Hiernaast was de gemiddelde toename in de lage ISQ signi-
ficant verschillend tussen de beide groepen, in het voordeel van de testgroep. In geen van 
de groepen gingen implantaten verloren, en andere klinische uitkomsten, zoals het aantal 
complicaties en relevante huidreacties, waren vergelijkbaar tussen de twee groepen. Deze 
korte termijn resultaten suggereren dat het nieuwe implantaat een goede optie is onder 
de diverse huidige percutane implantaten. De studie wordt voortgezet tot 3 jaar en de 
resultaten van deze langere follow-up verschijnen binnenkort.
Gedurende lange tijd was uitdunning van weke delen rond het implantaat een vast on-
derdeel van de chirurgische techniek waarmee percutane implantaten worden geplaatst. 
Het werd aangenomen dat een dunne, relatief weinig mobiele huid rond het koppelstuk 
een belangrijke factor was in het voorkomen van postoperatieve huidproblemen. Echter, 
werden er door een ander centrum eerste resultaten vermeld van een nieuwe chirurgische 
techniek waarbij deze huidreductie stap werd overgeslagen. In hoofdstuk 7 wordt deze 
weefselsparende techniek bestudeerd en de resultaten van patiënten geopereerd met deze 
nieuwe methode vergeleken met resultaten van patiënten in een eerdere studie (beschreven 
in hoofdstuk 6). De resultaten van deze nieuwe techniek bleken over het algemeen ade-
quaat, met vergelijkbare uitkomsten op audiologisch gebied; met hierbij een reductie in 
operatietijd (25 versus 32 minuten, p<0.001). Echter, gedurende de eerste 6 maanden, 
werden er in onze studie meer huidreacties geobserveerd in de weefselsparende techniek 
(n=7 versus n=1, p=0.049). De toename van huidreacties was niet evident in andere 
studies nadien en de weefselsparende techniek is tegenwoordig breed toegepast als stan-
daard chirurgische methode. De resultaten van onze studie na 3 jaar worden binnenkort 
verwacht.
Hoofdstuk 8 beschrijft de uitkomsten van een studie naar een nieuw transcutaan implantaat 
systeem van Cochlear™. Dit systeem werd geëvalueerd in 54 patiënten waarbij gekeken 
werd naar klinische resultaten, audiologische gegevens en het (subjectieve) oordeel van 
patiënten. De audiologische uitkomsten werden vergeleken met een situatie met een 
beengeleidingstoestel op een softband en een ongeholpen situatie binnen elke patiënt. 
Het bestudeerde systeem is een zogenaamd passief transcutaan systeem, welke gepaard 
gaat met een minder efficiënte geluidsoverdracht vergeleken met percutane systemen. Aan 
de andere kant kent een transcutaan systeem voordelen, zoals geen dagelijkse zorg van 
de huid en minder risico op huidinfectie en implantaatverlies. Deze voor- en nadelen 
waren onderwerp van studie in hoofdstuk 8. Postoperatieve huidproblemen, zoals gevoel-
loosheid en pijn/discomfort rond het implantaat, werden relatief vaak genoemd door 
de deelnemende patiënten (21% gevoelloosheid en 38% (enige) pijn/discomfort na 6 
182
maanden). De vooraf gekozen primaire uitkomstmaat, de gemiddelde drempel in het vrije 
veld op 500-1000-2000-4000Hz, toonde een verbetering met het implantaat vergeleken 
met een ongeholpen situatie voor patiënten met conductief of gemengd gehoorverlies, 
en voor patiënten met single-sided deafness (SSD). Deze testen werden uitgevoerd met 
het niet-aangedane oor geblokkeerd. Verbeteringen vergeleken met de ongeholpen situ-
atie werden ook waargenomen in de spraak in stilte en spraak in ruis testen voor de 
conductief/gemengd gehoorverlies groep en de voor spraak in stilte test in de SSD groep. 
Hiernaast werden goede resultaten waargenomen op de vragenlijsten. De uitkomsten van 
het nieuwe implantaatsysteem bleken over het algemeen vergelijkbaar met de situatie met 
het beengeleidingsimplantaat gedragen op een softband. Voor patiënten die meer ver-
sterking nodig hebben, bijvoorbeeld door een significante perceptieve component in het 
gehoorverlies of in geval van SSD, kan de minder efficiënte geluidsoverdracht problemen 
geven, en wordt een beperktere indicatiestelling geadviseerd.
De multicenter opzet van de studie, en de vooraf geselecteerde verschillende indicatie-
typen resulteerde in uitdagingen in de analyse van de data en soms lastig te interpreteren 
resultaten. Geconcludeerd kan worden, dat de proef met een beengeleidingsimplantaat 
op softband een goede preoperatieve indicator is van het uiteindelijke audiologische 
resultaat. Lange termijn resultaten moeten worden afgewacht voordat criteria voor juiste 
selectie van patiënten voor dergelijke implantaten kunnen worden vastgesteld.
In dit proefschrift worden uiteenlopende onderwerpen binnen de beengeleidingsimplanta-
ten bestudeerd en bediscussieerd. Enkele van de recente ontwikkelingen in percutane en 
transcutane implantaten, nieuwe chirurgische technieken en klinische uitkomsten worden 
geëvalueerd. Dit proefschrift draagt hiermee bij aan de beschrijving van de ontwikkelingen 
op het gebied van beengeleidingsimplantaten. De besproken ontwikkelingen zullen naar 
verwachting de komende jaren verder evolueren en verder analyse ondergaan.
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